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Abstract 
 
A medicine will not elicit its desired therapeutic effect if the patient is not able or willing 
to take it. The specific needs of the target population must be taken into account in the 
design of medicines. Evaluation of the effect of formulation factors on patient’s 
acceptability could guide the development of better medicines for children. Flexible solid 
oral dosage forms, including multiparticulates and (oro)dispersible formulations, offer 
advantages over conventional solid and liquid dosage forms to meet the needs of 
paediatric patients. These advantages include favourable stability profile, suitability for 
taste masking, flexibility of dose titration and convenient administration.  
The overall aims of this research were to identify barriers for the development of 
acceptable medicines for children, to explore methodology for palatability and patient’s 
acceptability testing and to generate evidence of acceptability of flexible solid oral 
dosage forms. Methodological tools for the assessment of palatability and acceptability 
were developed and the use of such tools was explored through a series of investigations 
in healthy volunteers using model placebo formulations. Pharmaceutical formulation 
work was performed to optimise formulation design and choice of excipients, integrating 
manufacturability and patient’s acceptability criteria. 
A direct comparison between palatability and acceptability outcomes in children and 
adults was performed, which highlighted the value of conducting studies in adults to 
provide initial guidance on formulation design. Some of the key formulation factors that 
affect acceptability of flexible solid oral dosage forms were identified, which can be used 
to guide the development of more palatable and acceptable medicines. This research 
also evidenced methodological barriers in the assessment of palatability and patient’s 
acceptability which are thoroughly discussed in this thesis and will need to be overcome 
in the future. The knowledge generated by this research is applicable not only to the 
development of medicines for children, but also for other subsets of the population.   
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Impact statement 
 
The lack of acceptable medicines for children is a burden to patients, caregivers and 
healthcare professionals. Medicines designed to meet the needs of the target patient 
population can facilitate administration and improve patient’s adherence, having positive 
repercussions on the wellbeing of patients and the healthcare system.  
Previous research suggests enormous cost-saving potential of dispensing solid dosage 
forms to children instead of liquids, indicating that the main limitation to this practice is 
the size of the solid formulations available (Lajoinie et al., 2014). Flexible solid oral 
dosage forms such as multiparticulates and (oro)dispersible formulations offer potential 
to overcome this barrier by providing ease of swallowing and facilitating administration. 
The present research continues to support the use of solid dosage forms in children by 
providing evidence of the suitability of multiparticulates in children (4-12 years). 
The development of acceptable medicines for children must encompass a three-fold 
endeavour: (1) understanding patient needs, (2) optimising methodology and criteria for 
acceptability testing and (3) improving formulation design (Ternik et al., 2017). The 
research described in this thesis attempts to tackle these three forefronts. This research 
provides evidence to optimise methodology for palatability and acceptability testing and 
exemplifies the use of palatability and patient’s acceptability studies to guide excipient 
selection and improve dosage form design.  
As such, the evidence and knowledge generated in this research can be valuable to 
formulation scientist working on the development of future medicines for children and to 
regulatory agencies making decisions on marketing authorisations and PIP applications. 
Ideally, patient’s acceptability should be measured as a secondary outcome in clinical 
trials and, hopefully, this research is a step forward in this process. The outcomes of this 
research will be informative to researchers and regulators with the aim to optimise 
methodology for the evaluation of palatability and patient’s acceptability.  
6 
Table of Contents 
 
Declaration .................................................................................................................. 2 
Acknowledgements .................................................................................................... 3 
Abstract ....................................................................................................................... 4 
Impact statement ........................................................................................................ 5 
Table of Contents ....................................................................................................... 6 
Abbreviations ............................................................................................................ 11 
List of Tables ............................................................................................................ 13 
List of Figures ........................................................................................................... 15 
Chapter 1. Introduction ............................................................................................ 22 
1.1 Formulating medicines for children ............................................................... 22 
1.1.1 Limitations of conventional solid and liquid dosage forms ...................... 25 
1.1.2 The era of flexible solid dosage forms ................................................... 26 
1.2 Formulation design and patient’s acceptability .............................................. 34 
1.2.1 Palatability and acceptability testing: methodological considerations ..... 35 
1.3 Evidence of acceptability of flexible solid dosage forms ................................ 39 
7 
1.3.1 Results of a semi-systematic literature review ....................................... 41 
1.4 Identifying knowledge gaps and research needs .......................................... 57 
1.5 Thesis Aims and Outline ............................................................................... 59 
Chapter 2. Optimisation of research methodology for assessment of palatability 
and acceptability of multiparticulates ..................................................................... 61 
2.1 Introduction ................................................................................................... 61 
2.2 Aims and objectives ...................................................................................... 64 
2.3 Materials and methods ................................................................................. 64 
2.3.1 Materials ................................................................................................ 64 
2.3.2 Material characterisation ........................................................................ 65 
2.3.3 Sensory evaluation experiments ............................................................ 66 
2.4 Results and discussion ................................................................................. 70 
2.4.1 Material characterisation ........................................................................ 70 
2.4.2 Sensory evaluation study ....................................................................... 71 
2.5 Conclusions .................................................................................................. 84 
Chapter 3. Palatability and acceptability of multiparticulates: a comparison 
between children and adults .................................................................................... 87 
3.1 Introduction ................................................................................................... 87 
8 
3.2 Aims and objectives ...................................................................................... 91 
3.3 Materials and methods ................................................................................. 92 
3.3.1 Materials ................................................................................................ 92 
3.3.2 Material characterisation ........................................................................ 92 
3.3.3 Sensory evaluation study ....................................................................... 93 
3.3.4 Contributors statement ........................................................................ 100 
3.4 Results and discussion ............................................................................... 101 
3.4.1 Morphological characterisation of multiparticulates .............................. 101 
3.4.2 Demographics ..................................................................................... 103 
3.4.3 Acceptability comparison between children and adults ........................ 103 
3.4.4 Effect of formulation factors on palatability and acceptability ............... 112 
3.5 Conclusions ................................................................................................ 122 
Chapter 4. Development of oral vehicles to improve palatability and acceptability 
of multiparticulates ................................................................................................. 125 
4.1 Introduction ................................................................................................. 125 
4.2 Aims and objectives .................................................................................... 128 
4.3 Materials and methods ............................................................................... 128 
9 
4.3.1 Materials .............................................................................................. 128 
4.3.2 Preparation and characterisation of liquid vehicles .............................. 129 
4.3.3 Sensory evaluation study ..................................................................... 132 
4.4 Results and discussion ............................................................................... 135 
4.4.1 Rheological properties of model liquid formulations ............................. 135 
4.4.2 Development of suspending media for multiparticulates ...................... 138 
4.4.3 Sensory evaluation studies .................................................................. 145 
4.5 Conclusions ................................................................................................ 160 
Chapter 5. Evaluating manufacturability and patient acceptability to guide the 
choice of excipients in (oro)dispersible tablet formulations ............................... 163 
5.1 Introduction ................................................................................................. 163 
5.2 Aims and objectives .................................................................................... 167 
5.3 Materials and methods ............................................................................... 168 
5.3.1 Materials .............................................................................................. 168 
5.3.2 Powder and tablet characterisation ...................................................... 169 
5.3.3 Physical characterisation of dispersions .............................................. 171 
5.3.4 Evaluation of palatability and patient acceptability ............................... 172 
10 
5.4 Results and discussion ............................................................................... 174 
5.4.1 Powder and tablet characterisation ...................................................... 174 
5.4.2 Physical characterisation of dispersions .............................................. 181 
5.4.3 Palatability and acceptability of co-processed excipients ..................... 187 
5.5 Conclusions ................................................................................................ 196 
Chapter 6. General discussion, conclusions and future work ............................ 198 
6.1 Importance of evaluating patient’s acceptability .......................................... 198 
6.2 Rationale for investigating flexible solid oral dosage forms ......................... 200 
6.3 Overview of original contributions and implications of the research ............ 201 
6.4 Methodological limitations in the evaluation of patient’s acceptability .......... 203 
6.5 Future work: towards better medicines for children ..................................... 207 
6.6 Conclusions ................................................................................................ 209 
Research publications ............................................................................................ 210 
References .............................................................................................................. 212 
Annexes .................................................................................................................. 231 
  
11 
Abbreviations  
 
API ............................................................................. Active Pharmaceutical Ingredient 
CDT .................................................................................... Centre for Doctoral Training 
CG ...................................................................................................... Carrageenan gum 
CI ...................................................................................................... Confidence Interval 
CMC ....................................................................................... Carboxy-Methyl Cellulose 
CQA......................................................................................... Critical Quality Attributes 
CTIMP ............................................. Clinical Trials of Investigational Medicinal Products 
DT ...................................................................................................... Dispersible Tablet 
EMA................................................................................... European Medicines Agency 
EPSRC ....................................... Engineering and Physical Sciences Research Council 
ERN ......................................................................................... Ethics Research Number 
FDA ............................................................................... Food and Drugs Administration 
FDC ......................................................................................... Fixed-Dose Combination 
GG ..................................................................................................................Guar Gum 
GRAS ................................................................................ Generally Regarded As Safe 
HPMC .......................................................................... Hydroxy-Propyl-Methyl Cellulose 
IDDSI ..................................... International Dysphagia Diet Standardisation Association 
JAR............................................................................................ Just About Right (scale) 
L-HPC ............................................................ Low-substituted Hydroxy-Propyl Cellulose 
MCC ........................................................................................ Microcrystalline cellulose 
MAS.................................................................................. Medication Acceptance Scale 
MCS ...................................................................... Manufacturing Classification System 
12 
NM ............................................................................................................ Not Measured 
ODF ................................................................................................ Oro-Dispersible Film 
ODMT .................................................................................. Oro-Dispersible Mini-Tablet 
ODT ............................................................................................. Oro-Dispersible Tablet 
PIP .................................................................................. Paediatric Investigational Plan 
PSD .......................................................................................... Particle Size Distribution 
PVA .................................................................................................... Poly-Vinyl Alcohol 
PVAc ................................................................................................. Poly-Vinyl Acetate 
QTT .................................................................................. Quality Target Product Profile 
REC .................................................................................... Research Ethics Committee 
RPM ...........................................................................................Revolutions Per Minute 
SATMED-Q .................................................... Satisfaction with Medicines Questionnaire 
SD .................................................................................................... Standard Deviation 
SEM................................................................................. Scanning Electron Microscopy 
SPaeDD-UK ...................................................Smart Paediatric Drug Development - UK  
SSF ........................................................................................ Sodium Stearyl Fumarate 
TS ......................................................................................................... Tensile Strength 
TSQN ............................................ Treatment Satisfaction Questionnaire for Medication 
USP ................................................................................. United States Pharmacopoeia 
VAS ............................................................................................. Visual Analogue Scale 
WHO ...................................................................................... World Health Organisation 
XG ............................................................................................................ Xanthan Gum 
YPSG ........................................................................... Young Person’s Steering Group 
  
13 
List of Tables 
 
Table 1.1. List of requirements for age-appropriate oral drug delivery systems, according 
to Sam et. al, 2012 (Sam et al., 2012). ........................................................................ 23 
Table 1.2. Potential advantages and disadvantages of multiparticulates as a technology 
platform for the preparation of age-appropriate medicines for children. ....................... 27 
Table 1.3. Potential advantages and disadvantages of (oro)dispersible tablets as a 
technology platform for the preparation of age-appropriate medicines for children. ..... 29 
Table 1.4. Potential advantages and disadvantages of orodispersible films as a 
technology platform for the preparation of age-appropriate medicines for children. ..... 31 
Table 1.5. Potential advantages and disadvantages of chewable formulations as a 
technology platform for the preparation of age-appropriate medicines for children. ..... 33 
Table 1.6. Search terms for systematic literature review of Embase, Medline and 
PubMed. ..................................................................................................................... 40 
Table 1.7. Evidence of acceptability of multiparticulate formulations (i.e. coated 
pellets/granules and mini-tablets administered in multiplicity). .................................... 43 
Table 1.8. Evidence of acceptability of (oro)dispersible tablet formulations (i.e. 
dispersible, effervescence, orodispersible and sublingual tablets). ............................. 49 
Table 1.9. Evidence of acceptability of orodispersible film formulations ...................... 56 
Table 1.10. Evidence of acceptability of chewable formulations .................................. 56 
Table 2.1. Methodological considerations in the design of sensory evaluation studies, 
such as palatability and acceptability testing; adapted from (ASTM, 2003; Mason and 
Nottingham, 2002). ..................................................................................................... 63 
Table 2.2. Particle size descriptors of Cellets as provided by the manufacturer. ......... 65 
Table 2.3. List of formulations assessed in sensory evaluation experiments. .............. 67 
Table 3.1. Summary of skills and behaviours of children, adapted from (ASTM, 2003).
 ................................................................................................................................... 89 
Table 3.2. Comparison of exploratory trial in adults and current trial in adults and children.
 ................................................................................................................................... 90 
Table 3.3. Summary of multiparticulate formulations investigated by children and adults.
 ................................................................................................................................... 92 
14 
Table 3.4. Dosing schedule for the sensory evaluation of multiparticulates. Numbers 
indicate the order in which samples were administered in each of the eight sessions (S1-
S8). ............................................................................................................................. 95 
Table 3.5. Researcher observations 12-point tick chart for assessing negative facial 
expressions and behaviours of participants prior to, during and after sample intake. .. 95 
Table 3.6. Demographic characteristics of the study participants. ............................. 103 
Table 3.7. Comparison of multiparticulates acceptability outcomes in children and adults.
 ................................................................................................................................. 109 
Table 4.1. Quality Target Product Profile (QTPP) for a pharmaceutical liquid vehicle 126 
Table 4.2. List of liquid vehicles assessed in sensory evaluation experiments. ......... 132 
Table 4.3. Rheological characteristics of model liquid formulations, including oral 
suspending vehicles, medicines in the form of oral suspensions, food thickeners and 
various types of yogurt. ............................................................................................. 136 
Table 4.4. Rheological characteristics of XG and CMC hydrogels prepared at a range of 
concentrations (0.15-1.50% w/v). .............................................................................. 139 
Table 5.1. Manufacturing specifications for (oro)dispersible tablets by direct 
compression. ............................................................................................................ 164 
Table 5.2. Individual constituents of the co-processed excipients ............................. 168 
Table 5.3. Fineness of dispersion results for (oro)dispersible tablets dispersed in 10 ml 
of water. .................................................................................................................... 180 
Table 5.4. Particle size distribution of co-processed excipients measured by laser 
diffraction. ................................................................................................................. 183 
Table 5.5. Particle size distribution of powder and tablet dispersions in water by laser 
diffraction. ................................................................................................................. 184 
Table 5.6. Theoretical and experimental insoluble particle fraction of excipients. ...... 186 
Table 5.7. Summary of in vitro tablet characterisation experiments .......................... 187 
  
15 
List of Figures 
 
Figure 1.1. Flow-chart illustrating selection process for inclusion in the semi-systematic 
review. ........................................................................................................................ 41 
Figure 2.1. Diagram depicting the randomised, factorial, two-session, single-blind study 
design. ........................................................................................................................ 66 
Figure 2.2. Hedonic scales for evaluation of swallowing, grittiness, sample volume and 
taste. ........................................................................................................................... 68 
Figure 2.3. SEM micrographs of Cellets with 250x magnification: (a) Cellets 200, (b) 
Cellets 350, (c) Cellets 500 and (d) Cellets 700. Cellets 200 and Cellets 500 were 
investigated in the present exploratory study, whereas other size fractions were used in 
future investigations. ................................................................................................... 70 
Figure 2.4. Particle size distribution of Cellets assessed by laser diffraction using dry 
dispersion (solid lines) and wet dispersion (dotted lines) methods. ............................. 71 
Figure 2.5. Interval plots for grittiness, sample volume and taste as a function of 
formulation (1-8) and testing methodology (session 1 = swirl and spit; session 2 = 
swallowing). Markers represent the population mean for the hedonic ratings (where 1 is 
the best possible rating and 5 is the worst possible rating) and bars show the 95% CI for 
the mean. ................................................................................................................... 72 
Figure 2.6. Interval plots for grittiness, taste, sample volume and ease of swallowing as 
a function of the administration approach (Dry: multiparticulates administered directly in 
the mouth followed by water; Wet: multiparticulates pre-dispersed in water before 
administration). Markers represent the population mean for the hedonic ratings (where 1 
is the best possible rating and 5 is the worst possible rating) and bars show the 95% CI 
for the mean. .............................................................................................................. 75 
Figure 2.7. Interval plots for grittiness and taste as a function of the administration 
approach, the size of the multiparticulates and the amount administered. Markers 
represent the population mean for the hedonic ratings (where 1 is the best possible rating 
and 5 is the worst possible rating) and bars show the 95% CI for the mean. ............... 76 
Figure 2.8. Interval plots for sample volume and ease of swallowing as a function of the 
administration approach, the size of the multiparticulates and the amount administered. 
Markers represent the population mean for the hedonic ratings (where 1 is the best 
possible rating and 5 is the worst possible rating) and bars show the 95% CI for the 
mean. ......................................................................................................................... 78 
Figure 2.9. Ratings of grittiness and taste (1 – best possible rating and 5 – worst possible 
rating) as a function of the administration approach, the size of the multiparticulates and 
the amount administered. Results expressed as percentage of the total respondents (N 
= 24). .......................................................................................................................... 79 
16 
Figure 2.10. Ratings of sample volume and swallowing (1 – best possible rating and 5 – 
worst possible rating) as a function of the administration approach, the size of the 
multiparticulates and the amount administered. Results expressed as percentage of the 
total respondents (N = 24). ......................................................................................... 80 
Figure 2.11. Proportion of volunteers ‘willing to take the sample everyday if it was a 
medicine’, expressed as a percentage of the total population (N = 24). ...................... 81 
Figure 2.12. Interval plots for grittiness, taste, sample volume and ease of swallowing for 
samples that participants would be willing or not willing to take every day. Markers 
represent the population mean for the hedonic ratings (where 1 is the best possible rating 
and 5 is the worst possible rating) and bars show the 95% CI for the mean. ............... 82 
Figure 2.13. Volume of water consumed as a function of the administration approach, 
the size of the multiparticulates and the amount administered. Centre lines show the 
median, box limits indicate the 25th and 75th percentiles and outliers are denoted by 
asterisks. Water used to pre-disperse wet samples (10 ml) was not considered part of 
the water consumed. .................................................................................................. 83 
Figure 2.14. Quantity of Cellets remaining in dosing vial after sample administration 
(expressed as % w/w of the initial amount of multiparticulates) as a function of the 
administration approach, the size of the multiparticulates and the amount administered. 
Centre lines show the medians, box limits indicate the 25th and 75th percentiles and 
outliers are denoted by asterisks. ............................................................................... 84 
Figure 3.1. Schematic representation of the study design for the evaluation of palatability 
and acceptability of multiparticulate formulations in children and adults. ..................... 93 
Figure 3.2. Samples of 500 mg of multiparticulates dispersed in 3 ml of spring water on 
a medicine dosing spoon. Particle size of the multiparticulates varies, from left to right: 
200-355, 350-500, 500-710 and 700-1000 μm. Each size was available as coated and 
uncoated versions. ...................................................................................................... 94 
Figure 3.3. Paper-based structured questionnaire used for data collection of subject-
reported outcomes of palatability and acceptability. .................................................... 97 
Figure 3.4. Particle size distribution of Cellets assessed by laser diffraction (dry 
dispersion method). .................................................................................................. 101 
Figure 3.5. SEM micrographs of uncoated and coated Cellets with 250x magnification.
 ................................................................................................................................. 102 
Figure 3.6. Proportion of participants who swallowed, spat out or refused 
multiparticulates. ....................................................................................................... 104 
Figure 3.7. Proportion of participants displaying negative facial expressions upon sample 
intake. ....................................................................................................................... 104 
Figure 3.8. Rating of palatability attributes in hedonic scales (1 - best possible rating to 
5 - worst possible rating). Centre lines show the median, box limits the 25th and 75th 
17 
percentiles, notches represent the 95% confidence interval of the median and outliers 
are denoted by dots. ................................................................................................. 105 
Figure 3.9. Histograms of ratings using hedonic scales. Dark blue bar represents median.
 ................................................................................................................................. 107 
Figure 3.10. Proportion of volunteers ‘willing to take the sample every day if it was a 
medicine’. Seven children (3%) refused the sample and thus, although their willingness 
response was not collected, these were reported as not willing to take the sample every 
day if it was a medicine. ............................................................................................ 108 
Figure 3.11. Hedonic rating as a function of the reported willingness to take the sample 
every day. Markers represent the mean hedonic rating and bars show the 95% CI for the 
mean. ....................................................................................................................... 108 
Figure 3.12. Comparison of multiparticulates acceptability outcomes in children and 
adults. ....................................................................................................................... 109 
Figure 3.13. Probability of participants to report willingness to take multiparticulates every 
day as a function of their responses to hedonic scales (samples were considered 
accepted based on hedonic ratings when all sample attributes were rated in the neutral 
to positive end of the scale). ..................................................................................... 110 
Figure 3.14. Probability of participants to report willingness to take multiparticulates every 
day as a function of their negative facial expression (samples were considered accepted 
based on facial expressions when no negative facial expressions were observed during 
sample intake). ......................................................................................................... 111 
Figure 3.15. Interval plots for grittiness and mouthfeel as a function of multiparticulate 
size (results of Sessions 1-4), by population group. Markers represent the population 
average hedonic rating (1 - best possible rating and 5 - worst possible rating) and bars 
show the 95% CI for the mean. ................................................................................. 114 
Figure 3.16. Interval plots for sample volume and taste as a function of multiparticulate 
size (results of Sessions 1-4), by population group. Markers represent the population 
average hedonic rating (1 - best possible rating and 5 - worst possible rating) and bars 
show the 95% CI for the mean. ................................................................................. 115 
Figure 3.17. Willingness to take the multiparticulate sample every day if it was a medicine 
as a function of the size of the multiparticulates. ....................................................... 116 
Figure 3.18. Interval plots for grittiness and mouthfeel as a function of polymeric coating 
(results        of Sessions 5-8), by population group. Markers represent the population 
average hedonic rating (1 - best possible rating and 5 - worst possible rating) and bars 
show the 95% CI for the mean. ................................................................................. 117 
Figure 3.19. Interval plots for sample volume and taste as a function of polymeric coating 
(results of Sessions 5-8), by population group. Markers represent the population average 
hedonic rating (1 - best possible rating and 5 - worst possible rating) and bars show the 
95% CI for the mean. ................................................................................................ 118 
18 
Figure 3.20. Willingness to take the multiparticulate sample every day if it was a medicine 
as a function of presence of polymeric film coating. .................................................. 119 
Figure 3.21. Volume of water (ml) consumed during the administration of 
multiparticulates, as a function of their size and coating. Centre lines show the median, 
box limits represent the 25th and 75th percentiles and outliers are denoted by asterisks.
 ................................................................................................................................. 120 
Figure 3.22. Proportion of participants that reported they could still feel residual 
multiparticulates in their mouth after administration of multiparticulates, as a function of 
their size and coating. ............................................................................................... 121 
Figure 4.1. Adapted set up of rheometer with petri dish as sample holder for hydration 
experiments. ............................................................................................................. 131 
Figure 4.2. Overview of the 3-way crossover study design where all possible sequence 
orders between treatments were considered (T1: no particles; T2: small particles; T3: 
large particles). ......................................................................................................... 133 
Figure 4.3. Photographs of samples composed of 250 mg of Cellets 200 (a) and Cellets 
700 (b) dispersed in different liquid vehicles on 5-ml plastic medicine spoons. Water + v. 
represents water to which 0.1% w/v vanillin was added; the consistency level of XG and 
CMC hydrogels is depicted as L1 (Level1), L2 (Level 2) and L3 (Level 3). The set of 
samples of liquid vehicles without multiparticulates was not photographed and is not 
shown in the image. .................................................................................................. 134 
Figure 4.4. Consistency index of XG (filled squares) and CMC (filled circles) hydrogels 
as a function of the polymer concentration. ............................................................... 140 
Figure 4.5. Flow behaviour index of XG (open squares) and CMC (open circles) 
hydrogels as a function of the polymer concentration. .............................................. 140 
Figure 4.6. Viscosity of hydrocolloids at shear rate of 10s-1 during hydration experiments 
in water. Results expressed as normalised viscosity with respect to the viscosity of fully 
hydrated samples. .................................................................................................... 141 
Figure 4.7. Sedimentation time of multiparticulates of two different sizes, Cellets 200 
(top) and Cellets 700 (bottom), as a function of the apparent viscosity at 0.1 s-1 (very low 
shear rate, representative of the sample at rest) of XG and CMC hydrogels prepared with 
increasing polymer concentration. A trendline was fit to the data by linear regression 
(dotted line). n.b. the scale range is different in each graph to improve visualisation. 142 
Figure 4.8. Sedimentation time (minutes) of Cellets 200 and Cellets 700 in XG and CMC 
hydrogels prepared with increasing polymer concentration (% w/v). Sedimentation was 
observed for a maximum period of 30 minutes; bars extending over that limit represent 
sedimentation times longer than 30 minutes. ............................................................ 144 
Figure 4.9. Consistency index of XG and CMC hydrogels prepared to three different 
consistency levels: Level 1 – Syrup (yellow), Level 2 – Custard (orange), Level 3 – 
Pudding (red) as described by the IDDSI (IDDSI, 2015). .......................................... 145 
19 
Figure 4.10. Interval plot for appearance (top) and mouthfeel (bottom) of different liquid 
vehicles. Markers represent the population mean for the hedonic ratings (where 1 is the 
best possible rating and 5 is the worst possible rating) and bars show the 95% CI for the 
mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency 
level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 
3). ............................................................................................................................. 147 
Figure 4.11. Interval plot for taste (top) and ease of swallowing (bottom) of different liquid 
vehicles. Markers represent the population mean for the hedonic ratings (where 1 is the 
best possible rating and 5 is the worst possible rating) and bars show the 95% CI for the 
mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency 
level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 
3). ............................................................................................................................. 149 
Figure 4.12. Interval plot for appearance (top) and mouthfeel (bottom) as a function of 
the vehicle used as suspending media and the size of the dispersed multiparticulates: 
200-355 µm (Cellets 200) or 700-1000 µm (Cellets 700). Markers represent the 
population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the 
worst possible rating) and bars show the 95% CI for the mean. Water + v. represents 
water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC 
hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). ....................... 152 
Figure 4.13. Interval plot for taste (top) and ease of swallowing (bottom) as a function of 
the vehicle used as suspending media and the size of the dispersed multiparticulates: 
200-355 µm (Cellets 200) or 700-1000 µm (Cellets 700). Markers represent the 
population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the 
worst possible rating) and bars show the 95% CI for the mean. Water + v. represents 
water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC 
hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). ....................... 154 
Figure 4.14. Interval plot for grittiness (top) and residue of multiparticulates in mouth after 
swallowing (bottom) as a function of the vehicle used as suspending media and the size 
of the multiparticulates: 200-355 µm (Cellets 200) or 700-1000 µm (Cellets 700). Markers 
represent the population mean for the 5-point magnitude scale (where 1 is the lowest 
possible and 5 is the highest possible intensity of the stimulus) and bars show the 95% 
CI for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; the 
consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) 
and L3 (Level 3). ....................................................................................................... 156 
Figure 4.15. Radar chart for appearance, taste, grittiness, mouthfeel, ease of swallowing 
and residue of multiparticulates in mouth as a function of the vehicle used as suspending 
media and the size of the multiparticulates: 200-355 µm (Cellets 200) or 700-1000 µm 
(Cellets 700). Each palatability item is described by its population mean for the 5-point 
scale (where 1 is the lowest possible and 5 is the highest possible intensity of the 
stimulus). The consistency level of XG and CMC hydrogels is described as L1 (Level1), 
L2 (Level 2) and L3 (Level 3). ................................................................................... 158 
Figure 4.16. Proportion of volunteers ‘willing to take the sample everyday if it was a 
medicine’, expressed as a percentage of the total population (N = 30), for samples 
20 
containing Cellets 200 (top) or Cellets 700 (bottom) dispersed in different liquid vehicles.
 ................................................................................................................................. 159 
Figure 5.1. Sensory evaluation study design. In Session 1, each participant received nine 
samples (s1-s9) in randomised order, in three blocks of three samples. In Session 2, 
seven samples were tested, two of which were repeated (r1, r2) in the last block. .... 173 
Figure 5.2. Carr’s Index of co-processed excipients; results expressed as mean (N=3).
 ................................................................................................................................. 174 
Figure 5.3. Tablet compression profiles (tensile strength as a function of the compaction 
pressure). ................................................................................................................. 175 
Figure 5.4. Capping post-tableting (left) and after hardness testing (right), observed for 
tablets prepared using Pearlitol Flash and SmartEx QD50 at high compression forces (> 
200 MPa). ................................................................................................................. 176 
Figure 5.5. Disintegration time of co-processed excipients (oro)dispersible tablet 
formulations. Results expressed as the time taken for the last tablet to disintegrate (N=4).
 ................................................................................................................................. 178 
Figure 5.6: Optical microscopy images of the co-processed excipients (powder dispersed 
in water) at 10x magnification (scale bar: 400µm). Only those excipients with adequate 
compressibility (max. TS > 3.0 MPa), disintegration time (< 60 s) and friability (< 1% in 
10 min.) were imaged. .............................................................................................. 181 
Figure 5.7: Particle size distribution of co-processed excipients evaluated by laser 
diffraction in wet dispersion using water as dispersant. ............................................. 183 
Figure 5.8. Insoluble particle fraction of excipients calculated by gravimetric analysis after 
excipient dispersion and dissolution of soluble components in 10 ml of water (N=3). 185 
Figure 5.9: Forced-choice ranking order, shown as proportion of participants who 
selected each excipient as “best”, “middle” or “worst” within randomised combinations of 
three excipients. ....................................................................................................... 188 
Figure 5.10. Key palatability attribute selected by participants to justify ranking of 
excipients dispersions as ‘best’ or ‘worst’ out of three random samples. ................... 189 
Figure 5.11: Interval plot of hedonic ratings (1 – very acceptable, 5 – very unacceptable). 
Markers represent the population mean and bars show the 95% CI for the mean. .... 190 
Figure 5.12: Hedonic rating for each excipient, showing the proportion of participants 
which selected each level of the 5-point hedonic scale (1 – very acceptable, 5 – very 
unacceptable). .......................................................................................................... 192 
Figure 6.1. Diagram of the Acceptability by Design concept by which the selection of 
excipients, manufacturing process and dosage form are guided by understanding of 
patient’s acceptability. ............................................................................................... 199 
21 
 
 
 
 
 
“A problem well-stated is a problem half-solved” 
Charles Kettering 
 
  
22 
Chapter 1 
1. Introduction 
 
This chapter introduces the background of the thesis. The current formulation strategies 
for the development of oral paediatric medicines are described and their benefits and 
limitations critically discussed. Then, considerations in the design and implementation of 
palatability and acceptability studies of medicinal products are explored. Finally, previous 
studies of acceptability of flexible solid dosage forms are systematically reviewed, with 
emphasis on methodological aspects as well as evidence of acceptability of different 
dosage form designs. After a detailed overview of the research field, scientific knowledge 
gaps are identified and the overall aims of the experimental work described within this 
thesis are outlined. 
1.1 Formulating medicines for children 
Paediatric patients require different oral medications than other subsets of the population 
due to their continuing development hence dosing and administration requirements 
(EMA, 2013). Conventional formulations are not designed for this patient group, thus 
manipulation and compounding of medicines, as well as unlicensed or off-label use, have 
become common practice (Conroy et al., 2000; Richey et al., 2013). Age-appropriate 
dosage forms developed to meet the needs of the paediatric population are therefore 
desired. Since the Paediatric Regulation (Regulation EC 1902/2006) came into force in 
Europe (and parallel regulations in other parts of the world), the development of 
medicines specifically designed for children is not only a moral but also a regulatory 
obligation. Companies willing to bring a new drug product into market need to consider 
the needs of paediatric patients under a Paediatric Investigational Plan (PIP) and to 
develop a specific formulation for children. 
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The development of pharmaceutical products is a challenging task due to the broad 
range of pharmaceutical and clinical aspects that must be considered to ensure the 
quality, safety and efficacy of the final product. The development of paediatric medicines 
is even more complex due to the additional needs and demands of this target population 
with respect to adults (van Riet-Nales et al., 2016). The numerous criteria that must be 
considered to meet with the needs of patients, caregivers, manufacturers and healthcare 
providers has been classified into three main categories: (i) factors related to efficacy 
and ease of use, (ii) those related to patient safety, and (iii) factors influencing the access 
of patients to medicines, as detailed in Table 1.1 (Sam et al., 2012).  
Table 1.1. List of requirements for age-appropriate oral drug delivery systems, according to Sam 
et. al, 2012 (Sam et al., 2012). 
Benefit/risk Criterion for drug product Product requirements 
Efficacy/Acceptability Dosage Dose flexibility 
Acceptability of size/volume 
Preparation /administration Easy and convenient handling 
Easily administered (correct use) 
Compliance 
 
Minimal impact on lifestyle 
Acceptable appearance and taste 
Minimal administration frequency 
Patient safety Bioavailability Adequate bioavailability 
Excipients Minimal number of excipients 
Tolerability  
Stability Stable during shell life 
Stable in-use 
Medication error Minimal risk of dosing error 
Patient access Manufacturability Robust manufacturing process 
Commercial viability 
Affordability Acceptable cost to patients/payers 
Easily transported and stored 
Low environmental impact 
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The pharmacokinetic and pharmacodynamic profile of a drug varies broadly depending 
on the developmental stage of a child, necessitating dose flexibility to suit the dosing 
requirements across all age groups (Batchelor and Marriott, 2013). Excipients commonly 
regarded as safe may represent a safety risk for children adding other considerations 
into the formulation development (Salunke et al., 2013). Palatability and ease of 
swallowing are also considered critical attributes for the acceptability of medicines 
intended for children, who possess distinct preferences and swallowing abilities than 
other subsets of the population. In many cases, the dependence on caregivers also 
influences the administration and acceptability of medicines (Ivanovska et al., 2014).  
The manufacturing process of pharmaceutical products must be robust and able to 
deliver medicines of adequate quality at affordable price. Packaging and administration 
devices must be seen as an integral part of the product as these affect the overall quality, 
acceptability and cost (Kozarewicz, 2014; Wening and Breitkreutz, 2011). The 
affordability of medicines is crucial for the development of pharmaceutical products for 
global market, including developing countries (Sosnik et al., 2012). The utilisation of cost-
effective and readily-available technologies is desired to maximise the affordability and 
accessibility of medicines, which ultimately benefits patients. Therefore, balance 
between innovative technologies and patient access to medicines must be sought. 
Considering the number of parameters that needs to be fulfilled, flexible technology 
platforms which enable the delivery of multiple drugs, dose strengths and release profiles 
should be prioritised to broaden acceptability to a larger population group (EMA, 2013; 
WHO, 2012). There are cases where paediatric age-appropriate formulations are not 
only favourable for children but also for other special patient groups, including elderly 
and adults with swallowing difficulties (Hanning et al., 2016; Liu et al., 2014). Targeting 
a larger patient population may improve the commercial viability of paediatric products 
but caution must be taken to ensure that this practice does not undermine the 
requirements of each patient group.  
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1.1.1 Limitations of conventional solid and liquid dosage forms  
Liquid formulations have been, traditionally, the formulation of choice for paediatric 
patients, based on their suitability for dose titration (e.g. using an oral syringe) and ease 
of administration to young children compared to tablets or capsules. However, liquid 
dosage forms have several drawbacks with regards to patient’s safety and acceptability. 
For instance, taste-masking of liquids is technologically challenging and poor taste of 
liquid medicines is perhaps the major barrier to patient’s acceptability (Venables et al., 
2015). Similarly, controlled release from liquid formulations is problematic, resulting in 
the need to administer multiple doses throughout the day. In addition, the stability of 
liquid medicines (physical, chemical and microbiological) is poor as compared to solid 
formulations. To overcome these challenges, additional excipients are often required, 
such as sweeteners to improve the taste and/or preservatives to improve stability. 
Unfortunately, these excipients often have poor and/or unknown safety profile, which can 
put patients at risk. Finally, liquid formulations are often more expensive to produce, store 
and transport, which poses an important barrier to improve access to age-appropriate 
essential medicines for young children, especially in low- and middle-income countries 
(Robertson et al., 2009). 
Due to the inherent limitations of liquid dosage forms with respect to solid dosage forms, 
the efforts of formulation scientists have been directed towards the development of solid 
formulations over liquids. However, conventional solid dosage forms may not be suitable 
for paediatrics and other patients with swallowing difficulties, which results in the need 
for manipulation and compounding (Richey et al., 2013; Stegemann et al., 2012). 
Another limitation of conventional tablets is their poor flexibility of dose; inevitably pill 
splitting has become common practice to obtain various dose strengths, despite the 
safety and efficacy risk of this practice (Margiocco et al., 2009; van Riet-Nales et al., 
2014). Smaller tablets and capsules emerge as an alternative to conventional solid 
dosage forms with improved dose flexibility and ease of swallowing. Several studies have 
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shown that pre-school children and neonates are able to swallow single mini-tablets 
(Klingmann et al., 2015; Spomer et al., 2012; Thomson et al., 2009). Nevertheless, the 
maximum dose that can be delivered by single-unit mini-tablets will always be limited by 
their small size and, in consequence, several of these small-sized tablets will be required 
to achieve the targeted dose. The administration of multiple mini-tablets is further 
discussed in the section dedicated to multiparticulate formulations. 
1.1.2 The era of flexible solid dosage forms 
In recent years there has been an increased focus on the development of age-
appropriate formulations for children, supported by modifications in the regulatory 
framework (Turner et al., 2014). This has resulted in a noticeable increase in formulation 
designs that has been investigated and commercialised, including multiparticulate 
formulations, (oro)dispersible tablets, oral thin films and chewable formulations. Such 
solid dosage forms, which do not require to be swallowed whole, can be grouped under 
the definition of flexible solid dosage forms (WHO, 2012). These formulations may 
provide advantages over conventional solid and liquid medicines, facilitate administration 
to paediatric patients and improve patient’s acceptability. 
1.1.2.1 Multiparticulate formulations 
Multiparticulate drug delivery systems are composed of multiple solid dosage units, such 
as pellets or mini-tablets. Multiparticulates, in the form of pellets or beads, are highly 
spherical granules of small diameter (typically below 1.5 mm) and narrow size 
distribution, usually prepared by fluidised bed technologies such as active layering or 
direct pelletisation (Priese et al., 2014). Mini-tablets can also be considered under the 
definition of multiparticulate formulations when administered in multiplicity; mini-tablets 
have a diameter of 1-3 mm and can be prepared using conventional tableting equipment 
fixed with specialised accessories (Tissen et al., 2011). Characteristic advantages and 
limitations of multiparticulate drug delivery systems are summarised in Table 1.2.  
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Table 1.2. Potential advantages and disadvantages of multiparticulates as a technology platform 
for the preparation of age-appropriate medicines for children. 
Product characteristic Advantages Disadvantages 
Efficacy/Acceptability   
Dosage Excellent flexibility of dose 
Small size/swallowing is aided 
Grittiness/mouthfeel may be an 
issue 
Preparation Flexibility of administration Need for preparation or 
reconstitution 
Compliance Ease of functionalisation 
Suitable for taste masking 
 
Safety profile   
Bioavailability Targeted release profiles can be 
achieved 
Avoidance of dose dumping 
Co-administration with food/drinks 
may alter bioavailability 
Excipients Use of Generally Regarded As 
Safe (GRAS) excipients 
 
Stability  Food-drug compatibility needs to 
be studied 
Medication error  Limited control over dose intake 
when mixed with food 
Patient access   
Manufacturability  May need specialise equipment or 
accessories 
Affordability Manufacturing technology readily 
available 
Packaging/dosing technology may 
need to be developed 
 
Multiparticulate products are usually suitable for controlled release and taste masking by 
means of film-coating technologies, which can benefit patient’s acceptability. Moreover, 
multiparticulates can be expected to be easier to swallow than monolithic dosage forms 
(i.e. tablets and capsules) based on their reduced size. However, there is a lack of 
evidence on the size and amount of multiparticulates that is acceptable to patients of 
different ages, although recent FDA guidance suggests a maximum size of 2.5 mm (FDA, 
2012a). The quantity and size of multiparticulates given in a single dose can influence, 
not only the ability to swallow the formulation, but also the mouthfeel and overall 
palatability. Previous studies suggest that oral grittiness perception might be a barrier to 
palatability and acceptability of multiparticulates (Kimura et al., 2015; Lopez et al., 2016).  
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The multi-unit composition of multiparticulates offer attractive opportunities for the 
preparation of fixed-dose combinations and products with targeted release profiles which 
can reduce the burden of repeated administration (Desai et al., 2013). This can be 
achieved by simply combining multiparticulates with different APIs and/or different 
release characteristics into the same dosage form. An advantage of multiparticulates 
over single-unit formulations is that controlled release can be provided while avoiding 
the risk of dose-dumping (Abdul et al., 2010). Multiparticulates also offer potential for 
dose titration although this would require the utilisation of dosing devices to allow dose 
adjustment; research has been conducted in this direction with devices ranging from 
dosing spoons to electronic dispensers (Wening and Breitkreutz, 2010) 
Multiparticulates can be administered directly in the mouth or dispersed in a vehicle prior 
to administration as preferred; water, milk, juice or apple sauce are potential vehicles 
commonly proposed (WHO, 2009). The administration in admixture with food 
(‘sprinkling’) is often indicated to improve the organoleptic properties and thus the 
acceptability of these formulations. However, the need for product preparation may 
actually have a negative impact on the overall acceptability of the product as shown in 
recent studies (Den Uyl et al., 2010; MacDonald et al., 2006). Co-administration of drug 
products with food or drinks also poses safety concerns, such as poor control over dose 
intake and impact on drug’s bioavailability (Batchelor et al., 2014).  
1.1.2.2 (Oro)dispersible tablets 
Dispersible and orodispersible tablets (DTs and ODTs) are designed to disintegrate 
within a matter of seconds, avoiding the need for swallowing the tablet as a whole (Liang 
and Chen, 2001). DTs are intended to be dispersed in a vehicle (typically water) before 
administration, whereas ODTs are designed to be dispersed directly in the mouth. In 
practice, ODTs may be dispersed directly in the mouth or pre-dispersed in a suitable 
vehicle, as preferred, offering great flexibility of administration. In some cases, when the 
disintegration/dissolution is sufficiently fast, the use of water can also be avoided. Owing 
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to these benefits, patients’ acceptability and compliance can be improved with respect 
to conventional formulations. The main benefits and limitations of (oro)dispersible tablets 
as a formulation of choice for the paediatric population are summarised in Table 1.3 and 
are further discussed below. 
Table 1.3. Potential advantages and disadvantages of (oro)dispersible tablets as a technology 
platform for the preparation of age-appropriate medicines for children. 
Product characteristic Advantages Disadvantages 
Efficacy/Acceptability   
Dosage  Various dosage strengths required 
Preparation Flexibility of administration 
Swallowing is aided 
Water is not required (ODTs) 
Lack of mechanical strength 
Compliance Preferred over conventional 
formulations 
Controlled-release is challenging 
Taste masking is challenging 
Safety profile   
Bioavailability May be improved by buccal 
absorption 
 
Excipients  Excipients of unknown safety 
profile may be required 
Stability  Packaging and storage conditions 
can be critical 
Medication error  Retention time in mouth may alter 
bioavailability 
Patient access   
Manufacturability  Difficult to balance mechanical 
strength and fast disintegration 
Affordability Manufacturing technology readily 
available  
Some technologies subjected to 
intellectual property rights 
 
Although DTs and ODTs facilitate administration and swallowing, this formulation design 
does not bring an advantage in terms of dose flexibility with respect to conventional 
tablets, meaning that various dosing strengths would be required to fulfil the needs of all 
populations. DTs and ODTs are often porous and fragile (to aid quick disintegration), 
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thus tablet splitting is usually contraindicated which may further reduce dose flexibility 
(Buck and Health, 2013). To overcome these limitations, dose flexibility could be 
achieved via a multi-step process where the tablet is pre-dispersed in water and, 
subsequently, the required dose is measured and administered using an oral syringe, as 
indicated in a recently marketed ODT (FDA, 2012b). Alternatively, the preparation of 
‘orally disintegrating mini-tablets’ (ODMT) is an interesting opportunity to combine the 
benefits of multiparticulates and ODTs (Stoltenberg and Breitkreutz, 2011).  
Since the drug is subject to the patients’ taste buds in the mouth, taste masking is a 
requirement of orally disintegrating formulations with unpleasant tasting APIs. Improved 
palatability is traditionally achieved by addition of sweeteners and flavours to the 
formulation. However, the efficacy of this approach is often limited and, in addition, the 
use of these excipients poses safety concern (especially for paediatric patients) (Walsh 
et al., 2014). Coating of the drug particles represent an effective way of taste masking, 
however technologically more challenging (Stange et al., 2014; Walsh et al., 2014). 
Nevertheless, patented ODT technologies have been able to overcome this challenge 
through the preparation and subsequent compression of microencapsulated drugs for 
improved organoleptic properties and/or polymer coated particles for customised release 
(Venkatesh et al., 2012). 
1.1.2.3 Orodispersible films 
Orodispersible films (ODFs) based on polymeric matrices can be designed to 
disintegrate quickly in the mouth releasing the active ingredient. Swallowing is aided by 
the quick disintegration/dissolution of ODFs in the oral, eliminating the need of water for 
their administration. An added benefit of films in comparison to tablets is their increased 
flexibility of dose, since different strengths can be achieved by simply cutting films of the 
required size (Hoffmann and Breitenbach, 2011). A summary of advantages and 
disadvantages of ODFs is provided in Table 1.4.  
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Table 1.4. Potential advantages and disadvantages of orodispersible films as a technology 
platform for the preparation of age-appropriate medicines for children. 
Product characteristic Advantages Disadvantages 
Efficacy/Acceptability   
Dosage Excellent dose flexibility  
Preparation Water is not required 
Swallowing is aided 
 
Compliance May be preferred over 
conventional formulations 
Controlled-release is challenging  
Taste masking is challenging 
Safety profile   
Bioavailability May be improved by buccal 
absorption 
 
Excipients  Excipients of unknown safety 
profile may be required 
Stability  Specialised packaging often 
required 
Medication error  Retention time in mouth may alter 
bioavailability 
Patient access   
Manufacturability Continuous manufacturing can be 
achieved 
Uniformity of dose may be 
challenging 
Only low doses can be 
incorporated 
Affordability  Technologies subjected to 
intellectual property rights 
Manufacturing process is 
sometime solvent-based 
 
An important limitation of ODFs is that taste masking and controlled release result 
technologically challenging. The utilisation of coating techniques for these purposes is 
limited by the own nature of the manufacturing process which usually involves 
solubilisation of the API (Hoffmann and Breitenbach, 2011). In some cases, sustained 
release has been achieved through the preparation of multi-layered films by combining 
layers with different release-controlling polymers. However, the fast-disintegrating 
advantage is not purposeful anymore as they are often designed to adhere onto the 
buccal mucosa and release the active ingredient in a timely manner (Mura et al., 2015).  
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ODFs are composed of a polymeric matrix with a drug embedded, typically manufactured 
by means of solvent casting method (Hoffmann and Breitenbach, 2011). Regardless of 
the manufacturing method, the amount of drug that can be loaded in ODFs is very limited 
(typically less than 60-70 mg (Nagaraju et al., 2013)) owing the ODFs reduced size (2 - 
9 cm2) and thickness (25 µm to 2 mm), thus only potent drugs with specific 
physicochemical properties can be successfully delivered. Moreover, the need for 
specialise manufacturing and packaging equipment may reduce the viability of ODF 
technologies. In fact, several ODF products have been recalled from the market due to 
manufacturing issues and poor revenue (Buck and Health, 2013).  
1.1.2.4 Chewable formulations 
Chewable formulations (i.e. chewable tablets, soft-chews and chewing gum) are 
designed to be mechanically processed in the mouth to aid disintegration and/or 
dissolution of the API. These products offer administration advantages in that swallowing 
is aided (or avoided in the case of chewing gum) and water is not required. However, as 
in the case of ODTs, chewable products do not offer an advantage in terms of dose 
flexibility with respect to conventional tablets. The main advantages and limitations of 
chewable formulations are summarised in Table 1.5. 
Disintegration and swallowing of chewable dosage forms is aided by the patient by 
means of chewing and/or sucking. Taste and mouthfeel become critical attributes and 
thus a considerate decision should be made on the selection of excipients (Mishra et al., 
2009). Sugar-based fillers and sweeteners such as mannitol, sucrose and sorbitol are 
often used to improve palatability. A specific disadvantage of chewable products is their 
poor suitability for taste masking and controlled release by coating techniques, since the 
formulation is subjected to a great mechanical stress upon administration. In addition, 
the drug release process and thus the therapeutic effect is dependent on the patient’s 
chewing ability, which may result in intra- and inter-individual variability.  
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Table 1.5. Potential advantages and disadvantages of chewable formulations as a technology 
platform for the preparation of age-appropriate medicines for children. 
Product characteristic Advantages Disadvantages 
Efficacy/Acceptability   
Dosage  Various dosage strengths required 
Preparation Water is not required 
Swallowing is aided 
 
Compliance May be preferred over 
conventional formulations 
Controlled-release is challenging  
Taste masking is challenging 
Safety profile   
Bioavailability May be improved by quick 
disintegration and dissolution 
May be improved by buccal 
absorption 
Bioavailability may be altered 
depending on chewing ability 
Excipients  Excipients of unknown safety 
profile may be required 
Stability  Soft-chews may be problematic 
due to water content 
Medication error  Retention time in mouth may alter 
bioavailability 
Possible overdose if misused as 
confectionary 
Patient access   
Manufacturability  May need specialised equipment 
or accessories 
Affordability Manufacturing technology readily 
available 
 
 
Although available data suggest that chewable tablets are safe and well-tolerated in 
children from 2 years of age (Michele et al., 2002), the need for chewing of the dosage 
form may represent a limitation for the applicability of chewable formulations in neonates 
and elderly patients. In terms of medicated chewing gum, there is a lack of evidence 
about its safety in young children and current guidelines only recommend its use for 
children of 6 years or older (EMA, 2006). Besides, concerns have been raised about the 
possible misused of these products which may be appreciated by children as 
confectionery (EMA, 2006).  
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1.2 Formulation design and patient’s acceptability 
Selection of the most appropriate formulation design and excipients needs to be guided 
by a compendium of patient’s safety, manufacturability and end-user requirements. 
Attempts have been made to define the most appropriate formulation for each particular 
patient subgroup (EMA, 2006; Sam et al., 2012). However, given the paucity of evidence, 
these attempts have often been based on the opinions and experience of healthcare 
professionals rather than scientifically sound evidence of patient’s acceptability.  
Patient’s acceptability has been defined by the EMA as “the overall ability and willingness 
of the patient to use and its caregiver to administer the medicine as intended”, and it is 
influenced by the characteristics of the end-users (age, ability, disease type and state) 
and the characteristics of the medicinal product (EMA, 2013). The characteristics of the 
medicinal product that can play a role on patient’s acceptability include palatability (e.g. 
taste, smell and texture), swallowability (e.g. size and shape), appearance (e.g. colour, 
shape and embossing), complexity of modification prior to administration (if required), 
required dose (e.g. dosing volume for liquids or quantity for solids), required dosing 
frequency and duration of treatment, selected administration device (if any) and primary 
and secondary container closure system (Kozarewicz, 2014). 
Palatability is a key element of the medicinal product and often regarded as one of the 
main elements influencing acceptability of oral medicines (although not the only 
parameter that requires consideration). Palatability, as it relates to oral medicines, can 
be defined as “the overall appreciation of a medicine by organoleptic properties such as 
appearance, smell, taste, aftertaste and mouth-feel” (EMA, 2013). In particulate, taste, 
texture and dose volume have been identified as the main barriers to palatability and 
acceptability and most common reasons for manipulation of paediatric oral medicines 
(Venables et al., 2015). 
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Patient’s acceptability is the first step required to ensure patient’s adherence to a 
therapeutic regime. Previous research suggest that subject-reported attitudes towards 
taking a medication or to continue with a therapeutic regime are good predictors of 
patient adherence (Godin et al., 2005; Kreivi et al., 2014). Obviously, patients ‘not able’ 
and/or ‘not willing’ to take their medicines are not going to obtain any therapeutic benefit. 
As such, evaluation of palatability and patient’s acceptability should form an integral part 
of the pharmaceutical development studies and the Paediatric Investigational Plan (PIP), 
as recommended by the EMA (EMA, 2013). Selection of the most appropriate 
formulation design and excipients must be guided by evidence gathered in such studies. 
Patient’s acceptability must be considered at an early stage of the drug product 
development pathway rather than just tested on the final product. In this regard, in vitro 
tools and animal models offer opportunities to assess and predict organoleptic properties 
of APIs and/or formulations, even when toxicological data is not yet available (Mohamed-
Ahmed et al., 2016). Nevertheless, studies in human subjects remain the gold standard 
for palatability and acceptability testing. Some of the key considerations when conducting 
such in vivo studies are outlined below.  
1.2.1 Palatability and acceptability testing: methodological considerations 
Clinical Trials of Investigational Medicinal Products (CTIMPs) must adhere to the 
European Clinical Trials Directive (2001/20/EC), the Medicines for Human Use (Clinical 
Trials) Regulations 2004 and the Good Clinical Practice Directive (2005/28/EC). 
However, palatability and acceptability are not pharmacological effects, therefore the 
purpose of palatability and acceptability studies falls outside this definition and such tests 
are not classified as CTIMPs. Nonetheless, when a palatability study is nested within 
another clinical study it may be classified as a CTIMP (Batchelor et al., 2015). Although 
assessment of the palatability and patient acceptability would not be classified as CTIMP 
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in most cases, such studies would be subject to local research governance policies, e.g. 
Research Ethics Committees (Batchelor et al., 2015). 
Despite the requirement to evaluate palatability and patient’s acceptability of paediatric 
medicines as part of the PIP, there is limited guidance on how to perform such studies 
(Kozarewicz, 2014). Paradoxically, there is a guideline on the demonstration of 
palatability and acceptability of veterinary medicinal products, including study design, 
number of animal subjects required and selection of outcome measures (EMA, 2012), 
but similar guidance for studies in humans is not available. Interestingly, the food industry 
took the lead in investigating palatability and acceptability in human subjects and a range 
of Sensory Standards are available for the evaluation of food products (Mason and 
Nottingham, 2002). Specific guidance on the design of acceptability studies of food 
products in children can also be found in the literature (Guinard, 2000). Some of these 
standards for food evaluation might be applicable to testing of pharmaceuticals, although 
caution is advised when transferring knowledge between both fields given the potential 
differences in objectives and endpoints. 
Due to the lack of standardise methodology, a variety of study designs and assessment 
tools have been used in the evaluation of palatability and acceptability of drug products. 
Such tools include visual analogue scales (VAS), hedonic scales, Likert-type scales, rank 
order assessment and verbal descriptive responses, used solely or in combination 
(Davies and Tuleu, 2008; Mistry and Batchelor, 2017; Squires et al., 2013). Other 
outcome measures employed in previous research include observations of facial 
expressions during administration, ability to swallow the dosage form, prevalence of 
complaints or refusal to take the medicine, time taken to administer the medicine and 
willingness to use or take the medicine again (Mistry and Batchelor, 2017). Proxy-
reported outcomes and assistance provided by parents or caregivers were common in 
studies with younger children (Squires et al., 2013).  
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As recommended by the EMA, palatability and acceptability studies should be carried 
out in the target population age group, since sensory perception, swallowing function 
and cognitive abilities will vary with age and developmental stage (EMA, 2013). 
Differences in patient acceptability, attitudes and preferences for different dosage form 
designs as a function of age is a matter that is not well understood; although differences 
can be expected even within children of different ages, as supported by a recent study 
(Ranmal et al., 2016). Despite the acknowledged differences between patient groups, 
paediatric drug development still relies vastly on adults’ data, given the ethical and 
practical barriers of conducting studies in children. Nevertheless, pilot studies in adults 
can provide valuable information, not only to improve the formulation but also to optimise 
the study design and outcome measures of palatability and acceptability. 
Palatability and acceptability testing can be carried out in patients or in healthy 
volunteers. Studies with patients are often nested to a clinical trial (where acceptability 
measures are recorded as a secondary outcome), e.g. (Guffon et al., 2012; Musiime et 
al., 2014); whereas studies with healthy participants are purposely designed with the 
primary objective to measure palatability and acceptability, e.g. (Ameen et al., 2006). 
Traditionally, acceptability and adherence were measured simultaneously in clinical trials 
by merely counting the number of doses not taken by the patient, although this practice 
provides very limited information about the causes for refusal. More recently, a few 
clinical trials have used more specific measures of acceptability, such as hedonic scales, 
VAS scales and other tools discussed before, e.g. (Cohen et al., 2009; Musiime et al., 
2014; Nasrin et al., 2005). Similarly, acceptability studies in healthy participants tend to 
use specific evaluation tools, since this is the primary objective of such studies. 
In terms of the characteristics of the formulation, acceptability studies can be carried out 
using drug-loaded formulations or placebo. Exploratory studies using placebo aim to 
obtain fundamental understanding of acceptability and preference for different dosage 
form designs. For example, to determine acceptability of mini-tablets in young children, 
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e.g. (Klingmann et al., 2013; Spomer et al., 2012). On the contrary, studies with drug-
loaded samples aim to obtain specific information about a formulation of interest. For 
example, to establish the efficiency of different taste-masking strategies to conceal the 
taste of a certain API, e.g. (Liew et al., 2014; Mishra et al., 2009; Preis et al., 2015). 
Palatability is regarded as the most important determinant of acceptability (especially for 
liquid and dispersible formulations) and, as such, some studies have focussed on the 
evaluation of palatability as a surrogate of patient acceptability. In these studies, the swirl 
and spit methodology is often employed, whereby participants place the formulation in 
their mouth for a short time and then spit it out without swallowing it. This approach is 
useful to minimise the risk of adverse reactions, although it is limited in its resemblance 
of the real use of a drug product. Individuals participating in taste panels can be untrained 
or, alternatively, trained panellists (i.e. experts trained to distinguish specific palatability 
attributes and their intensity). The benefit of trained panellists is that they can provide 
better discrimination between samples (Mason and Nottingham, 2002). However, 
research suggests that untrained panellists can provide the same level of discrimination 
as trained panellists when the number of subjects in the former is sufficiently large 
(Husson and Pages, 2003; Mason and Nottingham, 2002). 
The number of test samples that can be evaluated in a single study will vary depending 
on the study design, methodology and population. Studies nested to a clinical trial often 
focus on one or two formulations only, whereas palatability and acceptability studies in 
healthy volunteers usually investigate several formulations at a time. In such cases, it 
will be appropriate to test a larger number of samples using a swirl and spit methodology 
than if samples are required to be swallowed. In general terms, the number of samples 
should always be kept to a minimum to minimise discomfort and fatigue and maintain 
participants’ motivation (Mason and Nottingham, 2002); this is particularly important for 
studies involving children participants. 
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1.3 Evidence of acceptability of flexible solid dosage forms 
During the past decade, evidence on the evaluation of palatability and acceptability of 
different dosage form designs have been extensively reviewed (Davies and Tuleu, 2008; 
Drumond et al., 2017; Liu et al., 2014; Mistry and Batchelor, 2017; Ranmal, 2014; 
Squires et al., 2013; Thompson et al., 2013; van Riet-Nales et al., 2010). All previous 
reviews coincide that there is very limited evidence on patient’s acceptability of different 
dosage form designs in peer-reviewed journals. Evidence of acceptability of flexible solid 
dosage forms (i.e. multiparticulates, orodispersible tablets, orodispersible films and 
chewable tablets) is particularly important given the potential of these formulations for 
children, although especially limited given the novelty of these technology platforms. 
Although recent reviews in the field exist, it was deemed appropriate to perform a 
literature review to fill in the gaps of previous reviews. For example, Drumond et al. and, 
previously, Van Riet-Nales et al. focussed on comparative studies which included two or 
more different dosage form designs (Drumond et al., 2017; van Riet-Nales et al., 2010); 
however, studies of palatability and acceptability of a single dosage form might also 
provide illustrative information about patient acceptability. In addition, the systematic 
review by Liu and co-workers and Squires and colleagues were directed toward special 
populations (such as paediatrics and geriatrics), excluding studies in adults (Liu et al., 
2015; Squires et al., 2013); although valuable information can be found in adult trials, for 
example regarding outcome measures and evaluation tools employed. 
A semi-systematic literature review of the evidence of acceptability of flexible solid 
dosage forms was carried out, which included a systematic literature review of Embase, 
Medline and PubMed databases (January 2011 to April 2017), plus a review of the 
primary references included in previous systematic literature reviews, including studies 
since 1990 (Drumond et al., 2017; Liu et al., 2014; Ranmal, 2014; Squires et al., 2013; 
van Riet-Nales et al., 2010).  
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A systematic review of the literature on acceptability of flexible solid dosage forms was 
conducted using the key words shown in Table 1.6. The search was combined with 
Boolean operators (“AND”), using any of the search terms shown in Table 1.6 (“OR”). 
The search obtained 496 hits which were thoroughly screened. 
Table 1.6. Search terms for systematic literature review of Embase, Medline and PubMed. 
 
In addition, primary references included in previous literature reviews of the research 
field were also screened (Drumond et al., 2017; Liu et al., 2014; Ranmal, 2014; Squires 
et al., 2013; van Riet-Nales et al., 2010). These reviews comprised a total of 89 records 
(excluding duplicate studies). 
Screened studies were selected for full review based on the following inclusion criteria:  
(1) assessment of one or more oral flexible solid dosage form, such as multiparticulates 
(i.e. pellets/coated-granules/mini-tablets administered in multiplicity), (oro)dispersible 
tablets (including orodispersible, dispersible and effervescent tablets), orodispersible 
films, and chewable formulations;  
(2) reported one or more outcome(s) of palatability, swallowability, patient’s acceptability, 
satisfaction or preference;  
(3) compared outcomes between formulations (e.g. flexible solid dosage form versus 
conventional formulation) or investigated a single formulation (no comparator); and 
(4) were carried out on a population larger than 10 subjects.  
Keywords  Synonyms 
Population Subject, volunteer, children, infant, paediatric, adolescent, adult, elderly, geriatric 
Formulation Granule, sprinkle, pellet, bead, fast-dis*, rapidly-dis*, *dispersible, mini-tablet 
Assessment Accept*, swallow*, palatability, satisfaction, preference 
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Articles were excluded based on the following exclusion criteria: 
(1) studies not related to oral flexible solid dosage forms (e.g. studies of conventional 
tablets or capsules, studies of formulations not related to the oral route etc.); and 
(2) methodological information was insufficient to interpret acceptability results. 
The identification and selection process of articles for this semi-systematic literature 
review is depicted in Figure 1.1. 
 
Figure 1.1. Flow-chart illustrating selection process for inclusion in the semi-systematic review. 
1.3.1 Results of a semi-systematic literature review 
1.3.1.1 Multiparticulates formulations 
This review combined studies of mini-tablets as well as pellets or coated granules within 
the scope of multiparticulate formulations. Evidence about products labelled for ‘sprinkle’ 
(i.e. indicated to be co-administered with food or drinks) was only considered relevant 
when an indication was given that the dosage form was coated or taste-masked (i.e. 
powders or granules for oral solution/suspension were not considered multiparticulates). 
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Similarly, minitablets were only considered relevant to this section when administered in 
multiplicity (i.e. studies relating to the administration of a single minitablet were not 
included). Evidence of acceptability of multiparticulate dosage forms in children and 
adults’ populations is summarised in Table 1.7. 
Several studies have investigated palatability and acceptability of multiparticulates in 
children. Saez-Llorens and co-workers performed two studies in children (1-12 years) 
receiving famciclovir sprinkles dispersed in 5 mL of Ora-Sweet, a single-dose study (51 
subjects) and a multi-dose study (100 subjects); children and their caregivers rated the 
formulation as ‘well’ or ‘very well’ accepted in 56.6% of occasions (Saez-Llorens et al., 
2009). Zannikos et al. investigated raveprazol coated beads dispersed in 10 ml of 
strawberry flavour vehicle in children (1-11 years) and found the formulation to be broadly 
acceptable, with 85.1% of caregivers reporting ‘good’ to ‘excellent’ palatability and ease 
of swallowing (Zannikos et al., 2011). Similarly, van de Vijver and colleagues evaluated 
ease of swallowing of pancreatin coated mini-tablets in 16 children (0.5-3 years) and 
found swallowing to be ‘fair’ to ‘good’, although limited conclusions regarding overall 
acceptability were reached by the authors (Van de Vijver et al., 2011). 
A recent exploratory study with placebo mini-tablets in children volunteers indicated that 
2-year-old and 3-year-old children could swallow up to 10 mini-tablets dispersed in a 
starch-based jelly in 75% and 93% of occasions respectively (Kluk et al., 2015). The 
sequential study designed involved certain training of children, since participants were 
presented with the jelly formulation first (containing no solids), followed by one 2-mm 
mini-tablet, ten 2-mm mini-tablets, one 3-mm mini-tablet and, finally, ten 3-mm mini-
tablets, during five consecutive days (mini-tablets dispersed in jelly in all cases). These 
findings served as a confirmation of the suitability of solid formulations in pre-school age 
children, after a few studies showing acceptance of a single mini-tablet (Spomer et al., 
2012; Thomson et al., 2009), and even favourable acceptance over syrups (Klingmann 
et al., 2013; van Riet-Nales et al., 2013, 2015).
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Table 1.7. Evidence of acceptability of multiparticulate formulations (i.e. coated pellets/granules and mini-tablets administered in multiplicity).  
Population Dosage form Assessment tool(s) Summary of outcome(s) References 
Children     
Children, N=16 
(0.5-3 years) 
Coated mini-tablets 
(pancreatin, 2 mm) 
Caregiver reported ease of swallowing [4-point 
Likert-type scale]; no comparator 
Ease of swallowing varied from ‘poor’ to 
‘excellent’, being ‘fair’ to ‘good’ on average 
(Van de Vijver et 
al., 2011) 
Children, N=27 
(1-11 years) 
Coated beads 
(rabeprazole, 470 µm) 
Caregiver reported palatability [4-point Likert-type 
scale]; no comparator 
Most parents found palatability to be good 
(40.7%) or excellent (44.4%) 
(Zannikos et al., 
2011) 
Children, N=151 
(1-12 years) 
Sprinkles 
(famciclovir) 
Subject reported (> 5 years) and caregiver 
reported (< 5 years) taste and acceptability [5-
point hedonic scale]; no comparator 
Taste of sprinkles dispersed in OraSweet was 
rated mostly neutral (53.2%) and were ‘well’ or 
‘very well’ accepted by 56.6% 
(Saez-Llorens et 
al., 2009) 
Children, N=60 
(2-4 years) 
Mini-tablets 
(placebo, 2-3 mm) 
Researcher observation of formulation intake [5-
point criteria]; single versus 10 mini-tablets at a 
time and 2-mm versus 3-mm mini-tablets 
[sequential design]   
Most children (75% of 2 years and 93% of 3 
years) swallowed 10 mini-tablets dispersed in 
starch-based jelly; chewing reflect increased with 
amount and size of the mini-tablets 
(Kluk et al., 2015) 
Children, N=77 
(3-13 years) 
Minitab (pellet) sprinkles 
(lopinavir/ritonavir) 
Caregiver reported acceptability (issues with 
administration); compared to syrup (<4 years, 
N=45) and to conventional tablets (>4 years, 
N=32) [crossover design] 
Administration issues were more common with 
syrups than minitabs but more common with 
minitabs than tablets; taste was similar for syrup 
and minitabs, both worse than tablets  
(Kekitiinwa et al., 
2016; Musiime et 
al., 2014) 
Children, N=15 
Adults, N=5 
(4-64 years) 
Taste-masked granules 
(phenylbutyrate) 
Subject reported bitterness and acceptability 
[100-mm VAS]; compared to other medication if 
taken previously (N=14 children) [sequential 
design] 
Reduced bitterness score (11.6 versus 55.2%) 
and higher acceptability (85.1 versus 17.7%) of 
taste-masked granules; 10 out of 14 subjects 
preferred granules compared to other forms 
(Kibleur et al., 
2014) 
Children, N=108 
(6.7±3.6 years) 
Sprinkle microspheres 
(valproate) 
Subject reported palatability (children > 4 years, 
N=53) [5-point hedonic scale] and caregiver 
reported ease of use; compared to liquid taken 
previously [sequential design] 
Palatability of sprinkles (3.83) was significantly 
higher than solution (2.09) and administration 
issues were significantly lower with sprinkles 
(15.7%) than liquid (68.5%) 
(Verrotti et al., 
2012) 
Children, N=40 
(0.5-3 years) 
Microgranules  
(pancreatin) 
Caregiver reported preference; smaller granules 
in multi-dose container with measuring spoon 
compared to larger granules in capsule 
[crossover design] 
Preference for multiparticulates in multi-dose 
container over capsule (51% versus 23%), due to 
practicability; effect of granule size on preference 
was not reported 
(Munck et al., 
2009) 
Children, N=150 
(5-7 months) 
Taste-masked sprinkles 
(iron supplement) 
Caregiver reported adherence and satisfaction; 
compared to oral drops [parallel design] 
Higher willingness to use sprinkles again (80%) 
than drops (69%) 
(Geltman et al., 
2009) 
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Table 1.7. (Continued). 
Children, N=98 
(0.5-1 year) 
Sprinkles 
(iron supplement) 
Caregiver reported ease of use and acceptability; 
compared to crushed tablets and spreadable lipid 
formulation [parallel design] 
Sprinkle was reported as ‘easy giving’ (96.9%) 
and ‘child accepted’ (89.6%); acceptability was 
comparable between formulations 
(Adu-Afarwuah et 
al., 2008) 
Children, N=302 
(2-14 years) 
Coated microgranules  
(valproate, <400 µm) 
Subject reported acceptability [2 to 4-point 
hedonic scale] and caregiver reported ease of 
use; compared to liquid if taken previously 
(N=199) [sequential design]  
Microgranules were well accepted (≈80% positive 
hedonic response), but 20% of carers reported 
administration issues; microgranules were 
preferred over liquid 
(Motte et al., 
2005) 
Children, N>490 
(0.5-2 years) 
Coated sprinkles 
(iron supplement) 
Caregiver reported adherence and ease of use; 
compared to oral drops [parallel design] 
Preference for sprinkles – Only 6-16% of children 
objected to take sprinkles versus 74-93% who 
objected to take drops 
(Zlotkin et al., 
2003, 2001) 
Children, N=12 
(5-16 years) 
Coated sprinkles 
(valproate) 
Subject and caregiver reported preference; 
compared to syrup [crossover design] 
Sprinkle formulation was preferred based on 
palatability and ease of administration  
(Cloyd et al., 
1992) 
Adults     
Adults, N=18 
(22.5±1.0 years) 
Mini-tablets 
(placebo, 3 mm) 
Subject reported ease of taking dosage form 
[VAS scale]; compared to ODMT, ODT and 
conventional tablet [direct comparison] 
Ease of taking 2 mini-tablets was considered 
better than a conventional tablet, but ease of 
taking 5 or 10 mini-tablets at a time was 
considered similar to a conventional tablet 
(Hayakawa et al., 
2016) 
Adults, N=30 
(20-25 years) 
Pellets 
(placebo, 90-263 µm) 
Subject reported oral grittiness [VAS scale] and 
preferred formulation; comparison between 
various pellet sizes and amounts and media 
viscosity [direct comparison] 
Grittiness perception increased as the size and 
amount of multiparticulates increased and as the 
viscosity decreased; very viscous media was less 
preferred despite reducing grittiness  
(Lopez et al., 
2016) 
Adults, N=15 
(23.0±2.6 years) 
Spherical granules 
(placebo, 250-850 µm) 
Subject reported feeling of roughness and total 
palatability [VAS score]; comparison between 
various particle sizes [direct comparison] 
Rough mouth-feel increased with increasing size 
of multiparticulates. A 244 µm threshold was 
proposed to minimise rough mouth-feel 
(Kimura et al., 
2015) 
Adults, N=21  
(23-55 years) 
Mini-tablets and pellets  
(placebo, 2-3 mm) 
(placebo, 250-850 µm) 
Subject reported oral perceptibility [4-point VAS 
scale] and researcher reported ease of 
dispersion; comparison between media of varying 
viscosity [direct comparison] 
Multiparticulates were more perceptible as size 
increased. Gels with medium viscosity performed 
best at dispersing and reducing oral perceptibility 
of multiparticulates 
(Kluk and 
Sznitowska, 
2014) 
Adults, N=13 
(19-50 years) 
Coated microgranules 
(phenylbutyrate) 
Subject reported bitterness, saltiness, sweetness 
and acceptability [100-mm VAS]; compared to 
uncoated granules [direct comparison] 
Uncoated granules were significantly more bitter 
and salty and were less acceptable than coated 
granules (42.1 versus 78.8%, respectively) 
(Guffon et al., 
2012) 
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Other studies have focussed on preference of multiparticulates over other dosage form 
designs, rather than acceptability per se. Studies comparing multiparticulates to liquid 
dosage forms in children have commonly showed preference for the solid over the liquid 
form. For example, a range of studies showed acceptance of iron supplement sprinkles 
and preference for these compared to oral drops in children with anaemia (Adu-Afarwuah 
et al., 2008; Geltman et al., 2009; Zlotkin et al., 2003, 2001). Likewise, three studies 
involving children suffering from epilepsy consistently showed preference for sprinkle 
formulations over syrup (Cloyd et al., 1992; Motte et al., 2005; Verrotti et al., 2012). 
Taste-masking of the poorly palatable drug was often reported as the key attribute which 
determined patients’ and caregivers’ preferences for sprinkles. 
In a recent study, children showed preference for sprinkles over syrup after 12-week 
antiretroviral therapy; 72% of children below 12 months and 64% of children between 1 
and 4 years preferred the multiparticulate dosage form (Kekitiinwa et al., 2016; Musiime 
et al., 2014). For those preferring syrups, key issues with pellets were problems masking 
the pellets with food and food refusal, and concerns about not giving the whole dose. 
However, multiparticulates overcome the storing and transporting issues of syrups, 
which was an advantage for caregivers. Similar outcomes were shown for children on 
antiretroviral therapy who swapped from syrup to scored-tablets at a median age: 2.9 
years, their caregivers showing preference for the solid form based on convenience, e.g. 
less transportation issues and easier dosing (Nahirya-Ntege et al., 2012). 
The study by Kibleur and co-workers, which evaluated palatability and acceptability of 
phenylbutyrate coated-granules, highlighted the importance of taste-masking as a key 
advantage of multiparticulates (Kibleur et al., 2014). When subjects had prior experience 
with a different formulation of the same drug (14 out of 25 subjects), they were asked to 
report their preference, results showing that 10 out of 14 subjects preferred the 
multiparticulate form. Four additional subjects, which were not under phenylbutyrate 
treatment due to the impossibility to take the marketed formulation, also reported better 
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acceptance of the coated granules. Vomiting and taste disturbances (dysgeusia), which 
are described as ‘frequent’ in the SmPC of marketed phenylbutyrate products, were not 
reported with the new formulation (Kibleur et al., 2014). This study was supported by a 
previous trial in children and adults which indicated reduced saltiness and bitterness and 
improved acceptance with the taste-masked formulation (Guffon et al., 2012). 
Munck et al. (2009) evaluated caregivers’ preferences for two different presentations of 
pancreatin sprinkles, a multi-dose bottle with a measuring spoon versus single-dose 
capsules which needs to be opened to measure the dose and administer the contents. 
Caregiver’s reported preference for the multi-dose container presentation (51%, with 
26% showing no preference for either formulation), giving reasons of ‘practicability’ and 
‘fewer symptoms’ (which could potentially be ascribed to better control over dose titration 
using the measuring spoon provided with the multi-dose container). The authors reported 
that the multi-dose presentation contained microgranules of smaller size than the 
capsules, although no reference to the effect of particle size on acceptability was 
provided in their manuscript (Munck et al., 2009). 
In most of the studies in children, multiparticulates are co-administered with foodstuff. 
Usually, caregivers were given the opportunity to decide between a range of liquid or 
semi-solid foodstuff, which included milk, jam, yogurt and porridge, e.g. (Adu-Afarwuah 
et al., 2008; Kekitiinwa et al., 2016; Verrotti et al., 2012). In two studies, multiparticulates 
were given in a small volume (5-10 ml) of a sweetened or flavoured pharmaceutical 
vehicle (Saez-Llorens et al., 2009; Zannikos et al., 2011). Only two studies reported 
direct administration of multiparticulates: Klibeur et al. (2014) reported direct intake of 
taste-masked granules (N=25), whereas Adu-Afarwuah et al. (2008) reported that just 3-
4% of parents (out of 98) followed this practice when given freedom to administer iron 
sprinkles as desired. Association between the administration vehicle and patients’ 
acceptability was not explored in any of these studies.  
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Multiparticulates are often designed as a paediatric formulation and, as such, most 
studies have evaluated acceptability of multiparticulates in children. However, a few 
studies of multiparticulates in adult populations were also identified. Exploratory trials 
with placebo multiparticulates in healthy adults include that of Hayakawa et al. (2016), 
who investigated the ease of taking mini-tablets compared to conventional tablets, ODTs 
and oro-dispersible mini-tablets (ODMT) in 18 healthy adults. Results indicated that a 
single mini-tablet, ODMT or ODT was significantly easier to take than a conventional 
tablet. However, administration of 5 and 10 mini-tablets at a time obtained similar ratings 
for ‘ease of taking’ than the conventional tablet (n.b. the total weight of 10 mini-tablets 
was equivalent to that of a conventional tablet). The administration of several ODMTs at 
a time was not investigated in this study.  
Kimura et al. investigated palatability of placebo multiparticulates in healthy adult 
volunteers, with focus on rough mouthfeel. Four different multiparticulate sizes were 
investigated within the range of 250-850 µm (at a fixed amount of 75 mg) using a swirl 
and spit methodology. The authors concluded that rough mouth-feel increased with 
increasing size of the multiparticulates and proposed a maximum threshold of 244 µm to 
minimise rough mouthfeel. However, the experience of roughness with particles of larger 
size was reported to be ‘tolerable’ (Kimura et al., 2015). 
Two other placebo exploratory studies in adult populations were identified, which 
investigated the effect of different administration media on perception of multiparticulates 
in the mouth using a swirl and spit methodology. Kluk and Sznitowska investigated the 
applicability of oral hydrogels (prepared to different viscosity levels) as media for the 
administration of pellets and mini-tablets (Kluk and Sznitowska, 2014). Participants 
reported reduced feeling of solids in the mouth with vehicles of higher viscosity. Similarly, 
a previous study by our research team investigated oral grittiness of placebo pellets 
dispersed in HPMC hydrogels at different viscosity levels, concluding that increasing 
viscosity of the media helped reducing oral grittiness perception (Lopez et al., 2016).  
 48 
1.3.1.2 (Oro)dispersible tablets 
This section includes tablets designed to be dispersed in a suitable vehicle before 
administration (e.g. dispersible and effervescence tablets) as well as tablets intended to 
be dispersed directly in the mouth (e.g. orodispersible and sublingual tablets). Only eight 
studies in children were identified, whereas twice as many studies were found and 
reviewed in adults. Based on the needs of the target population, most studies in children 
have focussed on the evaluation of dispersible tablets, as opposed to studies in adults 
which mainly focussed on orodispersible tablets (Table 1.8).  
Several studies investigated dispersible tablets in children, consistently supporting 
acceptability of this dosage form design, even in neonates (Nasrin et al., 2005; Ogutu et 
al., 2014; Winch et al., 2006). A few studies also showed preference of dispersible tablets 
over other paediatric formulations, such as syrups (Ameen et al., 2006; Nasrin et al., 
2005; Ogutu et al., 2014). In a study of two Fixed Dose Combination (FDC) antimalarial 
dispersible tablets, 67 and 82% of caregivers  found the two formulations ‘simple’ or ‘very 
simple’ to use, respectively, and a similar proportion preferred them over syrups (Ogutu 
et al., 2014). Difference in acceptability between the two dispersible tablets could be 
attributed to difference in taste between both formulations, which were ‘liked’ or ‘very 
much liked’ by 56 and 72% of participants, respectively.  
Acceptability of ODTs have only been evaluated in children older than 5 years. Three 
studies were identified showing excellent acceptance of ODTs with 100% successful 
intake (Cohen et al., 2005), preference over syrup (based on patients attitudes, as syrup 
was not included as comparator) (Tolia et al., 2005) and preference over conventional 
tablets (Lottmann et al., 2007). Interestingly, Lottman and co-workers showed preference 
for dispersible over conventional tablets in children below 12 years, but the opposite 
behaviour in children over 12 years, in a cohort of 210 children on nocturnal enuresis 
treatment (Lottmann et al., 2007). This was supported by a study investigating end-user 
perceptions and preferences for different dosage forms (Ranmal et al., 2016).
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Table 1.8. Evidence of acceptability of (oro)dispersible tablet formulations (i.e. dispersible, effervescence, orodispersible and sublingual tablets). 
Population Dosage form Assessment tool Summary of outcomes References 
Children     
Children, N=123 
(0-5 years) 
Dispersible tablet 
(zinc supplement) 
Caregiver reported administration issues and 
adherence; no comparator 
Almost 90 % of children accepted the 10-day 
course of treatment and only 6.5% of caregivers 
reported administration issues  
(Winch et al., 
2006) 
Children, N=303 
(0.25-5 years) 
Dispersible tablet 
(zinc supplement) 
Caregiver reported acceptability and adherence; 
no comparator 
DTs were reported equal or more acceptable 
than other medicines by 93.1% and 83.5% were 
willing to use it again 
(Nasrin et al., 
2005) 
Children, N=210 
(2-8 years) 
Dispersible tablet 
(roxithromycin) 
Caregiver reported acceptability based on 
intake/refusal and ease of use; no comparator 
DT was found to be convenient by 76% of 
caregivers; only 8 children refused medication 
(due to taste or vomiting) 
(Moniot-Ville et 
al., 1998) 
Children, N=250 
(0.5-5 years) 
Dispersible tablet 
(antimalarial FDCs) 
Caregiver reported acceptability and ease of use; 
two fixed-dose combination (FDC) products 
compared [parallel design] 
Caregivers considered DTs simple to use (82%, 
67%), reported good palatability (72%, 56%) and 
preferred DTs over syrup (76.8%, 62.3%) for both 
FDC products 
(Ogutu et al., 
2014) 
Children, N=102 
(4-8 years) 
Effervescent tablet 
(ranitidine) 
Subject reported taste preference and caregiver 
reported willingness to use; compared to syrup 
[crossover design] 
Most children (71%) preferred taste of the (citrus) 
effervescent tablet over the (peppermint) syrup; 
most caregivers (71%) would prefer the tablet  
(Ameen et al., 
2006) 
Children, N=210 
(5-15 years) 
Sublingual lyophilisate 
(desmopressin) 
Subject/caregiver reported ease of use [VAS 
scale] and subject reported preference; 
compared to conventional tablet [crossover 
design] 
Children below 12 years preferred ODT whereas 
children over 12 years preferred conventional 
tablet; ease of use was comparable with both 
formulations 
(Lottmann et al., 
2007) 
     
Children, N=104 
(6-11 years) 
Orodispersible tablet 
(lansoprazole) 
Subject reported degree of liking [5-point hedonic 
scale] and preference; compared to syrup 
[parallel design] 
The proportion of children who liked the syrup 
was lower than the proportion who liked the ODT; 
(strawberry) ODT was preferred over 
(peppermint) syrup by 92% 
(Tolia et al., 
2005) 
Children, N=62 
(5-11 years) 
Orodispersible tablet 
(ondansetron) 
Subject reported taste sensation and willingness 
to take medication again; compared to placebo 
ODT [parallel design] 
ODT was taken by 100% of participants; only 4 of 
31 would not want to use it in the future; the taste 
of drug-loaded ODT was scored lower than that 
of the placebo 
(Cohen et al., 
2005) 
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Table 1.8. (Continued). 
Adults     
Adults, N=150 
(18-80 years) 
Orodispersible tablet 
(placebo) 
Subject reported attitudes/preferences; towards 
dosage forms; no comparator 
Patients on oral antidepressants expressed 
preference for ODTs (84%) over other dosage 
forms and stated they would be more likely to take 
this type of tablet every day (75.4%) 
(Wade et al., 
2012) 
Adults, N=228 
(> 18 years) 
Orodispersible tablet 
(amlodipine) 
Subject reported palatability (including ease of 
ingestion) [interview]; no comparator 
Most patients reported ODT as easy to ingest 
(99.6%) due to ‘quick dissolution’, ‘not being rough 
in the mouth’ and having a ‘good taste’ 
(Fukui-Soubou 
et al., 2011) 
Adults, N=687 
(52.4±14.6 years) 
Orodispersible tablet 
(mirtazapine) 
Subject reported acceptability of ODT design; 
no comparator 
Most patients (80%) accepted the ODT formulation 
based on easy opening, choice of tablet, taste, 
texture and ease of use 
(Danileviciute et 
al., 2009) 
Adults, N=64 
(18-55 years) 
Orodispersible tablet 
(olanzapine) 
Subject reported impressions [7-point Likert-
type scale] and caregiver reported attitudes 
toward medication and compliance [5-point 
Likert-type scale]; no comparator 
Impressions about the medication showed positive 
acceptance, with scores improving over a 6-week 
assessment period 
(Kinon et al., 
2003) 
Adults, N=76 
(39.7±13.1 years) 
Orodispersible tablet 
(budesonide or placebo) 
Subject reported acceptance of taste, handling 
and administration time and formulation 
preference [interview]; compared to viscous 
suspension [parallel design] 
Patients preferred the effervescent tablet for oral 
dispersion over the viscous suspension (80% 
versus 17%); no data was reported about taste or 
ease of use 
(Miehlke et al., 
2017) 
Adults, N=524 
(35.6±11.3 years) 
Sublingual tablet 
(buprenorphine/naloxone) 
Subject reported preference in terms of taste, 
mouthfeel, ease of administration and overall 
preference; compared to oral thin film 
[crossover design] 
Patients favoured the sublingual tablet for taste 
(77.5%), mouthfeel (72.6%), ease of taking 
(71.5%), and overall preference (70.2%) 
(Gunderson and 
Sumner, 2016) 
Adults, N=30 
(18-63 years) 
Oral lyophilisate 
(cetirizine) 
Subject reported palatability (taste, sweetness, 
bitterness, mouthfeel, aftertaste, disintegration 
and overall acceptability) [hedonic and JAR 
scales]; low versus high levels of flavouring 
agents [direct comparison] 
Effective taste-masking, with at least 80% 
acceptance, was achieved with β-cyclodextrin and 
cherry/sucralose flavour; no difference in 
preference between low and high flavour levels 
(53.3% versus 46.7%, respectively) 
(Preis et al., 
2015) 
Adults, N=16 
(22-55 years) 
Orodispersible tablet 
(donepezil) 
Subject reported taste, after taste, mouth feel, 
ease of handling and acceptance [5-point Likert-
type scale]; comparison between various types 
of fillers [direct comparison] 
The bitter taste of the drug was masked using 
ammonium glycyrrhizinate; most palatable ODT 
was prepared using co-processed lactose/starch 
(85/15) as filler  
(Liew et al., 
2014) 
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Table 1.8. (Continued). 
Adults, N=89 
(41.0±12.1) 
Orodispersible tablet 
(lamotrigine) 
Subject/caregiver reported ease of use [7-point 
Likert-type scale]; compared to conventional 
tablets taken previously [sequential design] 
Preference for ODT; ODT considered to be 
extremely easy to use in 49% occasions 
compared to 3% for the conventional tablet 
(Sajatovic et al., 
2013) 
Adults, N=175 
(35.3±11.1 years) 
Orodispersible tablet 
(olanzapine) 
Patient reported preference; compared to 
conventional tablet [crossover design] 
ODT (61%) over conventional tablet (27%), but 
preference shift towards the dosage form taken 
lastly in the crossover design 
(Bitter et al., 
2010) 
Adults, N=35 
(18-65 years) 
Orodispersible tablet 
(zolmitriptan) 
Subject reported degree of liking [5-point Likert-
type scale]; compared to conventional tablet and 
nasal spray [mixed design] 
Patients preferred the ODT (42.9%) and nasal 
spray (40.0%), due to convenience and rapid 
onset, over the conventional tablet (17.1%)  
(Dowson et al., 
2007) 
Adults, N=36 
(64.5±11.8 years) 
Orodispersible tablet 
(placebo, 340 mg) 
Subject reported ease of swallowing [5-point 
Likert-type scale]; compared to conventional 
tablet [crossover design] 
Dysphagic patients (>75%) found ODTs easier to 
swallow than conventional tablets; greater 
proportion reported concern swallowing tablets 
compared to ODT (42% versus 25%)  
(Carnaby-Mann 
and Crary, 
2005) 
Adults, N=61 
(71.8±8.3 years) 
Orodispersible tablet 
(levodopa/carbidopa) 
Subject reported preference; compared to 
conventional tablets taken previously [sequential 
design] 
Preference for ODT over conventional tablet (45% 
versus 20%, with 35% showing no preference), 
due to ease and speed of use and reduced 
concern about swallowing 
(Nausieda et al., 
2005) 
Adults, N=365 
(52±12 years) 
Orodispersible tablet 
(ondansetron) 
Subject reported taste acceptability; compared to 
conventional tablet [parallel design] 
The taste of ODT was acceptable to most patients 
(89%) who received it 
(Davidson et al., 
1999) 
Adults, N=27 
(30±9.2 years) 
Sublingual tablet 
(buprenorphine/naloxone) 
Subject reported, acceptability, taste, mouthfeel 
and ease of administration [100-mm VAS 
scales], after-taste [4-point Likert-type scale] and 
preference; compared to oral thin film 
[crossover] 
The new formulation received higher VAS ratings 
for taste, mouthfeel and overall acceptability and a 
lower proportion of subjects reported unpleasant 
aftertaste; 88.9% preferred the new formulation 
(Fischer et al., 
2015) 
Adults, N=53 
(36±11.2 years) 
Sublingual tablet 
(buprenorphine/naloxone) 
Subject reported taste and overall formulation 
experience (disregarding effects/side effects) 
[10-point Likert-type scale] and preference; 
compared to marketed sublingual tablet 
[crossover] 
The new formulation (containing sucralose and 
menthol to mask the bitter taste) received 
significantly higher ratings for taste and 
acceptability and was preferred over commercial 
tablet (77.4%)  
(Fischer et al., 
2015) 
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In line with the findings in children, a range of studies in adults have shown preference 
for ODTs compared to other dosage forms, including oral suspension (Miehlke et al., 
2017), orodispersible films (Fischer et al., 2015; Gunderson and Sumner, 2016) and 
conventional tablets (Bitter et al., 2010; Carnaby-Mann and Crary, 2005; Nausieda et al., 
2005; Sajatovic et al., 2013). Reasons for acceptance and preference of ODTs included 
ease and speed of use, rapid onset of action and ease of swallowing (Danileviciute et 
al., 2009; Dowson et al., 2007; Nausieda et al., 2005). Based on the ease of swallowing, 
ODTs might be particularly suitable for patients with swallowing difficulties. In this regard, 
75% of 36 dysphagic patients preferred ODTs over conventional tablets because the 
former were easier to swallow (Carnaby-Mann and Crary, 2005), as supported by a 
previous study with dysphagic patients (Bayer et al., 1988).  
Appropriate taste is a critical attribute of orodispersible tablets however technologically 
challenging to achieve. In the study by Cohen and colleagues in children 5-11 years, 
placebo ODTs demonstrated better taste than ondansetron ODTs, suggesting taste-
masking was only partially achieved (Cohen et al., 2005); which is supported by a 
previous study of ondansetron ODTs in adults (Davidson et al., 1999). On the contrary, 
amlodipine ODTs palatability was reported to be appropriate by 99.6% of 228 adult 
patients in open-ended interviews with doctors (Fukui-Soubou et al., 2011). Differences 
in outcome measures and, particularly, differences between taste of the two APIs would 
explain these contradictory findings. Indubitably, some APIs will be more challenging to 
taste-mask due to their inherent strong taste; however, selection of the most appropriate 
dosage form and formulation design can enhance the chances of success. Two previous 
studies in children showed preference for citrus flavoured ranitidine effervescent tablets 
and strawberry flavoured lansoprazole ODTs compared to peppermint flavour syrups of 
the same drug (Ameen et al., 2006; Tolia et al., 2005).  
Unfortunately, studies investigating acceptability and patient preferences as a secondary 
outcome of a clinical trial do not usually describe the formulations composition, which 
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hinders association between formulation factors and patient reported outcomes. 
Conversely, those studies which focus on the development of new formulations tend to 
describe the formulation in sufficient detail to establish a relationship between 
formulation design and palatability or acceptability outcomes. For example, Liew and co-
workers concluded that appropriate masking of the bitter tasting drug donepezil 
hydrochloride was achieved using ammonium glycyrrhizinate as novel taste-masking 
flavouring agent, although the formulation also contained starch, mannitol and menthol, 
among other excipients which could contribute to the overall palatability of the 
formulations (Liew et al., 2014).  
A recent study by Preis and co-workers focussed on the development of cetirizine 
hydrochloride oral lyophilisates (Preis et al., 2015). A combination of ß-cyclodextrins, 
sucralose and black cherry flavour was employed as taste-masking system, which was 
selected based on preliminary evaluations using an in vitro electronic taste assessment 
tool (e-tongue). Then, two formulations were prepared, with high versus low flavour and 
sweetener content, and evaluated based on a swirl and spit methodology in a panel of 
30 adult volunteers. The higher level of flavouring agents was deemed too sweet by 50% 
of the adult volunteers, as opposed to 30% who though the sweetness level was right 
and 20% who though it was not enough. Despite these palatability findings, the authors 
reported adequate acceptance of both formulations in 80% or more of the volunteers and 
no significant differences between high and low level of flavour (Preis et al., 2015).   
1.3.1.3 Orodispersible films 
Only two studies of orodispersible films were identified in this literature review, one in 
adults and one in children; results are summarised in Table 1.9. Additionally, two studies 
reported a comparison between ODTs and ODFs in adult subjects, both of which 
indicated preference of the tablet design, as described in the previous section (Fischer 
et al., 2015; Gunderson and Sumner, 2016). 
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Rodd and co-workers investigated the acceptability of vitamin D film strips compared to 
oral drops in neonates, under 5 weeks of age (Rodd et al., 2011). Researchers used a 
modified Medication Acceptance Scale (MAS) initially developed by Kraus and 
colleagues to evaluates child’s reactions to medication based on facial expressions, 
reactions upon ingestion and amount of dose swallowed (Kraus et al., 2001). 
Additionally, caregivers reported acceptance on a questionnaire based on 10-point 
Likert-type scales, which included and ‘overall rating’ of the formulation and ‘willingness 
to continue using’ the dosage form, among other questions. Both researchers’ 
observations and caregiver-reported outcomes indicated better acceptance of the film 
formulation over oral drops. Patient’s compliance was also recorded, based on total 
medication consumption at the end of the trial; results were in line with previous findings 
showing also higher compliance scores for oral films than drops. 
A study of acceptability of oral films in the adult population was also identified. An 
antiemetic (dexamethasone) orodispersible film was developed and its oral acceptability 
compared against that of a conventional tablet in adult patients on chemotherapy 
(Nishigaki et al., 2012). Patients reported similar taste for both formulations, suggesting 
appropriate taste-masking in the oral films, which contained cocoa flavour; besides, the 
film formulation received significantly better ratings for ‘amount’ (i.e. dose volume) and 
‘ease in taking’. However, films contained 4 mg of dexamethasone compared to 0.5 mg 
in tablets, which meant that some patients had to ingest up to 16 tablets at a time to get 
the right dose. Thus, it is difficult to elucidate whether the improvement in patient’s 
acceptability was caused by the dosage form design or by the significantly higher number 
of dosage units that the patient had to take due to the difference in drug loading.  
1.3.1.4 Chewable formulations 
Evidence of acceptability of chewable formulations is summarised in Table 1.10. Studies 
on medicated chewing gum were not identified in either children or adults, thus only 
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studies with chewable tablets have been described in this section. Although chewable 
tablet medications in the market are approved and prescribed for children from 2 years, 
as shown by a previous review (Michele et al., 2002), no studies of acceptability of 
chewable tablets were identified in the peer-reviewed literature in children below 6 years.  
A multicentre study was carried out in children 6-11 years old assessing patients’ and 
caregivers’ preferences for montelukast chewable tablets compared to cromolyn 
metered dose inhaler (Volovitz et al., 2000). Both children and their caregivers showed 
preference for the chewable form versus the inhaler (82% vs. 17% and 87% vs. 13%, 
respectively). Volovitz and colleagues reported results of this multinational study 
(including 17 countries), whereas Bukstein and co-workers reported results of a single-
centre study conducted in United States; it was not possible to determine whether both 
reports belong to the same study, but both used the same methodology and showed 
comparable results. That is the only peer-reviewed evidence to support chewable tablets 
in children that was available in the public literature. 
Other studies evaluated acceptability of chewable tablets in adult populations. Three 
studies investigated the acceptability of calcium supplements compared to powders for 
oral solution. Reginster et al. and Den Uyl et al. followed a similar study designs, both 
excluding pregnant women in their studies (Den Uyl et al., 2010; Reginster et al., 2005); 
whereas Baxter et al. precisely focussed on pregnant women as subject of their study 
(Baxter et al., 2014). Irrespective of the studied population, all studies found better 
acceptance of chewable tablets than oral powders. However, Baxter and co-workers also 
introduced conventional tablets as a comparator, showing strong preference of pregnant 
women for conventional over chewable tablets. Finally, a study comparing lanthanum 
chewable tablets with an oral powder showed preference for powders in patients with 
chronic kidney disease, which were deemed easier to take, mainly due to avoidance of 
chewing up the medicine (Mukai et al., 2014).
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Table 1.9. Evidence of acceptability of orodispersible film formulations 
Population Dosage form Assessment tool Summary of outcomes References 
Adults     
Adults, N=19  
(41-70 years) 
Orodispersible film 
(dexamethasone) 
Subject reported taste, amount and ease in 
taking [3-point Likert-type scale]; compared to 
tablet [crossover design] 
Taste was scored similar for film and tablet 
(appropriate taste-masking); amount and ease in 
taking significantly better for film 
(Nishigaki et al., 
2012) 
Children     
Children, N=41 
(< 6 weeks) 
Film strip 
(vitamin D supplement) 
Researcher observation of ingestion [8-point 
criteria] and caregiver reported acceptance [10-
point Likert-type scale]; compared to oral drops 
[crossover design] 
Films strips received better ratings of acceptance 
by researchers and parents, 85% of whom 
preferred the film strip; this was aligned with 
higher compliance scores 
(Rodd et al., 
2011) 
 
Table 1.10. Evidence of acceptability of chewable formulations 
Population Dosage form Assessment tool Summary of outcomes References 
Adults     
Adults, N=79 
(33-85 years) 
Chewable tablet 
(lanthanum) 
Subject reported compliance and ease of taking 
medication; compared to oral powder taken 
subsequently [parallel design] 
Granules were easier to take for 46.8% of 
patients compared to chewables (25.3%), mainly 
due to avoidance of chewing 
(Mukai et al., 
2014) 
Adults, N=130 
(18-39 years) 
Chewable tablet 
(calcium supplements) 
Subject reported preference (only preferred 
dosage form was tested); compared to 
conventional tablet, unflavoured and orange 
flavoured oral powders [discrete-choice design] 
Pregnant women selected conventional tablets 
most commonly (62%), followed by chewable 
tablets (19%), flavoured powder (12%) and 
unflavoured powder (5%) 
(Baxter et al., 
2014) 
Adults, N>170 
(30-87 years) 
Chewable tablet 
(calcium supplements) 
Subject reported acceptability (administration, 
taste, time spent and convenience) [11-point 
Likert-type scale] and preference; compared to 
powder for oral solution [crossover design] 
Ratings consistently higher for chewable tablet 
than powder; just over two thirds (67-73%) 
reported preference for the chewable form 
compared to soluble powder, in both studies 
(Den Uyl et al., 
2010; Reginster 
et al., 2005) 
Children     
Children, N>300 
(6-11 years) 
Chewable tablet 
(montelukast) 
Subject/caregiver reported adherence and 
preference; compared to metered-dose inhaler 
(cromolyn) [crossover design] 
Preference for chewable tablets over inhaler in 
children (82% versus 17%) and their parents 
(87% versus 13%) 
(Bukstein et al., 
2003; Volovitz et 
al., 2000) 
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1.4 Identifying knowledge gaps and research needs 
There is a need to develop better medicines for children. Current medicines in the market 
are not always suitable for children, thus manipulation and compounding has become 
common practice. The development of age-appropriate pharmaceutical products is a 
challenging task due to the combined demands of industry, healthcare providers, 
caregivers and patients. Flexible solid dosage forms arise as suitable alternatives to 
conventional formulations with higher potential to meet such demands. 
Novel dosage form designs bring new opportunities in the field, but some technologies 
are still limited in their ability to meet the needs of all patients. For example, ODFs are 
becoming increasingly popular although there are technical barriers that need to be 
overcome to broaden the spectrum of APIs and doses that can be delivered; until these 
barriers are overcome, ODFs cannot be considered a flexible technology platform 
capable of meeting the needs of broad populations. Similarly, chewable tablets could be 
appropriate in some cases but, given the need to chew up the formulation, they have 
lower potential to be transferable to some of the patients in most need, such as geriatrics 
and neonates. Further consideration will not be given to ODFs and chewables, which 
were deemed out of the scope of this thesis. 
Some of the reviewed technology platforms for the preparation of age-appropriate 
medicines for children are already proving relative success. ODTs have been commonly 
used by industry in recent years to enable product line extension as well as addressing 
paediatric patient needs. Meanwhile, pellets and mini-tablets offer potential advantages 
for paediatric patients although there is still, even if encouraging, limited evidence to 
support their suitability for young children. The focus of the research described in this 
thesis was directed towards enhancing evidence of palatability and acceptability of these 
dosage form designs which hold high potential to become the formulations of choice for 
children and other patients in need.  
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There is still limited evidence and thus lack of understanding of the effect of drug product 
design on patient acceptability (van Riet-Nales et al., 2010). Although a range of studies 
investigating acceptability of flexible solid dosage forms in children were identified, 
details about the formulation were often not provided. In studies with (oro)dispersible 
tablets, the formulation composition is critical since the tablet needs to disperse rapidly 
and provide appropriate palatability, but information about excipients is very rarely 
disclosed (often due to intellectual property). Similarly, studies with multiparticulates not 
always provided essential details about the formulation, such as particle size, shape or 
amount of multiparticulates and vehicle used (if any). Research is required in this field to 
allow correlation between formulation factors and patient acceptability. 
It is acknowledged that patient acceptability is influenced not only by formulation 
attributes but also characteristics of the patient (e.g. disease type and stage). In this 
regard, acceptability studies performed in the targeted patient population could provide 
a more accurate insight into the true acceptability of the formulation. On the other hand, 
in studies nested to clinical trials, it can be difficult to deconvolute the effect of the dosage 
form design from the effect of the efficacy/safety balance of the drug product (e.g. 
appearance of adverse events). In contrast, studies in healthy subjects using placebo 
formulations can provide fundamental understanding of acceptability of different dosage 
form designs, which will be the focus of the work described in this thesis. 
Exploratory studies using placebo mini-tablets have dramatically changed our views on 
appropriateness and acceptability of solid dosage forms in children, indicating that solid 
dosage forms can be accepted by children from just 6 months of age (Klingmann et al., 
2013; Spomer et al., 2012; Thomson et al., 2009). These findings provide the foundation 
to conduct further studies of flexible solid dosage forms in children. Interestingly, such 
studies have focussed on the investigation of mini-tablet with a diameter of 2 to 3 mm, 
although there is still very scarce evidence of acceptability of multiparticulates of smaller 
size. Tabletting technologies can be used to prepare small tablets of a minimum diameter 
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around 2 mm, however, multiparticulate formulations based on pharmaceutical pellets or 
beads can be manufactured to smaller sizes, typically below 1 mm. Investigation of 
acceptability of such multiparticulate formulations is considered paramount. 
In their Expert Meeting Report on Dosage Forms of Medicines for Children, the World 
Health Organisation (WHO) identified a list of critical research needs in the development 
of age-appropriate paediatric medicines, including (i) investigation of the particle sizes 
than can be comfortably and safely ingested at different ages, (ii) requirements for 
‘granularity’ (i.e. size of the components of the medicine) and ‘texture’ or ‘mouth feel’ (i.e. 
the feeling of a suspension in the mouth) and (iii) development of standards for 
palatability and acceptability testing of pharmaceuticals (WHO, 2008). The experimental 
work described in this thesis attempts to bring some insight into these unexplored 
scientific questions. 
1.5 Thesis Aims and Outline 
The overall aims of this thesis are: 
1. To review knowledge and identify barriers for the development of age-appropriate 
medicines for children (Chapter 1). 
Although liquid dosage forms have been the formulation of choice for paediatrics, there 
has been a recent shift towards solid dosage forms. Research and development of 
flexible solid dosage forms, which can be administered in more than one manner, should 
be prioritised. These include multiparticulate formulations and (oro)dispersible tablets, 
which offer combined benefits of solids and liquid formulations, such as favourable 
stability profile, flexible dose titration and ease of administration. 
2. To optimise methodology for palatability and acceptability testing of pharmaceutical 
products in children and adults (Chapter 2 and Chapter 3). 
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The European Paediatric Regulation established an obligation to develop acceptable 
medicines for children. The design and development of paediatric medicines should be 
driven by the needs and preferences of the patient. However, ten years after this 
regulation came into force, there is still a lack of standardised methodology for palatability 
and acceptability testing. Development of best practices for palatability and acceptability 
testing could guide the development of better medicines. 
3. To generate evidence to fill some of the knowledge gaps around acceptability of 
flexible solid dosage forms (Chapter 3, Chapter 4 and Chapter 5).  
Despite potential benefits of flexible solid dosage forms, evidence of acceptability is still 
scarce. Evaluating and understanding the effect of different formulation factors on 
palatability and patient’s acceptability is paramount to enable patient-centric design of 
these formulations. This includes the effect of particle size, dose volume and liquid 
vehicle on acceptability of multiparticulates and the effect of excipients composition on 
palatability and acceptability of (oro)dispersible tablets.  
Specific aims and objectives are outlined further in each chapter.  
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Chapter 2 
2. Optimisation of research methodology for assessment of 
palatability and acceptability of multiparticulates 
 
This chapter describes a screening study to develop methodology for the assessment of 
palatability and acceptability of multiparticulate formulations. Twenty-four untrained adult 
panellists evaluated placebo formulations with different amounts and sizes of the 
multiparticulates; formulations dispersed in water were compared to multiparticulates 
administered directly in the mouth as a dry dose. During an initial session samples were 
evaluated using a swirl and spit methodology to allow familiarisation of the participants 
with the samples and the evaluation tools and, in a follow-up session, participants 
swallowed the samples reproducing the normal administration of a medicine. Based on 
the results of this trial, the methodology was optimised for future research. 
2.1 Introduction 
Multiparticulate formulations offer a range of potential advantages over conventional 
tablets and capsules for the paediatric population, such as ease of swallowing, increased 
flexibility of administration, and suitability for taste-masking and controlled-release 
(Lopez et al., 2015). Taste issues can be overcome via film-coating of multiparticulates 
to prevent release of the (poor tasting) drug(s) in the mouth. In turns, oral grittiness (i.e. 
rough mouth feel) becomes a major determinant of palatability of multiparticulates 
(Kimura et al., 2015; Lopez et al., 2016). Oral grittiness could have a detrimental effect 
on palatability and thus patient’s acceptability and compliance to a therapeutic regime. 
Evaluation of the effect of different formulation factors on grittiness and overall 
palatability of multiparticulates could guide the development of more palatable 
formulations that are better accepted by patients. 
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Multiparticulates could be administered directly in the mouth followed by water or, 
conversely, pre-dispersed in a suitable vehicle (such as water) to be taken as a 
suspension (EMA, 2006). The influence of the administration technique on palatability 
and product acceptance has not being investigated yet. Besides, the amount of 
multiparticulates that can be accepted in a single dose is unknown and the combined 
effect of size and amount of multiparticulates on palatability remains unclear. A previous 
study by Kimura et al. (2015) evaluated the effect of particle size on rough mouthfeel and 
overall palatability using a fixed amount of multiparticulates equal to 75 mg (Kimura et 
al., 2015). In the present study, greater amounts of multiparticulates were used, which 
would allow delivery of less potent drugs, such as antibiotics and anti-inflammatory 
drugs, which require doses greater than 100 mg (WHO, 2009). The effect of the 
administration approach and the amount and size of multiparticulates was evaluated 
simultaneously in the present study.  
Previous studies of palatability and acceptability of multiparticulates have been based on 
a swirl and spit methodology whereby palatability attributes are evaluated by placing a 
sample in the mouth and swirling it around for a predefined period of time before spitting 
it out (Kimura et al., 2015; Kluk and Sznitowska, 2014; Lopez et al., 2016). This 
methodology is generally accepted for the assessment of organoleptic properties of 
pharmaceutical products (most commonly taste assessment), e.g. (Kim et al., 2013; 
Mahrous et al., 2016; Maniruzzaman et al., 2012). However, swallowing of the samples 
would allow evaluation of ingestion and post-ingestion phenomena (e.g. ease of 
swallowing and presence of residual sample in the mouth after swallowing), which are 
also deemed important to the overall product acceptability. In the study described in this 
chapter, multiparticulates were evaluated via swirl and spit methodology and, in a 
subsequent session, after swallowing of the samples to reproduce the normal 
administration of a medicine. This allowed familiarisation of the participants with the 
formulations and evaluation tools during the initial swirl and spit session. 
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Evaluation of palatability and patient acceptability of placebo formulations in healthy 
volunteers can provide fundamental knowledge and understanding of dosage form 
design acceptability (Ranmal et al., 2016). Such studies require special consideration of 
a range of test methods and conditions which help to minimise biases which can arise 
by psychological and physiological factors (Table 2.1). 
Table 2.1. Methodological considerations in the design of sensory evaluation studies, such as 
palatability and acceptability testing; adapted from (ASTM, 2003; Mason and Nottingham, 2002). 
Parameter Considerations 
Population  
Skill development 
 
Test and evaluation tools should be designed based on the skills of 
participants (age, developmental stage, health condition, etc.) 
Prior training 
 
No need for training, but participants should be briefed in terms of method, 
questionnaire, length of trial and number of samples 
Number of subjects Varies based on objective, test design and scope. In general, pilot study = 
20+ participants; consumer panel = 100+ participants 
Testing area  
Location Easily accessible but in quiet position. Close proximity to preparation area, 
but separated. A separated waiting room can be useful.  
Space Sufficient space for movement of tasters and serving samples. Participants 
must be given sufficient level of intimacy while testing. 
Interferences Area must be free from noise and odours. Lighting, temperature and relative 
humidity should be constant, comfortable and controllable. 
Study design  
Procedure 
 
Affective test (consumer preference or acceptance), analytical test 
(discrimination/description of attributes) or combination of both 
Presentation Samples should be blinded and presented in randomised order 
Information about treatments should not be provided to participants 
Timing Length of the trial kept to a minimum to reduce fatigue, but sufficient time 
between samples to minimise discomfort and carry over effects 
Evaluation tool Hedonic scales, Likert-type scales, Visual Analogue Scales (VAS) or Just-
About-Right scales (JAR) are commonly used 
Legal aspects  
Safety It is responsibility of the investigators to make sure that no harm occurs as a 
result of faulty products or test facilities 
Ethics 
 
Studies should be reviewed by a Research Ethics Committee (REC) 
Participants must provide written consent to participate 
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A questionnaire for data collection was purposely designed for this study, using a range 
of hedonic scales and open-ended questions. This questionnaire was designed on the 
basis of previous research which gathered opinions and preferences of children and 
adolescents (Mistry et al., 2016). Design of an age-appropriate data collection form was 
considered important as this would allow transferability to studies in children in the future. 
A group of untrained panellists was recruited for the study to measure acceptability in a 
model population, without specific knowledge or training on palatability evaluation. 
Research suggest that untrained panellists can provide the same discrimination as 
trained panellists when the number of subjects in the former is sufficiently large (Husson 
and Pages, 2003). Previous studies have demonstrated that 15-18 participants are 
enough to detect significant differences between samples using categorical scales 
(Hayakawa et al., 2016; Kimura et al., 2015). A designated room at UCL School of 
Pharmacy was prepared for the study, based on the considerations listed in Table 2.1. 
2.2 Aims and objectives 
The aims of this study were to develop methodology for palatability and acceptability 
testing; to investigate the size and amount of multiparticulates that can be accepted by 
a model population of healthy adults; and to investigate the effect of the administration 
approach (dry dose versus pre-dispersion in water) on palatability and acceptability.  
2.3 Materials and methods 
2.3.1 Materials 
Microcrystalline cellulose (MCC) pellets (Cellets®) were provided by Pharmatrans Sanaq 
AG (Basel, Switzerland); a range of particle sizes were procured and characterised 
(Table 2.2). From those, Cellets 200 and Cellets 500 were used in the sensory evaluation 
study described in this chapter. Buxton spring water was procured from Nestle Waters 
Ltd. (Rickmansworth, Hertfordshire, UK); transparent 30ml polypropylene universal 
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tubes from Wheaton Ltd. (Rochdale, Lancashire, UK); and white plastic cup (180cc) were 
purchased from Office Depot Inc. (Raton, Florida, USA). 
Table 2.2. Particle size descriptors of Cellets as provided by the manufacturer. 
Sample ID Particle size (µm)† Sphericity Swelling (ml/g) 
Cellets 200 200-355 ≥ 0.9 ≤ 2 
Cellets 350 350-500 ≥ 0.9 ≤ 2 
Cellets 500 500-710 ≥ 0.9 ≤ 2 
Cellets 700 700-1000 ≥ 0.9 ≤ 2 
† Particle size provided by supplier, ≥ 85% of particles within given range 
 
2.3.2 Material characterisation 
The morphological features of Cellets were imaged using Scanning Electron Microscopy 
(SEM). Samples were adhered onto aluminium stubs (TAAB Laboratories, Reading, 
U.K.), sputter coated with gold under vacuum and then imaged at different magnification 
levels using a Quanta 200F instrument (FEI, Hillsborough, OR, USA). The aspect ratio 
of the particles was calculated as dmin/dmax (where dmax is the major diameter and dmin is 
the minor diameter) and the circularity factor was calculated as 4πA/P2 (where A is the 
area and P is the perimeter), by taking measurements of more than 50 particles using 
ImageJ software (National Institutes of Health, Bethesda, MD, USA). 
The particle size distribution of the granules was assessed by laser diffraction using a 
Mastersizer 3000 fitted to an Aero S and a Hydro MV feeding systems for dry and wet 
dispersion, respectively (Malvern Scientific, Worcestershire, UK). The air pressure and 
feeding rate were optimised to allow dry dispersion of the particles. Wet dispersion 
method was carried out using deionised water as dispersant; samples were pre-
dispersed in deionised water for nearly 60 min before analysis to allow water sorption 
equilibrium. Six replicates of each sample were tested; average values of six replicates 
were calculated for D10, D50 (median diameter) and D90 parameters. 
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2.3.3 Sensory evaluation experiments 
2.3.3.1 Study design 
Twenty-four healthy adult volunteers were enrolled in a single-centre, randomised, 
factorial, two-session, single-blind sensory evaluation. The study was approved by UCL 
Research Ethics Committee (ERN_4612-007) and was conducted in dedicated facilities 
at UCL School of Pharmacy.  
The study was conducted in two sessions taken place in two separate days (Figure 2.1). 
During the first session samples were evaluated using a ‘swirl and spit’ methodology 
whereby subjects placed the sample in their mouth for approximately 5-10 seconds 
before spiting it out. For the second session subjects were asked to swallow the sample. 
The same range of samples were evaluated in both sessions of the study, allowing 
comparison between both testing methodologies. 
 
Figure 2.1. Diagram depicting the randomised, factorial, two-session, single-blind study design. 
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During each session, volunteers were handed samples of Cellets in transparent plastic 
tubes, blinded with a random 3-digit code. The administration sequence was individually 
randomised for each participant. Samples contained a predefined amount of Cellets 
(either 250 or 500 mg) of distinct particle size distribution (either 200-350µm or 500-
710µm), as shown in Table 2.3. Half of the samples were pre-dispersed in 10ml of water 
(wet administration) whereas the other half were given as a dry amount of Cellets to be 
administered directly in the mouth followed by water (dry administration). In the case of 
pre-dispersed samples, subjects were advised to turn the sample upside down before 
administration to aid homogenous dispersion of Cellets. A 5-10-minute interval was 
respected between samples to minimise subject discomfort and carryover effect.  
Table 2.3. List of formulations assessed in sensory evaluation experiments. 
ID Administration Particle size (µm) Amount (mg) 
F1 Dry 200-355 250 
F2 Dry 200-355 500 
F3 Dry 500-710 250 
F4 Dry 500-710 500 
F5 Wet 200-355 250 
F6 Wet 200-355 500 
F7 Wet 500-710 250 
F8 Wet 500-710 500 
 
A plastic cup with 150 ml of water was provided alongside each sample and volunteers 
were asked to take as much water as needed to wash the sample out of their mouth 
(session 1) or to achieve complete sample intake (session 2). The volume of water 
consumed per sample was back-calculated by measuring the volume of water left in the 
cup after each sample. Additionally, subjects had free access to water during the inter-
sample intervals to clean their palate. 
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2.3.3.2 Evaluation tool and outcome measures 
A digitalized questionnaire (Qualtrics.com) was used for data collection. Immediately 
after sample expectoration or swallowing (session 1 and 2, respectively) volunteers were 
asked to rate several sample attributes using 5-point hedonic scales, including ease of 
swallowing (session 2 only), grittiness, sample volume and taste (Figure 2.2). Volunteers 
could also provide voluntary written feedback using their own words. Finally, the future 
willingness of the volunteers to take multiparticulates was measured using a bipolar 
(yes/no) question: “If this was a medicine, would you be willing to take it every day?”.  
 
Figure 2.2. Hedonic scales for evaluation of swallowing, grittiness, sample volume and taste. 
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2.3.3.3 Measurement of dosing accuracy 
During the first session of the study (swirl and spit methodology) it was observed that a 
significant proportion of volunteers did not take the full amount of multiparticulates, 
leaving a substantial residue in the dosing vial. During the second session of the study 
(swallowing methodology), sample vials were recovered immediately after administration 
by the volunteers and the remaining amount of Cellets in the sample was quantified to 
evaluate dosing accuracy. In the case of samples administered as a dry dose the residual 
amount of Cellets was directly weighed out. For samples administered pre-dispersed in 
water residual samples were oven-dried at 60 ºC until constant weight was reached. The 
quantity of residual Cellets was expressed as a percentage of the initial amount dose. 
2.3.3.4 Data analysis 
The number of participants required to detect significant differences between samples 
was estimated based on power calculations assuming parametric unimodal distribution, 
significance (α) of 0.05 and 80% power; a sample size of 14 would show the difference 
between two samples where the difference was 1 face and the standard deviation was 
also 1 face on the 5-point hedonic scale. This is supported by previous studies which 
demonstrated that a group of 15-18 participants is sufficiently large to detect significant 
differences between samples based on a swirl and spit methodology and using 
categorical scales for sample evaluation (Hayakawa et al., 2016; Kimura et al., 2015). 
For data analysis, the different categories of the hedonic scales were assigned numeric 
scores (1-5) from lowest to highest stimuli perception, respectively. The volume of water 
consumed and the amount of multiparticulates left in the dosing vials were treated as 
non-normally distributed variables based on the Kolmogorov–Smirnov test. Statistical 
analysis was performed using non-parametric Kruskal-Wallis analysis of variance 
followed by Dunn’s test as post hoc for pairwise comparison, both with 95% confidence. 
Minitab 17 (Minitab Inc., State College, Pennsylvania, USA) was used for data analysis. 
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2.4 Results and discussion 
2.4.1 Material characterisation 
Microcrystalline cellulose pellets used as model multiparticulates were characterised as 
white, non-friable, rounded particles. SEM images of model multiparticulates revealed 
their spherical morphology and smooth surface properties, as shown in Figure 2.3. 
Average particle circularity was determined to be ≥ 0.85 and the aspect ratio ≥ 0.90 for 
all particle size fractions, demonstrating highly spherical morphology. 
 
Figure 2.3. SEM micrographs of Cellets with 250x magnification: (a) Cellets 200, (b) Cellets 350, 
(c) Cellets 500 and (d) Cellets 700. Cellets 200 and Cellets 500 were investigated in the present 
exploratory study, whereas other size fractions were used in future investigations. 
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All samples exhibited a narrow, symmetric, unimodal particle size distribution, as shown 
in Figure 2.4. When assessed by dry dispersion method, the median particle size of 
Cellets 200, 350, 500 and 700 was 274, 401, 616 and 888 μm, respectively. When 
Cellets were dispersed in water their median particle size shifted to 305, 494, 635 and 
942 μm, respectively. This subtle increase in particle size (11-23% increase with respect 
to their original size) can be attributed to water sorption and moderate swelling of the 
cellulosic particles, although all samples retained their narrow, unimodal size distribution. 
 
Figure 2.4. Particle size distribution of Cellets assessed by laser diffraction using dry dispersion 
(solid lines) and wet dispersion (dotted lines) methods. 
2.4.2 Sensory evaluation study 
2.4.2.1 Demographics 
A total of 24 volunteers (10 male and 14 female) participated in the sensory evaluation 
study. The average age was 26 years, with a standard deviation of 3 years (min. 21 
years, max. 33 years) and median at 25 years. 
2.4.2.2 Comparison between testing methodologies 
Results of hedonic rating for grittiness, sample volume and taste obtained in Session 1 
(swirl and spit) and Session 2 (swallowing methodology) are shown in Figure 2.5.  
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Figure 2.5. Interval plots for grittiness, sample volume and taste as a function of formulation (1-
8) and testing methodology (session 1 = swirl and spit; session 2 = swallowing). Markers represent 
the population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the worst 
possible rating) and bars show the 95% CI for the mean. 
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Ratings of grittiness perception were consistently higher when assessed by swirl and spit 
methodology (Session 1) than when participants swallowed the samples (Session 2); the 
difference between both sessions of the study was statistically significant (p < 0.001). 
Similarly, the sample volume was considered larger when assessed by swirl and spit 
methodology than when the samples were swallowed by the volunteers (p < 0.001); with 
greater differences being found for samples administered wet (i.e. pre-dispersed in 
water, Formulations 5-8) compared to those administered as a dry form (i.e. directly in 
the mouth, Formulations 1-4). On the contrary, no significant differences were found 
between testing methodologies in the assessment of taste (p = 0.191). 
Discrepancies between both testing methodologies could be ascribed to differences in 
retention time in the mouth and oral processing of samples, which would result in 
dissimilar appreciation of the sensory stimuli being evaluated. During the first session, 
participants were instructed to swirl the sample around the mouth for a period of 
approximately 5-10 seconds before spitting it out whereas in the second sessions 
participants were instructed to swallow the sample normally (i.e. no instruction regarding 
retention time in the mouth was given). The duration of the oral preparatory phase in a 
normal swallowing of samples which do not require mastication can be expected to be 
shorter than 5 seconds based on previous research; moreover, subjects would attempt 
to position the sample between the tongue and the hard palate for subsequent transport 
to the throat rather than swirling the sample around the mouth (Soares et al., 2015).  
The longer retention time and swirling of the samples in the mouth would explain the 
overestimation of the tested stimuli by the former methodology compared to the latter. 
This was supported by anecdotal feedback, e.g. “Given the administration, the grittiness 
is bearable; however, if tried to move the pellets around in the mouth the feeling would 
be different” (Participant 07, Formulation 1); or “as [the sample was] swallowed quickly 
[it was] not as easy to assess as in the previous [swirl and] spit test” (P15, F5). However, 
differences in taste perception were not apparent between both sessions. This could be 
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explained by the fact that samples were neutral tasting receiving most ratings towards 
the positive end of the scale (i.e. oral processing of samples becomes trivial as the 
samples have a plain taste anyway). 
Despite the differences in results with regards to the absolute ratings of grittiness and 
sample volume, the trends obtained in both sessions (i.e. the relative ratings between 
formulations) were almost identical, as shown in Figure 2.5. This suggests that both 
methodologies could be equally valid when the aim is to compare between samples and 
to identify sample preferences. Moreover, all participants performed the swirl and spit 
session before the swallowing session and thus differences in results could be due to 
carry over effects; habituation of the participants to the gritty feeling of the samples would 
explain the more positive results obtained during the second session of the study. 
Nevertheless, given the differences found between testing methodologies (or, at least, 
between sessions of the study), further evaluation of results was carried out using the 
data obtained during the second session, when participants had to swallow the sample. 
This methodology can be considered more representative of the actual administration of 
a medicine. In addition, information about the swallowing phase can only be obtained 
using this methodology and not with the swirl and spit approach. 
2.4.2.3 Effect of the administration approach 
Pre-dispersion of multiparticulates in water (i.e. wet administration) had a beneficial 
impact grittiness and ease of swallowing, as demonstrated by the reduction of mean 
hedonic ratings (Figure 2.6). This was supported by anecdotal voluntary feedback, e.g. 
“it was very gritty initially but felt less so after taking water” (P08, F4) or “since it was 
given as a powder they [Cellets] stuck on tongue and teeth more than other [wet] 
samples” (P15, F2). Differences between dry and wet samples were more significant for 
ease of swallowing (p = 0.011) than grittiness (p = 0.031). The administration approach 
had no significant impact on the rating of sample volume (p = 0.634) or taste (p = 0.264). 
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Figure 2.6. Interval plots for grittiness, taste, sample volume and ease of swallowing as a function 
of the administration approach (Dry: multiparticulates administered directly in the mouth 
followed by water; Wet: multiparticulates pre-dispersed in water before administration). Markers 
represent the population mean for the hedonic ratings (where 1 is the best possible rating and 5 is 
the worst possible rating) and bars show the 95% CI for the mean.  
2.4.2.4 Effect of amount and size of the multiparticulates 
Oral grittiness was the main barrier to palatability and acceptability, receiving more 
negative ratings than the rest of the attributes tested (Figure 2.7). This was expected 
based on previous studies which already reported grittiness as an important palatability 
barrier, even though smaller particles (Lopez et al., 2016) or inferior amounts of 
multiparticulates (Kimura et al., 2015) were investigated. Participants reported feeling of 
multiparticulates in their “mouth”, “lips”, “tongue”, “teeth”, “gums” and “throat” within their 
voluntary open-ended feedback, regardless of the evaluation technique (swirl and spit or 
swallowing). Participants reported feeling of grittiness even after swallowing the sample, 
e.g. “I could fill the ‘bits’ in my mouth even after drinking water” (P08, F6) 
 76 
Grittiness perception from multiparticulate formulations increased with increasing 
amount and size of Cellets, as shown in Figure 2.7. Samples containing the largest 
amount and size of Cellets (i.e. 500 mg of Cellets 500) received grittiness mean scores 
greater than 3, both when administered as a dry form (3.71) or pre-dispersed in water 
(3.50). In contrast, samples containing fewer Cellets of the smallest size (i.e. 250 mg of 
Cellets 200) scored about 1.5 points lower on average (2.25 when administered dry and 
1.88 when administered wet). Differences in grittiness perception between formulations 
were statistically significant (p = 0.003 for amount and p < 0.001 for size effect). 
 
 
Figure 2.7. Interval plots for grittiness and taste as a function of the administration approach, the 
size of the multiparticulates and the amount administered. Markers represent the population mean 
for the hedonic ratings (where 1 is the best possible rating and 5 is the worst possible rating) and 
bars show the 95% CI for the mean. 
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Placebo cellulose pellets used as model multiparticulates were considered “tasteless” 
and “plain”, as described by the volunteers. In agreement, the mean scores for taste 
were below 3 for all samples investigated. This is a positive outcome since the samples 
are intended to represent a taste-masked formulation, which would have no strong taste 
(if the polymer coating works as intended, avoiding drug release in the mouth). There 
were minimal differences between samples (Figure 2.7), which were not statistically 
significant based on the amount (p = 0.854) or the size (p = 0.074) of multiparticulates. 
The sample volume seemed acceptable for an adult population, receiving mean scores 
below 3 for all formulations investigated (Figure 2.8). This was supported by voluntary 
feedback, where participants described the volume as “suitable”, “not excessive” or 
“acceptable”. Although these results suggest that the amount of Cellets was acceptable, 
the volume of water used for pre-dispersion of wet samples (10 ml) seemed to be too 
large for some volunteers, who reported their concern, e.g.  “the volume is much, the 
liquid in the sample make the drug [Cellets] hard to be all swallowed” (V17, F8). The 
volume of water used for pre-dispersion of wet samples was described as “a mouthful” 
by the adult volunteers, which suggests that this volume would be too large for a 
paediatric population. Moreover, a significant effect in volume perception was recorded 
when the amount of Cellets was doubled from 250 to 500 mg and when the size of the 
particles was increased from 200-355 to 500-710 µm (p = 0.016, in both cases); sample 
volume being considered larger as the size and/or amount of particles increased. 
Overall, ease of swallowing obtained neutral to positive ratings (Figure 2.8), although 
swallowing issues were reported in some cases. Swallowing difficulties were associated 
to the multi-unit composition of the formulations and thus the difficulty to swallow the full 
amount of Cellets in a single gulp, e.g. “needed several mouthfuls of water to wash the 
sample completely away” (P01, F6), or “particles kept getting stuck in back of my teeth - 
not easy to swallow” (P13, F2). Swallowing was considered more troublesome with larger 
Cellets (p < 0.001). Surprisingly, the amount of Cellets had no significant effect on the 
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reported ease of swallowing (p = 0.131), although the trend suggests that 500 mg were 
slightly more difficult to take than 250 mg (Figure 2.8). Only one participant reported the 
need to chew on the Cellets to aid swallowing of the formulation (P03, F8). 
 
 
Figure 2.8. Interval plots for sample volume and ease of swallowing as a function of the 
administration approach, the size of the multiparticulates and the amount administered. Markers 
represent the population mean for the hedonic ratings (where 1 is the best possible rating and 5 is 
the worst possible rating) and bars show the 95% CI for the mean. 
As shown herein, the mean hedonic scores of sample attributes can be used to compare 
between formulations and assess the effect of formulation factors on preferences. In 
addition, it might be beneficial to assess percentage scores (e.g. the proportion of 
participants who rated sample attributes in the neutral-positive range of the scale), as 
this would be informative of the acceptability of the sample. 
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2.4.2.5 Acceptability based on hedonic ratings 
Although grittiness was the main barrier to palatability, as described above, more than 
half of the participants rated grittiness in the neutral-positive range for five out of eight 
samples (Figure 2.9). Furthermore, those formulations containing smaller 
multiparticulates (Cellets 200) received over 70% of neutral to positive ratings for 
grittiness perception. In contrast, taste was not an issue for the participants of the study 
since more than 85% of them provided neutral to positive evaluation for this attribute. 
 
 
Figure 2.9. Ratings of grittiness and taste (1 – best possible rating and 5 – worst possible rating) 
as a function of the administration approach, the size of the multiparticulates and the amount 
administered. Results expressed as percentage of the total respondents (N = 24).  
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Over 80% of the participants rated sample volume in the neutral-positive range of the 
scale for all formulations, confirming appropriateness of sample volume for the studied 
population (Figure 2.10). In terms of ease of swallowing, over 50% of the participants 
rated all formulations in the neutral-positive range, and this proportion increased to over 
80% for samples pre-dispersed in water. Overall, samples containing 200-355 µm 
particles pre-dispersed in water obtained over 80% of neutral-positive responses for all 
attributes evaluated (regardless of the amount of particles, either 250 or 500 mg). 
 
 
Figure 2.10. Ratings of sample volume and swallowing (1 – best possible rating and 5 – worst 
possible rating) as a function of the administration approach, the size of the multiparticulates and 
the amount administered. Results expressed as percentage of the total respondents (N = 24).   
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2.4.2.6 Willingness to take multiparticulates as a medicine 
The proportion of participants willing to take the sample every day if it was a medicine 
was calculated as a predictive measure of future acceptability (Figure 2.11). Participants 
were more willing to take multiparticulates every day when these were pre-dispersed in 
water before administration (p = 0.003), and the willingness to take the sample every day 
also increased with decreasing particle size (p < 0.001) and amount of multiparticulates 
(p = 0.049), in agreement with their hedonic evaluation of the samples. In other words, 
participants reported to be more willing to take every day those samples which they rated 
positively, as it can be expected. For samples of 200-355 µm pre-dispersed in water over 
80% of the volunteers would be willing to take the formulation every day.  
 
Figure 2.11. Proportion of volunteers ‘willing to take the sample everyday if it was a medicine’, 
expressed as a percentage of the total population (N = 24). 
Samples which participants would be willing to take every day received mean scores of 
2.30 for grittiness, 1.61 for taste, 1.59 for sample volume and 1.66 for ease of swallowing; 
whereas samples which participants would not be willing to take every day received 
mean scores of 3.79 for grittiness, 2.49 for taste, 2.70 for sample volume and 3.27 for 
ease of swallowing (Figure 2.12). This provides an indication of the association between 
both outcome measures (hedonic ratings and willingness to take multiparticulates). 
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Figure 2.12. Interval plots for grittiness, taste, sample volume and ease of swallowing for samples 
that participants would be willing or not willing to take every day. Markers represent the 
population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the worst 
possible rating) and bars show the 95% CI for the mean. 
2.4.2.7 Volume of water consumed 
Participants had free access to spring water after sample intake to facilitate swallowing 
of multiparticulates. The volume of water consumed during sample administration was 
recorded and results are shown in Figure 2.13.  
The average volume of water consumed per sample was 46 ml, although there was a 
large inter-individual variability (min. 0 ml, max. 150 ml and median 37 ml). The volume 
of water consumed was larger for samples administered dry (56 ml on average) than for 
samples pre-dispersed in water (37 ml on average). This difference was statistically 
significant based on Kruskal-Wallis test (p < 0.001). The volume of water needed to 
complete sample intake increased as the particle size (p = 0.007) and the amount of 
multiparticulates (p = 0.016) increased.  
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Figure 2.13. Volume of water consumed as a function of the administration approach, the size of 
the multiparticulates and the amount administered. Centre lines show the median, box limits 
indicate the 25th and 75th percentiles and outliers are denoted by asterisks. Water used to pre-
disperse wet samples (10 ml) was not considered part of the water consumed. 
2.4.2.8 Dosing accuracy 
Dosing vials were recovered after sample administration and the residual amount of 
Cellets left in the vial (if any) was quantified (Figure 2.14). Differences were found 
between dry and wet samples (p < 0.001). Volunteers achieved good dosing accuracy 
with dry samples, leaving a very small proportion of Cellets behind (2.17% w/w on 
average, with respect to the initial amount). On the contrary, wet samples seemed to be 
more difficult to administer, as suggested by the larger amount of Cellets found in the 
recovered vials (10.45% w/w on average). Administration issues with wet samples were 
identified and reported by some of the volunteers, e.g. “even with a good mix there are 
always Cellets that remain in the flask” (P04, F5, leftover = 23.2% w/w); or “the issue 
was trying to get the Cellets out of the flask, almost impossible!” (P14, F7, leftover = 
22.3% w/w). This can be explained by the fact that multiparticulates settled down very 
quickly and it was virtually impossible to administer the sample as a homogeneous 
suspension. The size and amount of multiparticulates did not have a significant effect on 
the dosing accuracy (p = 0.774 for size and p = 0.628 for amount). 
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Figure 2.14. Quantity of Cellets remaining in dosing vial after sample administration (expressed 
as % w/w of the initial amount of multiparticulates) as a function of the administration approach, 
the size of the multiparticulates and the amount administered. Centre lines show the medians, box 
limits indicate the 25th and 75th percentiles and outliers are denoted by asterisks. 
The poor dosing accuracy obtained with wet samples suggests that the administration 
approach and/or the dosing device were not appropriate to deliver the sample. This could 
be simply solved by the patient by rinsing the residual particles in the vial with more 
water, as reportedly done by some of the volunteers, e.g. “some particles were left in the 
tube so I needed to rinse it” (P09, F6, leftover = 1.5% w/w). Nevertheless, consideration 
must be given to the dosing device and administration approach in future studies and 
during product development of multiparticulate formulations. 
2.5 Conclusions 
Placebo multiparticulate formulations were investigated in a group of twenty-four healthy 
adult volunteers in a pilot study to develop methodology for palatability and acceptability 
testing. During an initial session, samples were tested using a swirl and spit methodology 
and on a follow-up session participants were asked to swallow the samples. Differences 
between swirl and spit and swallowing methodologies were observed and hypothesised 
that these differences were the results of a dissimilar retention time and oral processing 
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of the samples in each testing approach. However, all participants performed the swirl 
and spit session before the swallowing session and thus differences in results could also 
be explained by carry over effects. Based on the difference in results between sessions, 
it was decided to evaluate differences between formulations based on the results of the 
swallowing session. 
Evaluation of the samples by swallowing them rather than by swirl and spit methodology 
restricted the number of test samples that could be evaluated on a single session but, in 
turn, provided important information about the ease of swallowing the formulations. 
Swallowing the samples is preferred for being more representative of the normal 
administration of a medicine. This method could also be used in future studies to 
investigate post-ingestion phenomena, such as the presence of residual sample in the 
mouth after swallowing. 
Overall, methodology for the evaluation of palatability and patient acceptability was 
successfully developed in this study. Results demonstrated that the study design, 
evaluation tools and number of participants employed were appropriate to detect 
differences between samples and rank them in order of preference. Moreover, values on 
hedonic scales and responses about the ‘willingness to take the sample as a medicine’ 
provided an indication of the overall acceptability of the samples. Association between 
hedonic ratings and willingness to take the sample as a medicine suggested internal 
consistency (reliability) of the outcome measures.  
Eight different formulations were tested, half of them were given as a dry dose and the 
other half were pre-dispersed in water. Participants evaluated a range of sample 
attributes using hedonic scales. Overall, grittiness perception was found to be the main 
barrier to palatability and acceptability. Grittiness increased with increasing particle size 
and amount of multiparticulates, in line with previous studies (Lopez et al., 2016). 
Swallowing also became more troublesome as the amount and size of multiparticulates 
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increased, following same trend as grittiness perception. Moreover, the administration 
approach had a great influence on the acceptability of the product; pre-dispersed 
samples were considered less troublesome to swallow and less gritty. The taste of 
Cellets was deemed “neutral”, proving that Cellets can be used as a good surrogate of 
taste-masked multiparticulate formulations. In terms of sample volume, formulations 
containing either 250 or 500 mg of Cellets were both considered acceptable by the 
participants of the study. Ratings for taste and sample volume were positive for all 
formulations and were not affected by the different formulation factors, namely the 
administration approach, particle size and amount of multiparticulates. 
In addition to hedonic ratings of sample attributes, the willingness of participants to take 
multiparticulates in the future as a medicine was recorded using a bipolar scale. The 
willingness to take the sample in the future increased for samples pre-dispersed in water 
as well as for samples containing the smaller size and amount of multiparticulates. This 
outcome measure proved to be highly linked to the hedonic evaluations of the samples, 
which indicated correlation between the sample palatability and the willingness to take 
the sample (i.e. patient acceptability), as it could be expected. As such, this tool might 
be useful to obtain a comprehensive, net evaluation of the samples. 
Issues were found when administering wet formulations due to rapid settling down of 
multiparticulates in water, which resulted in poor dosing accuracy. This could be 
overcome in the future by using a different administration device, such as a dosing spoon 
instead of a dosing vial. In addition, the volume of water used for pre-dispersion needs 
to be suitable for the intended population. An aliquot of 10 ml was considered mouth-
filling and was reported to be too large by some adult volunteers. Thus, a smaller volume 
is suggested when targeting paediatrics. Nevertheless, additional water was needed to 
achieve full sample intake. This varied greatly between individuals, but on average the 
volume of water consumed was 20-60 ml (depending on the formulation). 
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Chapter 3 
3. Palatability and acceptability of multiparticulates: a comparison 
between children and adults  
 
This chapter describes a study of palatability and patient acceptability of multiparticulate 
formulations which encompasses a direct comparison between children and adults. 
Seventy-one children (4-12 years) and sixty-one adults participated in this study to 
evaluate the effect of multiparticulate size and the presence of polymeric coating on 
palatability and acceptability. A mixed-model approach was used for data collection, 
which included researcher observations (e.g. facial expressions) and subject-reported 
outcomes (e.g. ratings on hedonic scales). Comparison of outcome measures provided 
information of the suitability of different data collection tools to evaluate palatability and 
acceptability in both populations. The benefits and limitations of conducting studies in 
adult participants as a proxy in the development of paediatric medicines were explored. 
3.1 Introduction 
Multiparticulates are considered a flexible solid dosage form often proposed as an 
alternative to conventional solid and liquid formulations for children (EMA, 2006; WHO, 
2012). However, evidence to support the utilisation of multiparticulate formulations in 
children is still limited, even if encouraging. Several randomised trials have recently 
investigated the acceptability of a single mini-tablet (2-3mm in diameter) in children and 
neonates (0-6 years) (Klingmann et al., 2015, 2013; Spomer et al., 2012; Thomson et 
al., 2009; van Riet-Nales et al., 2013), although there is very limited evidence of the 
administration of multiple mini-tablets at a time (Klingmann et al., 2016; Kluk et al., 2015). 
Moreover, previous studies with smaller multiparticulates (up to 1 mm in diameter, which 
could be easier to swallow than larger mini-tablets) have only involved adult participants 
(Kimura et al., 2015; Lopez et al., 2016). More studies are thus required. 
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Evaluation of palatability and patient acceptability should form an integral part of the 
pharmaceutical development studies and the Paediatric Investigational Plan (PIP), as 
recommended by the EMA in their Guideline on Pharmaceutical Development of 
Medicines for Paediatric Use (EMA, 2013). Patient’s acceptability has been defined as 
the “ability and willingness” of the patient and their caregiver (defined as users) to use 
the medicine as intended (EMA, 2013). Therefore, acceptability is a multidimensional 
concept, although the large majority of studies reported in the literature have focussed 
on a single attribute, such as “palatability”, “ease of administration”, or “ability to swallow 
the formulation”. For example, previous studies with mini-tablets have investigated the 
success in swallowing the formulation as a surrogate of patient acceptability (Klingmann 
et al., 2015, 2013; Kluk et al., 2015; Thomson et al., 2009). In the present study, the 
ability to swallow the formulation was complemented with other outcome measures of 
acceptability based on researcher observations and subject reported outcomes. 
Ideally, palatability and acceptability testing of paediatric medicines should be carried out 
in the intended population group, i.e. children (EMA, 2013). However, the pharmaceutical 
development of paediatric medicines still relies on data from adult populations; although 
correlation between acceptability in children and adults remains unknown. Therefore, 
studies investigating the link between children and adults’ perceptions of medicines are 
desirable. Benefits of conducting studies in adults include relative simplicity of safety, 
ethical, logistic and methodological considerations. Testing with children requires special 
consideration to their language development, motor skills, and social and psychological 
development. A guideline of children’s skills and behaviours as they relate to sensory 
evaluation was proposed by the ASTM International in their Standard Guide for Sensory 
Evaluation of Products by Children (ASTM, 2003), as shown in Table 3.1.  
Special attention must be given to the wording of the questions, since children have 
limited vocabulary and tend to repeat adults’ statements and to respond affirmatively to 
positively-phrased questions (Guinard, 2000). In this study, ‘taste’, ‘texture’ and ‘sample 
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volume’ were evaluated, as these factors have been identified as significant barriers to 
the acceptability of oral medicines based on work conducted in a large population of 
children and adolescents (Venables et al., 2015). The questionnaire used was designed 
based on previous research which gathered opinions and preferences of children and 
adolescents (Mistry et al., 2016). Mistry et al. involved the Young Person’s Steering 
Group (YPSG) from the NIHR Clinical Research Network: West Midlands in the design 
of tools for patient-reported outcomes to ensure age-appropriateness of the scales and 
wording, so that it can be used without caregiver’s involvement (Mistry et al., 2016).  
Table 3.1. Summary of skills and behaviours of children, adapted from (ASTM, 2003). 
Skill/behaviour Toddler 
(1- 3 years) 
Pre-school 
(3-5 years) 
Readers 
(5-8 years) 
Pre-teen 
(8-12) 
Language Cannot read/write 
Rely on facial 
expressions 
Early language 
development 
Can respond to 
questions 
Developing 
vocabulary skills 
Early 
reading/writing 
Increasing verbal 
ability 
Self-expression 
improves 
Motor skills Gross motor skills, 
fine motor skills 
still limited 
Gross and fine 
motor skills 
increasing 
Hand to eye and 
other fine motor 
skills refining 
Fine motor skills 
developed 
Attention span Gaged by eye 
contact and body 
movement 
Gaged by eye 
contact or 
involvement with 
task 
Limited by 
understanding of 
task and interest 
level 
Increasing 
attention span 
Holding interest 
still critical 
Reasoning Limited, but 
concept on “no” 
becoming a factor 
Limited, but 
beginning to be 
able to verbalise 
likes and dislikes 
Developing with 
increased learning 
of cause/effect 
concepts 
Full ability for 
understanding and 
reasoning 
Decision 
making 
Do not make 
complex decisions, 
but “yes/no” can 
be decisive 
Limited, but able to 
choose one thing 
over another 
Ability to decide is 
increasing, but 
influence of adult 
approval is evident 
Capable of 
complex decision 
making 
Use of scales Do not understand 
scales 
Understanding of 
simple scales 
begins 
Understanding 
increasing. 
Simple is best 
Understand scales 
with instruction. 
Adult 
involvement 
Trained observer 
and caregiver 
Trained interviewer    
with or without 
caregiver 
Trained interviewer 
Able to self-
administer 
Trained interviewer 
Able to self-
administer 
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In addition to subject-reported outcomes (i.e. questionnaires and scales to be filled by 
the participants), researcher observations can also be used. Behavioural observations 
used in sensory evaluation studies include hand and eye movement, facial expressions, 
time of consumption and other means of interaction with the product (ASTM, 2003). 
Guidance on investigation of medicinal products to support labelling claims encourages 
the use of researcher observations in studies involving children (FDA, 2009; Matza et 
al., 2013). Thus, in this study, facial expressions and behaviours were recorded.  
Due to limited language, motor skills and attention span of children, the length of the 
testing sessions and the number of products that can be evaluated should be kept to a 
minimum (ASTM, 2003). Screening studies in the adult population can be a successful 
technique to reduce the number of samples and refine the study design (ASTM, 2003). 
The present study was guided by the preliminary trial described in Chapter 2; the main 
differences between both investigations are outlined in Table 3.2.  
Table 3.2. Comparison of exploratory trial in adults and current trial in adults and children. 
Parameter Exploratory trial Current trial Remarks 
Administration Dry dose vs. wet 
dose (in water) 
Pre-dispersed 
samples only 
Significantly worse palatability 
expected from dry dose and wet 
dose expected in practice 
Particle size Two sizes 
investigated 
Four sizes 
investigated 
Study extended to a broader size 
range as this is a critical 
formulation attribute  
Coating Uncoated samples Uncoated vs. 
coated samples 
Coated samples expected in 
practice but logistically more 
difficult to obtain 
Amount 250 vs. 500 mg 500 mg Larger dose was well tolerated in 
pilot study and allows delivery of 
less potent drugs 
Volume  10 ml of water 3 ml of water Volume of water used for pre-
dispersion of samples (10 ml) was 
considered too large 
Dosing device Dosing vial Dosing spoon Administration issues reported 
with dosing vial due to rapid 
sedimentation of particles 
Total samples  8 per participant 3 per participant Number of samples reduced to 
account for short attention span of 
children compared to adults 
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Evidence of acceptability of multiparticulates is still limited and more trials are required 
to investigate the impact of formulation factors on patient’s acceptability. For example, 
the size of multiparticulates might have an impact on ease of swallowing and mouthfeel 
perception. Larger multiparticulates can be expected to be less palatable and thus less 
acceptable than those of smaller size (Lopez et al., 2016). But particle size is an 
important feature of solid dosage forms which can have an impact on other properties of 
the formulation too. For instance, the release rate from coated granules has been shown 
to be proportional to their surface area, thus exponentially thicker coatings were required 
to control drug release from smaller granules (Ragnarsson and Johansson, 1988).  
Another important formulation factor which requires consideration is the application of 
polymeric coating. Multiparticulates are often designed for taste-masking, thus the final 
formulation would be film coated with a reverse-enteric coating (which is insoluble in 
saliva but releases the drug content at the lower pH of the stomach). A smooth polymeric 
film coating could improve surface properties by reducing surface roughness, which 
could have a positive impact on palatability. However, the application of a polymeric 
coating could also increase the size of the multiparticulates, which could have a negative 
impact on patient acceptability. There is very scarce evidence of the effect of coating on 
palatability and acceptability. Nevertheless, a previous study of acceptability of mini-
tablets (2 mm in size) in infants and pre-school children found no significant differences 
in acceptability between coated and uncoated minitablets (Klingmann et al., 2013). 
3.2 Aims and objectives 
The aims of this study were to evaluate palatability and acceptability of multiparticulates 
in healthy adults and children volunteers and compare the results in both population; to 
explore different methodologies and enhance knowledge of palatability and acceptability 
testing; and to assess the effect of formulation factors (particle size and presence of 
polymeric coating) on palatability and acceptability of multiparticulates.  
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3.3 Materials and methods 
3.3.1 Materials 
Microcrystalline cellulose pellets (Cellets®, Pharmatrans Sanaq, Basel, Switzerland) 
were used as model multiparticulates. The sizes investigated included those at 200-355, 
350-500, 500-750 and 700-1000 µm diameter and each particle size fraction was 
investigated in the form of uncoated and coated multiparticulates (Table 3.3). Coated 
multiparticulates were produced under Good Manufacturing Practices by Pfizer 
(Sandwich, United Kingdom) by coating Cellets® with Kollicoat® Smartseal 30D, a 
reverse enteric coating polymer intended for taste-masking applications.  
Table 3.3. Summary of multiparticulate formulations investigated by children and adults. 
Sample Particle size (µm) Polymer coating Fixed amount (mg) 
C200-u 200-355 Uncoated 500 
C350-u 350-500 Uncoated 500 
C500-u 500-710 Uncoated 500 
C700-u 700-1000 Uncoated 500 
C200-c 200-355 Coated 500 
C350-c 350-500 Coated 500 
C500-c 500-710 Coated 500 
C700-c 700-1000 Coated 500 
 
3.3.2 Material characterisation 
The particle size distribution of multiparticulates was assessed by laser diffraction using 
a Mastersizer 3000 fitted to an Aero S accessory for dry dispersion (Malvern Scientific, 
Worcestershire, UK). The air pressure and feeding rate were optimised to allow dry 
dispersion of the particles. Six replicates of each sample were tested; average values of 
six replicates were calculated for D10, D50 (median diameter) and D90 parameters. The 
morphological features of Cellets were imaged using Scanning Electron Microscopy 
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(SEM). Samples were adhered onto aluminium stubs (TAAB Laboratories, Reading, 
U.K.), sputter coated with gold under vacuum and then imaged at different magnification 
levels using a Quanta 200F instrument (FEI, Hillsborough, OR, USA).  
3.3.3 Sensory evaluation study 
3.3.3.1 Study design 
A palatability and acceptability study of multiparticulate formulations was conducted in 
children (inclusion criteria: 4-12 years old) and adults (inclusion criteria: 18-40 years old). 
The study in children was approved by the University of Birmingham Research Ethics 
Committee (ERN_15-1028) and took place in a designated room at Think-Tank Science 
Museum (Birmingham, United Kingdom); the study in adults was approved by the 
University College London Research Ethics Committee (ERN_6062-001) and was 
conducted in a designated room with a dispensary at the UCL School of Pharmacy. Adult 
participants and parents/carers of children participants received a detailed information 
sheet and signed informed consent; the study was also explained to children, who 
assented to participate in the study. The study design is outlined in Figure 3.1. 
 
Figure 3.1. Schematic representation of the study design for the evaluation of palatability and 
acceptability of multiparticulate formulations in children and adults. 
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Each participant received three 500 mg samples of placebo multiparticulates on a 
medicine spoon with approximately 3 ml of spring water that was added immediately 
before sample administration (Figure 3.2). Samples were self-administered by the 
participants, except for a few cases where the sample was administered to the child by 
one of the researchers to avoid spillages. Participants had free access to spring water 
as required to complete sample intake. An interval of 5-10 minutes was maintained 
between samples to minimise subject discomfort and carry over effect.  
 
Figure 3.2. Samples of 500 mg of multiparticulates dispersed in 3 ml of spring water on a medicine 
dosing spoon. Particle size of the multiparticulates varies, from left to right: 200-355, 350-500, 
500-710 and 700-1000 μm. Each size was available as coated and uncoated versions. 
The study took place over eight sessions (S1 - S8), with 6 to 14 participants per session 
to ensure a balanced ratio between participants and researchers (4-6 researchers). The 
first part of the study (S1 - S4) was dedicated to the evaluation of the effect of particle 
size and thus each participant received three samples of varying particle size (all 
samples were polymer coated for this part of the study). The second part of the study 
(S5 - S8) was dedicated to the evaluation of the effect of coating and thus each 
participant received two samples of identical particle size, one coated and one uncoated, 
plus an additional uncoated sample. The dosing schedule is summarised in Table 3.4.  
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Table 3.4. Dosing schedule for the sensory evaluation of multiparticulates. Numbers indicate the 
order in which samples were administered in each of the eight sessions (S1-S8). 
Sample S1 S2 S3 S4 S5 S6 S7 S8 
C200-c 1 3  2 1    
C350-c 2  3 1  2   
C500-c  2 1 3   2  
C700-c 3 1 2     1 
C200-u     2 3   
C350-u     3 1   
C500-u       1 3 
C700-u       3 2 
 
3.3.3.2 Evaluation tools and outcome measures 
Researcher observations 
Participants’ facial expressions and negative behaviours towards the samples were 
recorded prior to, during and post sample intake using a 12-point tick chart (Table 3.5). 
Each participant was observed by two researchers who evaluated the occurrence of 
facial expressions and behaviours listed on Table 3.5. Spontaneous verbal judgement of 
the samples was also recorded in researcher observation sheets.  
Table 3.5. Researcher observations 12-point tick chart for assessing negative facial expressions 
and behaviours of participants prior to, during and after sample intake. 
Negative behaviours  Facial expressions 
Before administration After administration  During administration 
 Refuses test sample  Spits out test sample   Pursed lips 
 Voices resistance  Voices disgust   Nose wrinkle 
 Cries/screams  Cries   Brow bulge (frown) 
 Requires restraint  Vomits   Eyes squeezed shut 
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The proportion of participants who swallowed the complete dose of multiparticulates (as 
opposed to those who spat out the sample or refused it) was determined as a simple and 
objective measure of the overall patient acceptability, as used in previous studies with 
mini-tablets (Klingmann et al., 2015, 2013; Kluk et al., 2015; Thomson et al., 2009).  
The sum of negative facial expressions and behaviours was calculated to investigate 
participants’ affective response and sample preferences. The proportion of participants 
who showed no negative facial expressions during sample intake was determined as a 
measure of acceptability based on facial expressions. Negative reactions recorded 
during sample intake are expected to be a good indicator of sample dislike, based on 
previous research with school-aged children (Zeinstra et al., 2009). 
Subject-reported outcomes 
Subject-reported outcomes were collected using a paper-based structured questionnaire 
(Figure 3.3) that was filled in by the participants of the study immediately after sample 
intake. The questionnaire was designed based on previous research which gathered 
opinions and preferences of children and adolescents (Mistry et al., 2016).  
Samples were evaluated using 5-point hedonic scales (from 1 – extremely liked to 5 – 
extremely disliked) for four different palatability attributes: grittiness, sample volume, 
overall mouthfeel and overall taste. The proportion of participants who rated all sample 
attributes in the neutral to positive range (hedonic rating = 1-3) was calculated as a 
measure of acceptability based on hedonic ratings. Participants could also provide 
voluntary open-ended feedback, which was used to facilitate interpretation of results. 
After completion of hedonic ratings, participants answered the following bipolar question: 
“If this was a medicine, would you be willing to take it every day?”. The proportion of 
participants that responded positively to this question was calculated as a predictive 
measure of future acceptability.  
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Figure 3.3. Paper-based structured questionnaire used for data collection of subject-reported 
outcomes of palatability and acceptability. 
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Figure 3.3 (Continued). Paper-based structured questionnaire used for data collection of subject-
reported outcomes of palatability and acceptability. 
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The total volume of water consumed for each sample was calculated by providing free 
access to water in cups with a pre-measured volume (150 ml). Additionally, the 
proportion of participants that reported that they could still feel the bits in their mouth 
after sample administration was determined based on participants’ responses to the 
bipolar question “Can you still feel any of the ‘bits’ in your mouth?”. 
3.3.3.3 Statistical analysis 
The number of participants required to detect significant differences between samples 
was estimated based on power calculations assuming parametric unimodal distribution, 
significance (α) of 0.05 and 80% power; a sample size of 14 would show the difference 
between two samples where the difference was 1 face and the standard deviation was 
also 1 face on the 5-point hedonic scale. This is supported by previous studies which 
demonstrated that a group of 15-18 participants is sufficiently large to detect significant 
differences between samples using categorical scales (Hayakawa et al., 2016; Kimura 
et al., 2015). Therefore, to enable analysis of the effect of particle size and coating on 
results, a minimum of 14 participants would be required in each part of the study.   
Statistical analysis of researcher observations and subject-reported outcomes was 
performed using non-parametric Kruskal-Wallis analysis of variance followed by Dunn’s 
test as post hoc for pairwise comparison, with 95% confidence. Size effect was estimated 
by analysis of subjects in Sessions 1-4 only as this enables a better within subject 
comparison of sizes. Similarly, coating effect was estimated by analysis of subjects in 
Sessions 5-8, excluding the sample with dissimilar size (i.e. sample 3). Association 
between evaluation parameters was investigated using Chi-Squared Test for Association 
with 95% confidence. The volume of water consumed was treated as a non-normally 
distributed continuous variable based on Kolmogorov–Smirnov test and analysis was 
carried out by Kruskal-Wallis test with 95% confidence. Minitab 17 (Minitab Inc., State 
College, Pennsylvania, USA) was used for data analysis.  
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3.4 Results and discussion 
3.4.1 Morphological characterisation of multiparticulates 
All samples exhibited a narrow, symmetric, unimodal particle size distribution (Figure 
3.4). The median particle size of uncoated multiparticulates was 279, 413, 594 and 871 
μm, for Cellets 200, 350, 500 and 700, respectively. The coated versions of Cellets were 
slightly larger, with median particle size of 290, 448, 615 and 921 μm, respectively. This 
represents a 3.5-8.5% increase with respect to their original size due to the application 
of the polymeric film around the particles. Thus, uncoated and coated versions of 
multiparticulates can be considered to have equivalent size, as such minor difference 
should not be expected to influence mouth-feel perception. 
 
Figure 3.4. Particle size distribution of Cellets by laser diffraction (dry dispersion method). 
SEM micrographs of multiparticulates are shown in Figure 3.5. The SEM images showed 
the highly spherical morphology of the model multiparticulates, which was maintained 
after coating of the particles. The surface of the multiparticulates was very smooth for 
both uncoated and coated versions, although coated particles showed presence of 
powder material on the surface, which could be ascribed to the addition of talc during 
manufacturing as adsorbent and anti-tacking agent. 
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Figure 3.5. SEM micrographs of uncoated and coated Cellets with 250x magnification. 
C200-u C200-c 
  
C350-u C350-c 
  
C500-u C500-c 
  
C700-u C700-c 
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3.4.2 Demographics 
A total of 132 participants were recruited, 71 children (4-12 years; median = 7 years) and 
61 adults (18-37 years; median = 22 years). Demographics are summarised in Table 3.6. 
Table 3.6. Demographic characteristics of the study participants. 
Session 
Children  Adults 
N Age (Ave ± SD)  N Age (Ave ± SD) 
1 9 6.6 ± 1.7  6 25.3 ± 5.2 
2 13 8.2 ± 2.2  12 23.0 ± 5.3 
3 8 6.6 ± 2.2  8 20.6 ± 3.0 
4 7 7.0 ± 2.1  7 20.7 ± 2.1 
Part 1 total 37 7.2 ± 2.1  33 22.4 ± 4.5 
5 8 7.1 ± 2.3  7 23.6 ± 4.9 
6 7 8.7 ± 2.0  7 24.7 ± 4.3 
7 12 6.8 ± 1.5  6 26.5 ± 4.3 
8 7 6.9 ± 2.4  8 26.6 ± 4.9 
Part 2 total 34 7.3 ± 2.1  28 25.4 ± 4.6 
Grand total 71 7.2 ± 4.0  61 23.7 ± 4.7 
 
3.4.3 Acceptability of multiparticulates: comparison between children and adults 
3.4.3.1 Success in swallowing the formulation 
The proportion of participants who swallowed the complete dose of multiparticulates, as 
opposed to those who spat out the sample or refused it, was 92% in children and 100% 
in adults (Figure 3.6). The sample was refused by five different children, two of whom 
refused two samples; the age of the children that refused the samples ranged from 5-8 
years with a median of 7 years. The sample was spat out by eight children, two of whom 
spat out two samples; the children that spat out the sample ranged from 4-10 years with 
a median of 8 years.  
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Figure 3.6. Proportion of participants who swallowed, spat out or refused multiparticulates. 
There were 10 occasions (5%) where children voiced resistance to taking the sample, 
and 20 occasions (9%) where children voiced disgust after sample administration. Other 
negative outcomes such as crying, screaming or vomiting were never observed in 
children participants before, during or after sample intake. No such negative behaviours 
were observed in adult participants, as it could be expected. 
3.4.3.2 Researcher observations of negative facial expressions 
Display of negative facial expressions upon sample administration was more common in 
children, although it was detected in both population groups (Figure 3.7).  
 
Figure 3.7. Proportion of participants displaying negative facial expressions upon sample intake. 
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Overall, researcher observations of negative facial expressions denoted a certain level 
of dislike or discomfort with the samples. The most commonly observed negative facial 
expression was ‘pursed lips’ (with 57% of children and 34% of adults displaying this 
behaviour), followed by ‘nose wrinkle’ (30% and 10%), ‘brow bulge’ (26% and 9%) and, 
lastly, ‘eyes squeezed’ (21% and 5%, respectively).  
Children displayed one or more negative facial expression 149 times (70%), whereas 
this measure accounted for 76 (42%) in adults. In other words, children showed neutral 
or positive attitudes towards the samples in 57 (27%) occasions and adults in 107 (58%) 
occasions. Seven children (3%) refused the sample and thus facial expressions were not 
recorded. Differences between populations were significant (p < 0.001). 
3.4.3.3 Subject-reported outcomes using hedonic scales 
Participants rated four different sample attributes using 5-point hedonic scales: grittiness, 
mouthfeel, taste and sample volume. Overall, grittiness was the most negatively rated 
attribute, with a median of 4 in both adults and children (Figure 3.8). The most favourably 
rated item was sample volume (median of 2 and 3 in adults and children, respectively).  
 
Figure 3.8. Rating of palatability attributes in hedonic scales (1 - best possible rating to 5 - worst 
possible rating). Centre lines show the median, box limits the 25th and 75th percentiles, notches 
represent the 95% confidence interval of the median and outliers are denoted by dots. 
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Overall, ratings of palatability descriptors were significantly worse in children than in 
adults, particularly for taste and sample volume. Adult participants rated at least one 
palatability attribute in the negative range of the scale in 105 cases (57%), whereas this 
value accounted for 145 (68%) in children. Therefore, multiparticulates received neutral-
positive evaluations in 61 (29%) occasions by children and 78 (43%) by adults, in close 
agreement with the findings based on researcher observations. Seven children (3%) 
refused the sample and thus hedonic ratings were not recorded. Differences between 
both populations in ratings of palatability descriptors were significant (p < 0.001). 
Participants’ spontaneous descriptions of the samples support the findings of hedonic 
scales; samples were often described as “tasteless” or as having “no flavour” but the 
feeling in the mouth was found to be “gritty” and “sandy”. Interestingly, the feedback 
provided by children often denoted the lack of flavour as a negative aspect of the 
formulation, e.g. “it was horrible because it had no flavour” or “if it had a flavour it would 
be nice”. This could explain the negative ratings given to taste in contrasts with adults. 
Moreover, children often employed the term “gritty” as a negative attribute of taste 
instead of mouthfeel, e.g. “I hated the gritty taste” or “the taste was bad because it was 
gritty”. This interconnection of responses to different sample attributes could have also 
contributed to the negative ratings of taste provided by children.  
Interconnection of responses in hedonic scales was common not only in children but also 
in adults. A significant association was found between each possible pair of palatability 
descriptors in both population groups (p < 0.001). This suggests the existence of a ‘halo 
effect’ by which participants’ responses to one attribute were influenced by their opinion 
and responses to other attributes. For example, when the mouthfeel of the sample was 
disliked, the taste of the sample would tend to be disliked too. This may indicate that the 
measures relate to the overall acceptance of the sample rather than to each parameter 
individually. Such phenomenon can be expected in sensory evaluation studies involving 
untrained panellists (Mason and Nottingham, 2002; Prescott et al., 2011). 
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In terms of the use of scales, differences between paediatric and adult populations were 
evident. In general, children used preferentially the extremes of the hedonic scales, as 
expected based on previous research (ASTM, 2003), whereas adults’ responses were 
evenly distributed throughout the five points of the hedonic scales (Figure 3.9). As 
previously discussed, ratings of sample volume and taste were significantly worse in 
children than adults, which could suggest different sensitivity and/or differences in the 
interpretation of palatability descriptors between populations. 
 
Figure 3.9. Histograms of ratings using hedonic scales. Dark blue bar represents median. 
3.4.3.4 Willingness to take multiparticulates every day as a medicine 
The proportion of participants willing to take the sample every day if it was a medicine 
was calculated as a predictive measure of future acceptability (Figure 3.10). Overall, 
children reported their willingness to take the sample every day in 63 occasions (30%), 
while their response was negative in 143 occasions (67%); seven children (3%) refused 
the sample and thus their response was not collected. Adults reported willingness to take 
the sample every day in 135 cases (74%), compared to 48 negative cases (26%); 
differences between both populations being significant (p < 0.001). 
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Figure 3.10. Proportion of volunteers ‘willing to take the sample every day if it was a medicine’. 
Seven children (3%) refused the sample and thus, although their willingness response was not 
collected, these were reported as not willing to take the sample every day if it was a medicine. 
A significant association was found between ratings of palatability descriptors and the 
willingness of participants to take the sample every day. This means that those patients 
who rated palatability positively would tend to be more willing to take the sample every 
day, as it could be expected. This association between hedonic ratings and willingness 
to take the sample is depicted in Figure 3.11. This association was stronger for grittiness, 
mouthfeel and taste (p < 0.001 in all cases) than it was for sample volume (p = 0.004).  
 
Figure 3.11. Hedonic rating as a function of the reported willingness to take the sample every day. 
Markers represent the mean hedonic rating and bars show the 95% CI for the mean. 
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3.4.3.5 Comparison between outcome measures 
The reported willingness to take the sample every day by children (30%) was aligned 
with their positive outcome based on researcher observations (23%) and hedonic ratings 
(29%), whereas adults reported to be willing to take the sample (74%) more frequently 
than expected based on researcher observations (58%) and hedonic ratings (43%). 
Results are summarised in Table 3.7 and graphically depicted in Figure 3.12. 
Table 3.7. Comparison of multiparticulates acceptability outcomes in children and adults. 
Evaluation criteria Outcome Children Adults 
Success swallowing Sample swallowed 196 (92%) 183 (100%) 
 Sample refused/spat out 17 (8%) 0 (0%) 
Facial expressions † No negative expressions 57 (27%) 107 (58%) 
 Negative expressions 149 (70%) 76 (42%) 
Hedonic ratings † All hedonic ratings ≤ 3 61 (29%) 78 (43%) 
 At least one rating > 3 145 (68%) 105 (57%) 
Willingness † Willing to take daily 63 (30%) 135 (74%) 
 Not willing to take daily 143 (67%) 48 (26%) 
† Seven children (3%) refused the sample, thus their negative facial expressions and responses to hedonic 
ratings and willingness to take the sample every day were not recorded. 
 
 
Figure 3.12. Comparison of multiparticulates acceptability outcomes in children and adults.  
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More detailed analysis of the link between outcome measures revealed that 21% of 
children and 58% of adults would be willing to take multiparticulates every day as a 
medicine despite their negative ratings of the samples using hedonic scales (Figure 
3.13). This indicates that some participants (especially adults) would be willing to take 
the sample even if palatability was not acceptable, which suggests that their responses 
were influenced by psychological factors such as the perceived need to take a medicine.  
From those participants who showed acceptance based on hedonic ratings, 95% of 
adults but only 53% of children reported their willingness to take multiparticulates every 
day as a medicine. Therefore, the reliability of adult responses was confirmed but the 
validity and reliability of children reported outcomes can be questionable. Children might 
have negative perceptions about the use of medicines (Ranmal, 2014), which could 
hinder their willingness to take medicines even if palatability is acceptable. Additionally, 
some children might have difficulties using the scales appropriately. Expert guidance on 
the design of evaluation tools for studies involving children highlights the difficulty of 
using subject-reported outcome measures and encourages the use of researcher 
observations instead (ASTM, 2003; FDA, 2009; Matza et al., 2013). 
 
Figure 3.13. Probability of participants to report willingness to take multiparticulates every day 
as a function of their responses to hedonic scales (samples were considered accepted based on 
hedonic ratings when all sample attributes were rated in the neutral to positive end of the scale). 
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Evaluation of negative facial expressions showed that 27% of children and 59% of adults 
would be willing to take multiparticulates every day despite showing facial signs of non-
acceptance (Figure 3.14). These values were comparable to those obtained for hedonic 
ratings and support the hypothesis that some participants (especially adults) might be 
willing to take medicines even if they dislike them.  
However, from those participants who showed acceptance based on facial expressions, 
only 40% of children and 84% of adults reported their willingness to take the sample 
every day. This compared to 53% and 95%, respectively, based on hedonic ratings. 
Thus, researcher observations of facial expressions seemed less sensitive than hedonic 
ratings to predict the willingness of participants to take multiparticulates. Poor correlation 
between outcome measures suggests questionable reliability of responses. There are 
several potential explanations: Firstly, facial expressions could have been the results of 
ingestion of a novel material rather than signs of non-acceptance. Moreover, participants 
(especially young children) might not understand the question about their ‘willingness to 
take the sample every day’. Finally, some participants (especially children) could reject 
medicines even if they think palatability is acceptable. 
 
Figure 3.14. Probability of participants to report willingness to take multiparticulates every day 
as a function of their negative facial expression (samples were considered accepted based on facial 
expressions when no negative facial expressions were observed during sample intake). 
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3.4.4 Effect of formulation factors on palatability and acceptability  
Eight different formulations were evaluated in this study, consisting on four sizes of 
multiparticulates, each available as coated and uncoated versions. However, each 
participant only evaluated three formulations. The first part of the study (Sessions 1-4) 
was dedicated to the analysis of the effect of particle size on palatability and acceptability 
and thus each participant had three samples of different particle size. The second part 
of the study (Sessions 5-8) was dedicated to the analysis of polymeric coating on 
palatability and acceptability and thus each participant evaluated coated and uncoated 
multiparticulates of the same particle size. Based on this study design, analysis of the 
effect of formulation factors was performed on Sessions 1-4 and Sessions 5-8 separately 
to enable within subject comparison of size and coating effects, respectively.  
3.4.4.1 Effect of formulation factors on researcher observations 
Looking at the proportion of participants who swallowed the formulations (as opposed to 
those who refused or spat out the sample), children accepted multiparticulates in 92% of 
attempts and adults accepted multiparticulates in all cases. Therefore, analysis of the 
effect of size and coating on acceptability was impractical. Based on this outcome 
measure, multiparticulates were well accepted regardless of the formulation properties.  
Similarly, based on researcher observations of negative facial expressions, no significant 
differences between different multiparticulate sizes and between coated or uncoated 
samples were found in either children (p = 0.923 and p = 0.800 for size and coating 
effects, respectively) or adults (p = 0.551 and p = 0.795, respectively). 
Differences between samples were expected based on previous research and were 
demonstrated by analysis of subject-reported outcomes such as ratings on hedonic 
scales, as outlined later in Section 3.4.4.2. Since no differences between samples were 
found based on researcher observations, this indicates that researcher observations 
were less discriminative than subject-reported outcomes. 
 113 
3.4.4.2 Effect of formulation factors on subject-reported outcomes 
Ratings of sample attributes on hedonic scales revealed acceptance of the sample by 
29% of children and 43% of adults. Looking at the effect of different formulation factors, 
adults perceived larger particles as being ‘grittier’ (p < 0.001). On the contrary, there was 
no real evidence of size effect in children (p = 0.214), although the larger two sizes 
received higher grittiness scores on average than the lower two sizes. There was some 
evidence of a coating effect on hedonic ratings in adults, with coated samples scoring 
lower on average, although this was not statistically significant (p = 0.079). The presence 
of polymeric coating had no significant effect on hedonic ratings in children (p = 0.451). 
Subject-reported willingness to take multiparticulates every day as a medicine suggested 
acceptance by 30% of children and 74% of adults. Considering formulation factors, 
particle size had a significant effect on the reported willingness to take the sample every 
day by adult participants, who showed preference for smaller particles (p = 0.042), in 
agreement with their responses to hedonic scales. In the case of children, particle size 
had no significant effect on the willingness to take the sample every day (p = 0.479), 
which is also in agreement with their responses to hedonic scales. The effect of coating 
on the reported willingness to take the sample every day as a medicine was trivial in both 
children and adults (p = 0.571 and p = 0.778, respectively). 
A detailed analysis of the effect of formulation factors on subject-reported outcomes of 
palatability and acceptability is outlined below: 
Effect of multiparticulate size 
As it can be expected based on previous research, adult participants perceived larger 
multiparticulates as being less palatable, based on ratings of grittiness (p < 0.001) and 
mouthfeel (p = 0.001), as shown in Figure 3.15. The grittiness score for the 200-355 µm 
multiparticulates was 2.6 on average, compared to 4.2 for the 700-1000 µm 
multiparticulates. Similarly, the mouthfeel score for the smallest particles was 2.1 on 
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average, compared to 3.3 for the largest particles. Surprisingly, children showed no 
preference towards any particle size based on hedonic ratings of grittiness (p = 0.504) 
and mouthfeel (p = 0.590). Children rated grittiness between 3.2 and 4.0 on average and 
mouthfeel between 3.0 and 3.6 on average. The negative ratings of grittiness and 
mouthfeel provided for all samples together with the broad inter-individual variability in 
children could have hindered evaluation of the true effect of particle size on grittiness 
and mouthfeel. Moreover, the ability of children to interpret and independently rate the 
different hedonic descriptors was further dubious, as previously discussed. 
 
 
Figure 3.15. Interval plots for grittiness and mouthfeel as a function of multiparticulate size 
(results of Sessions 1-4), by population group. Markers represent the population average hedonic 
rating (1 - best possible and 5 - worst possible) and bars show the 95% CI for the mean.  
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Although children provided similar grittiness and mouthfeel scores regardless of the size 
of the multiparticulates, scores of ‘sample volume’ worsened with increasing particle size 
(p = 0.065), as shown in Figure 3.16. Children scored the largest particles 1.0 point 
higher on average than the smallest particles. In the case of adults, the two larger sizes 
also received higher scores than the smaller two sizes (p = 0.042), although the effect of 
size on ratings of sample volume was less ostensible than in children. It seemed that, 
since larger multiparticulates felt coarser in the mouth, participants rated the sample 
volume as being larger, despite the quantity of multiparticulates being the same. 
 
 
Figure 3.16. Interval plots for sample volume and taste as a function of multiparticulate size 
(results of Sessions 1-4), by population group. Markers represent the population average hedonic 
rating (1 - best possible and 5 - worst possible) and bars show the 95% CI for the mean. 
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As shown in Figure 3.16, the size of the multiparticulates had no effect on the taste of 
the sample, for either adults (p = 0.238) or children (p = 0.951). However, children rated 
the taste of the samples in the negative range of the scale on average (3.2 – 3.4), 
whereas adults provided positive ratings for taste on average (2.0 – 2.5). This could be 
mainly ascribed to the lack of flavour of the sample, which could have been considered 
a negative attribute for children in contrast with adults. The inability of (some) children to 
interpret the different palatability attributes and rate them independently could have also 
contributed to the negative ratings of taste. As discussed before, a significant association 
was found between different palatability descriptors in both children and adults, which 
indicates that participants’ responses to one attribute were influenced by their opinion 
and responses to other attributes. This halo effect would also explain why adults rated 
the taste of the samples more negatively as the size of the multiparticulates increased.  
Particle size had a significant effect on the reported ‘willingness to take the sample every 
day if it was a medicine’ by adult participants (Figure 3.19), who showed preference for 
smaller multiparticulates (p = 0.042) but not in children (p = 0.479), in agreement with 
their responses to hedonic scales. 
 
Figure 3.17. Willingness to take the multiparticulate sample every day if it was a medicine as a 
function of the size of the multiparticulates. 
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Effect of presence or absence of polymeric coating 
There was some indication that the polymeric coating reduced grittiness and improved 
mouthfeel, since average ratings by adults improved by 0.5 and 0.3 points, respectively 
(Figure 3.18). However, differences in grittiness and mouthfeel between samples were 
not significant (p = 0.225 and p = 0.523, respectively). Similarly, negligible differences 
were found on the ratings of grittiness and mouthfeel in children (p = 0.226 and p = 0.432, 
respectively). Negligible differences between samples could be attributed to the smooth 
surface of both coated and uncoated multiparticulates, as demonstrated by SEM.  
 
 
Figure 3.18. Interval plots for grittiness and mouthfeel as a function of polymeric coating (results        
of Sessions 5-8), by population group. Markers represent the population average hedonic rating 
(1 - best possible rating and 5 - worst possible rating) and bars show the 95% CI for the mean. 
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Ratings of sample volume and taste were in line with the previous findings in that the 
presence or absence of polymeric film coating did not have a significant impact on 
palatability (Figure 3.19). There was some effect of coating on the ratings of sample 
volume by children, who rated uncoated samples at 2.8 on average compared to 3.4 for 
coated versions, although this difference was not statistically significant (p = 0.075). The 
effect of polymeric coating on sample volume was negligible in adults (p = 0.386). 
Ratings of taste were not influenced by the presence or absence of coating in either 
children (p = 0.753) or adult participants (p = 0.600). 
 
 
Figure 3.19. Interval plots for sample volume and taste as a function of polymeric coating (results 
of Sessions 5-8), by population group. Markers represent the population average hedonic rating 
(1 - best possible rating and 5 - worst possible rating) and bars show the 95% CI for the mean. 
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Since all samples contained the same amount of multiparticulates and the effect of 
polymeric coating on ratings of palatability was estimated between samples with the 
same particle size, differences in ratings of sample volume in children remained 
unexplained. Misinterpretation of palatability descriptors and the inherent intra-subject 
variability in responses could have contributed to the effect of polymeric coating on 
ratings of sample volume by children.  
In line with the ratings of palatability attributes, the effect of coating on the reported 
willingness to take the sample every day as a medicine was trivial in both children and 
adults (p = 0.788 and p = 0.571, respectively), as shown in Figure 3.20. Children were 
willing to take coated and uncoated multiparticulates in 26 and 29% of occasions, 
whereas adults would be willing to take these in 71 and 64% of occasions, respectively. 
 
Figure 3.20. Willingness to take the multiparticulate sample every day if it was a medicine as a 
function of presence of polymeric film coating. 
In summary, the presence or absence of polymeric coating did not have a significant 
impact on the ratings of palatability in either population group. Results were aligned with 
previous findings which suggested no significant differences in acceptability between 
coated and uncoated minitablets (Klingmann et al., 2013).  
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3.4.4.3 Water consumed and residual multiparticulates in the mouth 
In addition to the small volume of water used to pre-disperse multiparticulates on the 
dosing spoon (ca. 3 mL), participants had free access to spring water to complete sample 
intake. Children consumed 51 mL of water on average (median = 40 mL, min = 0 mL, 
max = 242 mL), whereas adults consumed 63 mL on average (median = 56 mL, min = 0 
mL, max = 150 mL). The water consumed was comparable between formulations, 
regardless of the particle size and coating (Figure 3.21); consequently, differences 
between samples were not significant in either children (p = 0.291) or adults (p = 0.161). 
 
 
Figure 3.21. Volume of water (ml) consumed during the administration of multiparticulates, as a 
function of their size and coating. Centre lines show the median, box limits represent the 25th and 
75th percentiles and outliers are denoted by asterisks.  
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After rinsing their mouth with water, participants were asked if they could still feel the 
multiparticulates in their mouth. Overall, adults reported that they could still feel residual 
particles in their mouth in 97 occasions (53%), whereas children reported they could feel 
remaining particles in 116 occasions (56%). In general, the reported feeling of residual 
multiparticulates increased with increasing particle size (Figure 3.22), although this effect 
was not statistically significant in either children or adults (p = 0.057 and p = 0.106, 
respectively). Coating had no significant impact on the reported feeling of residual 
multiparticulates in either children or adults (p = 0.620 and p = 0.427, respectively). 
 
 
Figure 3.22. Proportion of participants that reported they could still feel residual multiparticulates 
in their mouth after administration of multiparticulates, as a function of their size and coating. 
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3.5 Conclusions 
Results of this trial indicate acceptability of multiparticulates based on voluntary sample 
intake. Healthy adults swallowed the multiparticulate samples in all occasions, whereas 
healthy children accepted the sample in 92% of the occasions. Although the sample was 
refused or spat out by some children (3% and 5%, respectively), no undesirable effects 
such as coughing or vomiting with the sample were observed or reported.  
However, researcher observations and subject-reported outcomes denoted some level 
of discomfort and sample dislike by the participants of the study. Review of the number 
of occasions where participants showed no negative facial expressions, acceptability of 
multiparticulates could be determined as 27% in children and 58% in adults. These 
results were in line with the subject-reported outcomes for palatability, where only 29% 
of children and 43% of adults scored every palatability descriptor in the neutral to positive 
range of the hedonic scales. Moreover, the willingness to take the sample every day if it 
was a medicine was determined to be 30% in children and 74% in adults, based on 
subject-reported outcomes. These values were in contrast with the more optimistic 
results of acceptability obtained by simply measuring the proportion of volunteers who 
took the sample. Overall, adult participants showed broader acceptance than children, 
as consistently shown by each of the different outcome measures.  
Discomfort and dislike of the samples could be ascribed to the ‘gritty’ feeling in the mouth 
produced by multiparticulates, as demonstrated by the overwhelming proportion of 
negative ratings given to ‘grittiness’ and supported by spontaneous verbal judgment of 
the samples. These findings are aligned with previous research in adults (Kimura et al., 
2015; Lopez et al., 2016), as well as in the preliminary trial described in Chapter 2. In 
addition, over half of the participants reported a feeling of residual multiparticulates in 
the mouth after sample intake. Long-lasting sensation of rough mouthfeel was previously 
reported in a study in adults using a swirl and spit methodology (Kimura et al., 2015).  
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Development of a suitable vehicle for the administration of multiparticulates could have 
a beneficial impact on the final formulation via masking the presence of particles. Typical 
vehicles recommended for sprinkle products include apple sauce and yogurt that provide 
both flavour and viscosity to improve the overall palatability (including taste and texture) 
of multiparticulates. The results of this trial led to the development of oral vehicles for the 
administration of multiparticulates which is the focus of the work described in Chapter 4. 
Investigation into swallowing aids for the administration oral solid formulations have been 
the focus of previous research, with some products already in the market in the form of 
sprays, pastes or jellies (Bunupuradah et al., 2006; Diamond and Lavallee, 2010; Kluk 
and Sznitowska, 2014).  
As demonstrated in this trial, the methodology used to assess acceptability determines 
the percentage of participants that report the sample to be acceptable. Results indicate 
that a simple measure of the subject’s ability to take a sample might not be sufficient to 
evaluate patient’s acceptability, understood not only as the ability but also the willingness 
to take the product. Despite of the vast number of participants that accepted to take the 
sample, researcher observations and subject-reported outcomes showed a significant 
proportion of participant’s discomfort and dislike. Researcher observations of facial 
expressions and behaviours, participants’ hedonic ratings and spontaneous verbal 
judgement of the samples provided a valuable insight into patient’s acceptability and 
sample preferences.  
A significant association was found between hedonic ratings and willingness to take the 
sample every day, which confirms the link between palatability and acceptability, as 
supported by previous research (Baguley et al., 2012). Adults, however, were more 
willing to take the sample every day than expected based on hedonic rating, which 
suggests that psychological factors such as the perceived need to take a medicine might 
have influenced their response. In terms of sample preferences, children showed no 
significant preference for any sample, although there was some evidence to suggest 
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preference for the two smaller sizes. Meanwhile, adults showed strong preference for 
smaller multiparticulates based on hedonic ratings and willingness to take the sample 
every day. The presence of film coating on the multiparticulates did not seem to influence 
palatability and acceptability of the samples in either children or adults. 
Overall, the results of this trial suggest that multiparticulates could be used as a suitable 
formulation platform for the administration of medicines to adults and children as young 
as 4 years old, although palatability might be a barrier to patient’s acceptability due to 
the gritty mouthfeel of this type of formulation. This study should be extended to younger 
children based on the positive results of this trial in terms of safe administration. 
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Chapter 4 
4. Development of oral vehicles to improve palatability and 
acceptability of multiparticulates 
 
This chapter describes a set of experiments to investigate the applicability of liquid 
vehicles based on hydrocolloids as media for the administration of multiparticulates. A 
range of vehicles commonly used in practice for the administration of oral medicines 
were identified and characterised to be used as benchmark. Then, liquid vehicles with 
varying rheological properties were developed using hydrophilic polymers. Palatability 
and acceptability of placebo multiparticulates dispersed in such vehicles were evaluated 
in a panel of healthy adult volunteers to determine the target rheological properties of 
liquid vehicles for the administration of multiparticulates.  
4.1 Introduction 
Multiparticulate formulations emerge as a flexible solid oral dosage form with potential to 
overcome limitations of conventional solid and liquid medicines for the delivery of drugs 
to a broad range of patients, including paediatrics, geriatrics and patients with swallowing 
difficulties. However, previous studies involving  children and adults participants suggest 
that the gritty feeling in the mouth produced by these hard spheroids might be a barrier 
to palatability and patient acceptability (Kimura et al., 2015; Lopez et al., 2016). A 
potential solution to overcome palatability and patient’s acceptability issues could be co-
administration with a suitable vehicle which could help to conceal the presence of 
multiparticulates in the sample.  
Medicines are known to be mixed with liquid and semi-solid foodstuff to allow 
administration to children in clinical practice (Akram and Mullen, 2015, 2012). This 
includes tablets and capsules which are manipulated to be dispersed into foodstuff, but 
also multiparticulates which are purposely designed to be ‘sprinkled’ onto food or drinks, 
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e.g. (Adu-Afarwuah et al., 2008; Musiime et al., 2014; Verrotti et al., 2012). Solid 
medicines are also known to be mixed with thickened fluids to allow dosing to patients 
with swallowing dysfunctions (Fusco et al., 2016; Manrique et al., 2016); food thickeners 
promote safer swallowing by increasing the viscosity of food and beverages (Steele et 
al., 2015). However, this is not without the risks that mixing medication with foodstuff 
could alter bioavailability and introduce poor control over dose intake (EMA, 2013).  
The development of a standard pharmaceutical vehicle for the administration of 
multiparticulates could overcome some of the limitations of co-administration with food. 
The EMA mandates evaluation of the potential impact on patient acceptability, dosing 
accuracy, compatibility and drug bioavailability of the proposed vehicle(s) for co-
administration with medicines (EMA, 2013). That task becomes very impractical when 
medicines can be mixed with a range of foods with different composition and physical 
properties (e.g. rheology, pH, ionic strength). However, if the liquid vehicle is rationally 
designed and provided as part of the final product these investigations are more 
controlled and therefore facilitated. Ideally, such liquid vehicle should be formulated as 
a solid product for reconstitution given the inherent limitations of liquids. Some of the 
attributes which require consideration during the development of liquid vehicles for the 
administration of medicines are summarised on Table 4.1. 
Table 4.1. Quality Target Product Profile (QTPP) for a pharmaceutical liquid vehicle 
Critical Quality Attributes (CQAs) Target requirements 
Patient safety Excipients Generally Regarded As Safe (GRAS) 
Manufacturability Scalable for production at commercial scale 
Reconstitution Rapid reconstitution in water with minimal mixing 
Suspendability Forms stable suspensions during in-use conditions 
Dosing accuracy Appropriate instructions and dosing device provided 
Palatability Acceptable appearance, mouth-feel and taste 
Bioavailability Do not interfere with drug product bioavailability 
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The rheological properties of a pharmaceutical liquid vehicle require especial attention 
as these will have an impact on several critical quality attributes, such as suspendability, 
palatability (particularly appearance and mouth-feel) and drug bioavailability. In this 
regard, an essential excipient in the development of liquid vehicles for the administration 
of medicines will be viscosity modifiers or thickening agents. Hydrocolloids that have 
been frequently used as thickening agents include starch and modified starch, xanthan 
gum, galactomannans like guar gum and locust bean gum, acacia gum and cellulose 
derivatives like methylcellulose, hydroxypropyl cellulose and carboxymethyl cellulose. 
The thickening effect produced by these substances will depend on the type of 
hydrocolloid used, its concentration, the liquid in which it is dispersed and the 
temperature (Saha and Bhattacharya, 2010).  
The link between rheology and texture or mouth-feel perception has been extensively 
studied (especially in food products), although there are still many unknowns given the 
complexity and multifactorial nature of texture perception and palatability (Stokes et al., 
2013). The link between rheology and swallowing is also not fully understood given the 
complexity of such physiological process, although thicker liquids have been found to 
facilitate swallowing and reduce the risk of penetration-aspiration in patients with 
swallowing dysfunction (Steele et al., 2015). There is insufficient evidence to support 
delineation of viscosity boundaries related to such clinical outcomes, and there is no 
consensus for a shear rate that should be used as a reference for viscosity (Steele et al., 
2015). Viscosity measurements made at shear rates around 50 s−1 have been found to 
correlate with initial thickness perception and are commonly used as a reference value 
to compare between samples (Chen and Engelen, 2012; Stokes et al., 2013). 
Development of media for the administration of multiparticulates and evaluation of its 
effect on palatability has been the focus of two recent studies (Kluk and Sznitowska, 
2014; Lopez et al., 2016), both of which concluded that the use of polymeric hydrogels 
as administration vehicles could help conceal the presence of particles, reducing oral 
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grittiness perception. However, both studies focussed on a swirl and spit methodology, 
which overlooks other important sample attributes such as ease of swallowing. 
Moreover, neither of those studies investigated the palatability of the liquid vehicles 
alone, which limited their understanding on the effect of the palatability of the vehicle on 
the overall palatability and acceptability of the final formulations.  
4.2 Aims and objectives 
The aim of this work was to define the target rheological properties for an oral vehicle for 
the administration of multiparticulates with improved palatability and acceptability. 
Secondary objectives included to develop oral vehicles with contrasting rheological 
characteristics; and to evaluate the effect of oral vehicles on palatability and acceptability 
of multiparticulates in a study with healthy adult volunteers. 
4.3 Materials and methods 
4.3.1 Materials 
Model multiparticulates: Microcrystalline cellulose pellets (Cellets) were provided by 
Pharmatrans Sanaq (Basel, Switzerland). Oral suspending vehicles and oral paediatric 
medicines: Ora-Plus® (“Suspending vehicle A”) was supplied by Perrigo (Dublin, 
Ireland); SyrSpend® SF PH4 (“Suspending vehicle B”) and Simple syrup were supplied 
by Fagron (Waregem, Belgium). Nurofen® children Ibuprofen Oral Suspension 
100mg/5ml (“Ibuprofen suspension A”, Reckitt Benckiser), Fenpaed® Ibuprofen sugar-
free Oral Suspension 100mg/5ml (“Ibuprofen suspension B”, Pinewood Laboratories), 
Calpol® Infant Paracetamol Oral Suspension 120mg/5ml (“Paracetamol suspension A”, 
McNeil Products) and Boots® Paracetamol Oral Suspension 120mg/5ml (“Paracetamol 
suspension B”, The Boots Company) were purchased from a local Pharmacy. Food 
thickeners and food products: The xanthan-gum-based food thickener Resource® 
ThickenUp® (“XG thickener”) was provided by Nestle Health Science (Gatwick, Sussex, 
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UK) and the starch-based food thickener Multi-thick® (“Starch thickener”) was provided 
by Abbott Nutrition (Lake Bluff, Illinois, USA); both food-thickeners were prepared to two 
different consistency levels (Stage 1 and Stage 2) following manufacturers’ instructions. 
Vanilla-flavoured full-fat yogurt (Onken®), vanilla-flavoured fat-free yogurt (Onken®), 
vanilla-flavoured soya-based yogurt (“Dairy-free yogurt”, Alpro®) and vanilla-flavoured 
fromage-frais (“Children yogurt”, Petit Filous®) were purchased from a local supermarket 
(Waitrose, London, UK). Excipients for development of polymeric hydrogels: Xanthan 
gum (“XG”, Xantural 180) was supplied by CP Kelco (Leatherhead, Surrey, UK); sodium 
carboxymethyl-cellulose (“CMC”, Blanose 7HF-PH) was provided by Ashland 
(Covington, Kentucky, USA); guar gum (“GG”) and vanillin were procured from Sigma-
Aldrich (Irvine, Ayrshire, UK).  
4.3.2 Preparation and characterisation of liquid vehicles 
4.3.2.1 Preparation of liquid vehicles 
Polymeric hydrogels in the range of 0.15 – 1.50% (w/v) were prepared by slow addition 
of hydrophilic polymer (XG or CMC) into 100 ml of water under continuous stirring at 
room temperature. Samples were left stirring overnight to ensure complete polymer 
hydration and stored in the fridge for a maximum of one week. Samples were allowed to 
equilibrate to room temperature for at least 60 minutes before testing. 
4.3.2.2 Rheological characterisation 
A Bohlin CVO rotational rheometer system (Malvern Instruments Ltd, Malvern, UK) was 
used to investigate the flow properties of the samples using a cone and plate geometry 
(40 mm diameter, 4 º angle; gap size adjusted to 250 µm). A shear sweep measurement 
mode was employed, whereby the shear rate of the sample was advanced across the 
range of 0.1 to 200 s−1, with ascendant logarithmic progression. The temperature of the 
samples was maintained at 25 ± 0.2 ºC throughout testing.  
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The resulting data (shear rate vs. shear stress) was fitted to the power law model 
(equation 1) to describe the flow properties of the samples: 
𝜎 = 𝐾𝛾𝑛         (1) 
where σ is the shear stress (Pa), γ is the shear rate (1/s), K is the consistency index 
(Pas), and n is the flow behaviour index (dimensionless).  
The consistency index (K) corresponds to the viscosity at a shear rate of 1 s-1 and is a 
measure of the thickness of the sample; whereas the flow behaviour index (n) provides 
an indication of the deformation behaviour, where a value of 1 indicates Newtonian 
behaviour, 0-1 indicates shear-thinning behaviour and values greater than 1 indicate 
shear-thickening. The values of K and n were used to describe the rheological properties 
and compare between samples. In addition, the apparent viscosity at 50s-1 (ƞ at 50s-1), 
a reference shear rate for oral processing and swallowing, and the apparent viscosity at 
0.1s-1 (ƞ at 0.1s-1), a reference shear rate of the sample at rest, were measured by the 
rheometer along the ascendant shear ramp. This procedure was repeated three times 
for each sample. 
4.3.2.3 Polymer hydration experiments 
A test was developed to measure the hydration behaviour of hydrocolloids. A Bohlin CVO 
rotational rheometer system (Malvern Instruments Ltd, Malvern, UK) was adapted by 
fitting a glass petri dish (50 mm diameter, 15 mm height) as sample holder (Figure 4.1). 
A 40-mm diameter, 4 º angle plate was fitted to the instrument and the gap set at 250 
µm (from the base of the petri dish). The petri dish was filled with 10 ml of deionised 
water and a test sample of 100 mg of polymer was added while the viscosity was 
measured at a fixed shear rate of 10 s-1, at 30 second intervals for 30 minutes (ƞt=x). 
Separately, a sample of 100 mg of hydrophilic polymer was dispersed in water under 
continuous stirring at room temperature and left stirring overnight to ensure full hydration; 
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the viscosity of such sample was then determined at a shear rate of 10 s-1 to be used as 
a reference of viscosity after full hydration (ƞt=∞). Results of the hydration test were 
expressed as viscosity of the test sample compared to the viscosity of the fully hydrated 
sample (ƞt=x/ƞt=∞, normalised viscosity). Experiments were conducted in triplicate. 
 
Figure 4.1. Adapted set up of rotational rheometer using a petri dish as sample holder. 
4.3.2.4 Sedimentation time 
The ability of the oral vehicles to maintain multiparticulates in suspension was calculated 
based on sedimentation experiments. A sample containing 500 mg of Cellets and 50 ml 
of a liquid vehicle was filled into a 50-ml graduated plastic tube (30 x 115 mm; conical 
bottom; TPP Techno Plastic Products, Trasadingen, Switzerland). The tube was turned 
upside down until homogeneous dispersion of the particles. Then, the sample was left 
standing and sedimentation of Cellets in the media was recorded during a 30-minute 
period using a video camera (Samsung ST66, Samsung, Daegu, South Korea). The time 
taken for Cellets to clarify the top 15 ml of the dispersant (approximately one third of the 
media volume) was determined. This experiment was adapted from that described by 
Kluk and co-workers (Kluk and Sznitowska, 2014). Experiments were repeated using 
multiparticulates of two extreme particle sizes, Cellets 200 (200-355 µm) and Cellets 700 
(700 – 1000 µm), to account for the effect of particle size on sedimentation. The 
experiment was conducted in triplicate. 
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4.3.3 Sensory evaluation study 
4.3.3.1 Sample preparation 
Liquid vehicles were prepared as described in Section 4.3.2.1, with addition of 0.1% 
vanillin (when required) just before addition of the polymer (Table 2.3). The small amount 
of vanillin was added to mask any potential taste and smell of the polymers, which could 
have a negative impact in results. Spring water and vanilla-flavoured water were used 
as controls, to account for the effect of the flavouring agent.  
Table 4.2. List of liquid vehicles assessed in sensory evaluation experiments. 
ID Vehicle 
Polymer conc.   
(% w/v) 
Consistency level Flavour 
Water Water N/A Thin None 
Water + v. Water N/A Thin 0.1% vanillin 
XG L1 XG in water 0.25 Level 1 0.1% vanillin 
XG L2 XG in water 0.50 Level 2 0.1% vanillin 
XG L3 XG in water 1.00 Level 3 0.1% vanillin 
CMC L1 CMC in water 0.50 Level 1 0.1% vanillin 
CMC L2 CMC in water 1.00 Level 2 0.1% vanillin 
CMC L3 CMC in water 1.50 Level 3 0.1% vanillin 
 
Liquid vehicles were prepared within five days of the sensory evaluation study and kept 
in the fridge between manufacturing and testing (samples were allowed to equilibrate to 
room temperature for at least 90 minutes before sensory evaluation). Immediately before 
administration, Cellets (250 mg) were pre-dispersed in the liquid vehicles (approximately 
3 ml, for a total volume of 5 ml) inside 25-ml plastic dosing cups using wooden stirrers to 
ensure homogenous dispersion of the samples. Subsequently, samples were transferred 
from the dosing cup onto 5-ml plastic medicine spoons that were handed to participants 
of the study for tasting. 
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4.3.3.2 Study design 
Thirty healthy adult volunteers were enrolled in a single-centre, randomised, single-blind, 
3-treatment, crossover sensory evaluation. The study was approved by UCL Research 
Ethics Committee (ERN_4612-011). The study was conducted in three sessions taken 
place in three separate days. On each day, participants tested samples of liquid vehicles 
without Cellets (‘no particles’), with Cellets 200 (‘smaller particles’) and with Cellets 700 
(‘larger particles’). Participants were divided into six group to ensure that all possible 
sequence orders between treatments were considered, as shown in Figure 4.2. 
 
Figure 4.2. Overview of the 3-way crossover study design where all possible sequence orders 
between treatments were considered (T1: no particles; T2: small particles; T3: large particles). 
During each session, participants were handed eight samples of liquid vehicles on a 
dosing spoon (Figure 4.3), with or without Cellets (as per the study design depicted in 
Figure 4.2), in a randomised order. They were instructed to place the sample in their 
mouth and swallow it, then drink water as required. Participants had free access to spring 
water to complete sample intake and clean their palate. To minimise subject discomfort 
and carryover effect 5-10-minute intervals were respected between samples. 
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Figure 4.3. Photographs of samples composed of 250 mg of Cellets 200 (a) and Cellets 700 (b) 
dispersed in different liquid vehicles on 5-ml plastic medicine spoons. Water + v. represents water 
to which 0.1% w/v vanillin was added; the consistency level of XG and CMC hydrogels is 
depicted as L1 (Level1), L2 (Level 2) and L3 (Level 3). The set of samples of liquid vehicles 
without multiparticulates was not photographed and is not shown in the image. 
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4.3.3.3 Evaluation tool and outcome measures 
A digitalized questionnaire (Qualtrics.com) was used for data collection. Immediately 
after swallowing the sample, volunteers were asked to rate several sample attributes 
using 5-point hedonic scales; the attributes evaluated included appearance, ease of 
swallowing, mouth-feel and taste. In addition, the feeling of particles in the mouth during 
sample intake (i.e. grittiness perception) and the feeling of particles in the mouth after 
samples intake and after rinsing their mouth with water (i.e. residue in mouth) was 
assessed using 5-point magnitude scales. Finally, the future willingness of the volunteers 
to take multiparticulates was measured using a bipolar (yes/no) question: “If this was a 
medicine, would you be willing to take it every day?”. Participants could also provide 
voluntary feedback of each sample attribute using their own words. 
4.3.3.4 Data analysis 
The different categories of the 5-point scales were assigned numeric scores (1-5) from 
lowest to highest stimuli perception, respectively. Statistical analysis was performed 
using the non-parametric Kruskal-Wallis one-way analysis of variance with 95% 
confidence, followed by Dunn’s test as post hoc for pairwise comparison. Minitab 17 
(Minitab Inc., State College, Pennsylvania, USA) was used for data analysis. 
4.4 Results and discussion  
4.4.1 Rheological properties of model liquid formulations 
The rheological characteristics of a range of model liquid formulations were evaluated to 
be used as benchmarks in the development of liquid suspending media for the 
administration of multiparticulates. The products evaluated included (1) oral suspending 
vehicles commonly used for the manufacture of extemporaneous preparations for 
paediatric patients, (2) paediatric medicines in the form of oral suspensions, (3) 
commercially available thickening agents commonly used to modify the consistency of 
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food stuff for patients with swallowing dysfunction and (4) various types of yogurts as an 
example of food product known to be used by parents and caregivers to aid 
administration of medicines to children.  
The rheological characteristics of the different products evaluated are summarised in 
Table 4.3. Differences in consistency and rheological behaviour were found between 
samples, which are detailed below for each set of products. 
Table 4.3. Rheological characteristics of model liquid formulations, including oral suspending 
vehicles, medicines in the form of oral suspensions, food thickeners and various types of yogurt. 
Product ID 
Viscosity 
ƞ at 0.1s-1 
(Pas) 
Viscosity  
ƞ at 50s-1 
(Pas) 
Power law 
K (Pas) n (–) R2 
Suspending vehicle A 0.79 0.05 0.46 0.46 0.996 
Suspending vehicle B 6.04 0.14 1.52 0.38 0.976 
Simple syrup 0.13 0.13 0.11 1.00 0.999 
Ibuprofen suspension A 31.15 0.31 5.87 0.26 0.992 
Ibuprofen suspension B 12.01 0.18 3.10 0.27 0.995 
Paracetamol suspension A 5.09 0.24 1.84 0.49 0.994 
Paracetamol suspension B 3.36 0.16 1.44 0.45 0.983 
XG thickener Stage 1 8.92 0.15 3.32 0.21 0.998 
XG thickener Stage 2 25.49 0.29 9.16 0.12 0.971 
Starch thickener Stage 1 1.14 0.13 1.03 0.48 0.997 
Starch thickener Stage 2 114.8 0.95 16.73 0.26 0.991 
Full-fat yogurt 91.00 0.72 9.69 0.33 0.986 
Fat-free yogurt 45.86 0.50 4.51 0.42 0.974 
Children yogurt 24.20 0.66 5.16 0.47 0.997 
Dairy-free yogurt 135.07 0.69 14.35 0.23 0.996 
ƞ at 50s-1: Viscosity at shear rate = 50 s-1, reference shear rate of swallowing. 
K: Consistency index, calculated by fitting a power law model to rheology data. 
n: Flow behaviour index, calculated by fitting a power law model to rheology data. 
R2: coefficient of determination of the power law fitting to rheology data. 
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The large majority of samples exhibited some degree of shear-thinning behaviour (as 
shown by the value of the flow index behaviour, “n”, lower than 1), with exception of 
simple syrup, which is known to be a Newtonian fluid. Interestingly, the rheological 
properties of oral suspending vehicles commonly used in paediatric extemporaneous 
preparations varied noticeably between different brands (K = 0.5-1.5 Pas and n = 0.38-
0.46). Their different behaviour can be explained by differences in composition; Oral 
suspending vehicle A is based on a combination of MCC, CMC, XG and CG (plus buffers 
and preservatives), whereas Oral suspending vehicle B is based on modified food starch 
(plus buffers and preservatives).  
Similarly, the consistency and flow index behaviour of liquid medicines (oral 
suspensions) varied between medicines containing different drugs (K = 1.4-5.9 Pas and 
n = 0.26-0.49). Although only small differences were found between different brands of 
bio-equivalent medicines containing the same drug (K = 3.1-5.9 and n = 0.26-0.27 for 
ibuprofen; K = 1.4-1.8, n = 0.45-0.49 for paracetamol). Both ibuprofen oral suspensions 
contain XG as rheology modifier, paracetamol suspension A contains a combination of 
XG and dispersible cellulose (MCC/CMC), and paracetamol suspension B contains 
dispersible cellulose (MCC/CMC) and hydroxyethyl cellulose, as listed in their Summary 
of Products Characteristics (SmPCs). 
Thickening agents used to assist with the management of dysphagia can be prepared to 
different consistency levels to target the patient needs; as the swallowing dysfunction 
worsen the consistency level is usually increased to promote safer swallowing (Wright et 
al., 2006). However, large differences in rheological behaviour were found between 
brands of food thickeners when prepared to the same consistency level (K = 1.0-2.3 and 
n = 0.21-0.48 for Stage 1; K = 9.2-16.7 and n = 0.12-0.26 for Stage 2). These findings 
are supported by previous research which demonstrated differences in consistency and 
organoleptic properties of commercial thickeners (Pelletier, 1997). 
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Finally, the rheological properties of various types of yogurts were investigated. Broad 
differences in rheology were found between yogurts (K = 4.5-14.4 and n = 0.23-0.47). 
Fat-free yogurt exhibited the thinnest consistency among the yogurts tested whereas 
dairy-free yogurt based on hulled soya beans showed the thickest consistency. Again, 
these results highlight the importance of the ingredients used in the resulting rheological 
properties of the product.  
Although the organoleptic properties and performance of the product will be determined 
by its rheological characteristics, vehicles commonly used in practice for the 
administration of medicines do not share common rheological properties. On the 
contrary, a range of fluids with varying consistency and shear thinning behaviour have 
been identified. Thus, it would be necessary to study a range of different consistencies 
and flow behaviours to establish the target rheology characteristics of suspending media 
for the administration of multiparticulates. 
4.4.2 Development of suspending media for multiparticulates 
4.4.2.1 Rheological properties of polymeric hydrogels  
XG and CMC were selected as model excipients to develop polymeric hydrogels for the 
administration of multiparticulates. XG and CMC are Generally Regarded As Safe 
(GRAS) excipients commonly used in paediatric medicines and, additionally, they exhibit 
rapid hydration in water and are commonly used in medicines formulated as solid 
products for reconstitution into oral solutions or suspensions.  
The rheological properties of XG and CMC hydrogels were explored as a function of the 
concentration of polymer and results are summarised in Table 4.4. The consistency 
index of XG and CMC-based polymeric hydrogels increased as the concentration of 
polymer dispersed in water increased, as it can be expected. The increase in viscosity 
was more pronounced for XG than it was for CMC, revealing the higher ‘thickening 
power’ of XG (Figure 4.4). In addition, XG hydrogels exhibited a strong shear thinning 
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behaviour whereas CMC hydrogels showed a much lower degree of shear thinning; the 
flow behaviour index (n-value) of XG-based hydrogels was lower than that of CMC-based 
hydrogels throughout the range of concentrations tested (Figure 4.5). 
Table 4.4. Rheological characteristics of XG and CMC hydrogels prepared at a range of 
concentrations (0.15-1.50% w/v). 
Polymer 
Concentration 
(% w/v) 
 Viscosity 
ƞ at 0.1s-1 
(Pas) 
Viscosity 
ƞ at 50s-1 
(Pas) 
Power law 
 K (Pas) n (–) R2 
XG 0.15  0.53 0.02 0.06 0.51 0.995 
XG 0.25  1.81 0.07 0.56 0.39 0.984 
XG 0.50  16.15 0.18 2.98 0.19 0.964 
XG 0.75  41.70 0.27 5.69 0.15 0.980 
XG 1.00  66.07 0.41 9.39 0.13 0.955 
XG 1.50  79.29 0.57 18.13 0.13 0.975 
CMC 0.15  0.04 0.03 0.04 0.90 0.998 
CMC 0.25  0.11 0.04 0.08 0.79 0.993 
CMC 0.50  0.33 0.13 0.28 0.69 0.994 
CMC 0.75  1.46 0.30 1.03 0.63 0.988 
CMC 1.00  2.85 0.50 2.54 0.51 0.987 
CMC 1.50  14.54 1.15 9.50 0.45 0.992 
 
The contrasting rheological characteristics of XG and CMC made them ideal candidates 
to investigate the effect of shear thinning behaviour on their performance as a vehicle for 
the administration of multiparticulates. Based on previous research, shear thinning fluids 
can be expected to be easier to swallow than Newtonian vehicles, as the former would 
flow better when pushed by the tongue towards the throat (Steele et al., 2015). However, 
it could be hypothesised that shear thinning fluids would be less effective in ‘masking’ 
the presence of particles as these fluids would ‘get thinner’ (i.e. reduction in consistency) 
under oral processing (e.g. when pushed by the tongue towards the palate). 
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Figure 4.4. Consistency index of XG (filled squares) and CMC (filled circles) hydrogels as a 
function of the polymer concentration. 
 
Figure 4.5. Flow behaviour index of XG (open squares) and CMC (open circles) hydrogels as a 
function of the polymer concentration. 
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4.4.2.2 Hydration behaviour of hydrocolloids 
Rapid hydration in water is a desirable property for thickening agents intended for use 
as part of a solid product for reconstitution so that, once the formulation is added to water, 
reconstitution into a stable suspension occurs in a short period of time. The hydration 
and thickening behaviour of hydrocolloids was evaluated using a rotational rheometer 
with an adapted set up. The results of such experiments are illustrated in Figure 4.6.  
 
Figure 4.6. Viscosity of hydrocolloids at shear rate of 10s-1 during hydration experiments in water. 
Results expressed as normalised viscosity with respect to the viscosity of fully hydrated samples. 
As shown in Figure 4.6, full hydration and thickening of XG and CMC hydrogels occurred 
within 10 minutes under the conditions of the experiment (where polymers were 
dispersed in water by the rotational movement of the rheometer plate). Full hydration 
and thickening can be expected to be quicker with more efficient mixing under in-use 
conditions (e.g. mixing with a spoon in a glass or dosing cup). The hydration rate of XG 
and CMC was much faster than that of guar gum (GG), which was used as a comparator 
based on previous experiments that suggested slow hydration of GG compared to other 
hydrocolloids (Sanchez et al., 1995). 
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4.4.2.3 Ability to maintain multiparticulates in suspension 
Sedimentation time of multiparticulates in polymeric hydrogels was determined by 
measuring the time lapse between homogeneous dispersion of multiparticulates and 
clearance of the top layer of the liquid vehicle (15 out of 50 ml). Results of sedimentation 
time as a function of the media viscosity are depicted in Figure 4.7. 
 
 
Figure 4.7. Sedimentation time of multiparticulates of two different sizes, Cellets 200 (top) and 
Cellets 700 (bottom), as a function of the apparent viscosity at 0.1 s-1 (very low shear rate, 
representative of the sample at rest) of XG and CMC hydrogels prepared with increasing polymer 
concentration. A trendline was fit to the data by linear regression (dotted line). n.b. the scale range 
is different in each graph to improve visualisation.  
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Sedimentation time increased with increasing viscosity of the media and decreased with 
increasing size of the multiparticulates, as shown in Figure 4.7. This behaviour can be 
expected, in accordance to Stoke’s law: 
𝑣 =  
𝑑2(𝜌𝑝−𝜌𝑓)𝑔
18ƞ
          (2) 
where v is the velocity (m/s) of a spherical particle in suspension with a diameter equal 
to d (m), ρp and ρf are the mass densities (kg/m3) of the particle and the fluid, 
respectively, and g is the gravitational acceleration (≈ 9.8 m/s). Since v is equal to 
distance over time (i.e. time required for the particle to travel a certain distance), 
sedimentation time must be inversely proportional to diameter of the particle and directly 
proportional to the viscosity of the media. 
An ideal suspending vehicle should be able to maintain multiparticulates in suspension 
from dispersion of the particles in the media until administration by the patient. The 
viscosity required to maintain multiparticulates in suspension for five minutes (as an 
arbitrary measure of the estimated time spent by patients to take oral medicines) was 
determined from the plots in Figure 4.7. Results showed that hydrogels with an apparent 
viscosity at 0.1s-1 equal or higher to 0.2 and 0.6 Pas would be sufficient to maintain a 
homogeneous suspension of multiparticulates larger than 200 and 700 µm, respectively, 
for at least five minutes.  
This means that XG hydrogels prepared at 0.25% w/v would be sufficient to maintain 
both Cellets 200 and Cellets 700 in suspension, whereas a higher concentration of CMC 
(1.00% w/v) would be required to maintain the larger Cellets in suspension for at least 5 
minutes, as depicted in Figure 4.8. The lower concentration of XG required to maintain 
multiparticulates in suspension could be expected based on its stronger thickening power 
and its shear thinning character, which means that viscosity of XG hydrogels at low shear 
rates (i.e. shear rates relevant during sedimentation) is higher than CMC hydrogels. 
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Figure 4.8. Sedimentation time (minutes) of Cellets 200 and Cellets 700 in XG and CMC 
hydrogels prepared with increasing polymer concentration (% w/v). Sedimentation was observed 
for a maximum period of 30 minutes; bars extending over that limit represent sedimentation times 
longer than 30 minutes.  
4.4.2.4 Selection of liquid vehicles for sensory evaluation 
As discussed in Section 4.4.1, there is no evidence to suggest an appropriate 
consistency level for liquid vehicles used for the administration of oral solid dosage 
forms, based on the range of vehicles used in common practice. Therefore, XG and CMC 
hydrogels were prepared and evaluated at different consistency levels (Figure 4.9), with 
the aim to investigate the effect of viscosity on palatability and patient acceptability. XG 
hydrogels were investigated at 0.25, 0.50 and 1.00% w/v whereas CMC hydrogels were 
prepared and studied at 0.50, 1.00 and 1.50% w/v.  
These concentrations were targeted to meet the International Dysphagia Diet 
Standardisation Initiative (IDDSI) descriptors for Level 1, Level 2 and Level 3 consistency 
levels, respectively (Cichero et al., 2017). According to this framework, Level 1 fluids are 
“thicker than water but flow through a teat/nipple and straw”, Level 2 fluids “require effort 
to drink through a straw and flow quickly off a spoon” and Level 3 fluids are “difficult to 
suck through a straw and pour slowly off a spoon”.  
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Figure 4.9. Consistency index of XG and CMC hydrogels prepared to three different consistency 
levels: Level 1 – Syrup (yellow), Level 2 – Custard (orange), Level 3 – Pudding (red) as described 
by the IDDSI (Cichero et al., 2017). 
Polymeric hydrogels thickened to consistency Level 1 exhibited similar viscosity to that 
of oral suspending vehicles commonly used in paediatric extemporaneous preparations; 
as shown in the previous section, this consistency would be borderline for maintaining 
multiparticulates in suspension during in-use conditions, especially for multiparticulates 
of large size (over 700 µm). On the contrary, vehicles thickened to consistency Level 3 
were characterised by viscosity comparable to that of a yogurt; these vehicles would 
maintain multiparticulates in suspension for prolonged periods of time (i.e. several days 
or weeks). Finally, vehicles thickened to Level 2 showed intermediate viscosity, which 
was comparable to that of model paediatric oral suspensions presented in Section 4.4.1. 
4.4.3 Sensory evaluation studies 
The suitability of XG and CMC vehicles as suspending media for the administration of 
multiparticulates was investigated in healthy adult volunteers, with emphasis on 
palatability, ease of swallowing and overall patient acceptability. Water was used as 
comparator (positive control, as gritty feeling in the mouth can be expected). 
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4.4.3.1 Demographics 
A total of 30 volunteers (13 male and 17 female) participated in the sensory evaluation 
study. The average age was 23 years, with a standard deviation of 4 years (min. 19 
years, max. 33 years) and median at 22 years. 
4.4.3.2 Liquid vehicles without multiparticulates 
Participants of the sensory evaluation study tested liquid vehicles without Cellets in one 
of the three sessions of the study. The analysis of liquid vehicles without Cellets was 
performed in order to gain fundamental understanding of the properties of the liquid 
vehicles, such as appearance, mouthfeel, taste and ease of swallowing. 
All samples evaluated received average appearance ratings in the neutral to positive 
range of the scale (range: 1.70 – 2.37; Water – XG L2), except for XG L3 (average 
appearance rating = 3.17). According to participants responses to hedonic scales, the 
appearance of XG hydrogels was worse than the appearance of water and CMC 
hydrogels (p < 0.001), as shown in Figure 4.10. This was adscribed to the opaque 
appearance of XG hydrogels (in contrast with the transparent nature of water and CMC 
hydrogels), as supported by anecdotal feedback provided by the participants: e.g. “I 
personally prefer when the sample is limpid, this one was a bit opaque and it gives you 
an idea of dirt” (Participant 11, XG L3).  
Appearance ratings of hydrogel samples worsened as the concentration of polymer in 
the liquid vehicle was increased (i.e. as the consistency level increased). This indicates 
that the appearance of very thick samples (which retain their shape when placed on a 
spoon) was considered less appealing than thinner fluids. This effect was very evident 
for XG samples, which were also affected by the increased in opacity as the 
concentration of XG increased. However, differences between CMC hydrogels thickened 
to different consistency levels were minimal.  
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Figure 4.10. Interval plot for appearance (top) and mouthfeel (bottom) of different liquid vehicles. 
Markers represent the population mean for the hedonic ratings (where 1 is the best possible rating 
and 5 is the worst possible rating) and bars show the 95% CI for the mean. Water + v. represents 
water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC hydrogels is 
described as L1 (Level1), L2 (Level 2) and L3 (Level 3). 
The taste of all liquid vehicles evaluated received average ratings between 2 and 3 
(range: 2.33 – 2.63; XG L1 – Water), which indicates acceptable neutral taste (Figure 
4.10). Interestingly, samples containing vanillin received slightly better taste ratings than 
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pure water, although differences were negligible (not statistically significant). The very 
small differences between samples confirmed that the level of vanillin used was 
appropriate to mask the taste of the polymer without having a significant impact on 
results (as it was intended). However, the fact that average ratings for taste were closer 
to the centre of the scale than to the positive end of the scale may indicate participants’ 
expectations of a more intense, sweetened or flavoured taste for samples intended as 
(part of) a medicinal product. This was reinforced by voluntary feedback; e.g. “if this had 
added sugar/sweetener it would be a more enjoyable medicine to take” (P05, CMC L3). 
Mouthfeel ratings of XG and CMC hydrogels worsened as the consistency of the sample 
increased, revealing preference for thinner vehicles (Figure 4.11). However, all samples 
received average ratings in the neutral to positive range of the scale (range: 1.67 – 2.90; 
Water + v. – CMC L3), suggesting all vehicles prepared had an acceptable mouthfeel to 
be used as suspending media for the administration of multiparticulates. CMC hydrogels 
received slighly worse mouthfeel ratings than XG samples, which was attributed to a 
“greasy” or “oily” feeling in the mouth, as reported by the volunteers. The slimy texture 
of CMC hydrogels have been reported in previous research and attributed to its low 
degree of shear thinning (high n-value) (Cho et al., 2015; Szczesniak and Farkas, 1962). 
Nevertheless, mouthfeel differences between XG and CMC vehicles were not 
statistically significant, despite their contrasting rheological profiles.  
 All samples evaluated were considered ‘easy to swallow’ by healthy volunteers, 
receiving average ratings in the neutral to positive range of the scale (range: 1.07 – 2.57; 
Water + v. – CMC L3). This is not surprising as these samples were liquid vehicles 
(without multiparticulates) and subjects were healthy volunteers with normal swallowing 
function. However, samples were considered relatively more difficult to swallow as the 
consistency level increased (p < 0.001), as depicted in Figure 4.11. This can be attributed 
to the higher effort required to convey thicker fluids through the oral cavity, giving their 
higher viscosity (or, in other words, higher resistance to flow). In their open-ended 
 149 
feedback, participants described the need to swallow repetitively to achieve full ingestion 
of thicker samples; e.g. “the sample is very viscous and is difficult to swallow, it remains 
in my mouth after swallowing a few times” (P22, CMC L3). This is in line with previous 
research as thicker liquids have been shown to increase the risk of post-swallow residue 
in the mouth and pharynx (Steele et al., 2015). 
 
 
Figure 4.11. Interval plot for taste (top) and ease of swallowing (bottom) of different liquid 
vehicles. Markers represent the population mean for the hedonic ratings (where 1 is the best 
possible rating and 5 is the worst possible rating) and bars show the 95% CI for the mean. Water 
+ v. represents water to which 0.1% w/v vanillin was added; the consistency level of XG and 
CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). 
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It is well established that fluids with higher viscosity exhibit prolonged oral transit times 
as compared to thinner fluids such as water (Soares et al., 2015). This effect has been 
rationally exploited in the management of dysphagia, where texture modification has 
become one of the most common forms of intervention, since longer oral transit times 
favour control of the bolus minimising the risk of aspiration (Cichero and Lam, 2014; 
Soares et al., 2015; Steele et al., 2015). However, this seemed to have a detrimental 
impact for healthy volunteers with normal swallowing function, who preferred to swallow 
thinner fluids. Although thinner fluids were not expected to be easier or safer to swallow, 
they can be expected to be quicker to swallow, which seemed to have a positive effect 
on their hedonic responses. 
The trends in ratings of ease of swallowing indicate that XG hydrogels were slightly 
easier to swallow than CMC hydrogels, which was supported by anecdotal feedback; 
e.g. “this sample (CMC L2) is more difficult than the previous one (XG L2) in swallowing 
it as a whole, as it remains in my mouth after the first swallow” (P10, CMC L2). 
Differences between both sets of hydrogels were statistically significant (p < 0.018). This 
can be explained by the stronger shear thinning behaviour of XG hydrogels, as shown in 
Section 4.4.2.1. Shear thinning fluids can be expected to be easier to swallow due to 
lower resistance to flow under shear (Steele et al., 2015).  
Participants responses to certain samples attributes are expected to be influenced by 
their opinions and responses to other attributes, a phenomenon previously called ‘halo 
effect’ (Mason and Nottingham, 2002; Prescott et al., 2011). In this regard, responses to 
ease of swallowing and mouthfeel of XG hydrogels might have been negatively biased 
by the unpleasant appearance of the sample (especially those of thickest consistency). 
This was supported by open-ended responses, e.g. “found it quite difficult to ingest it, 
would be better if it was more aesthetically pleasing” (P15, XG L3). If this hypothesis was 
correct, perceived differences between XG and CMC hydrogels could have been 
maximised using vehicles which were not visually different. 
 151 
4.4.3.3 Multiparticulates dispersed in liquid vehicles 
The appearance of multiparticulate samples dispersed in different vehicles received 
average ratings around the neutral range of the scale (range: 2.70 – 3.40; CMC L1 – 
Water), as shown in Figure 4.12.  The size of the multiparticulates had no influence on 
the ratings of appearance (p = 0.074), whereas the vehicle used had a significant impact 
on the appearance of the final formulation (p < 0.001). The appearance of samples 
dispersed in polymeric hydrogels (2.96 for XG and 2.77 for CMC hydrogels, on average) 
was considered better than that of Cellets dispersed in water (3.33 with and 3.40 without 
vanillin). This was explained by the more homogenous appearance of samples dispersed 
in thickened vehicles as compared to multiparticulates dispersed in water.  
Cellets precipitated very quickly in water, due to its very low viscosity, leading to 
heterogenous samples with Cellets settled down on the bottom of the spoon and water 
on top. On the contrary, Cellets remained homogeneously dispersed in thicker hydrogels, 
which was considered a positive feature by the volunteers. Moreover, samples prepared 
in XG vehicles thickened to the highest consistency were rated more negatively than 
samples dispersed in other hydrogels, which can be expected based on the negative 
ratings of appearance received by this vehicle when evaluated without Cellets.  
The taste of the samples worsened when multiparticulates where added into the 
formulation and when the multiparticulate size increased (Figure 4.12); from 2.44 on 
average without presence of multiparticulates to 2.63 and 2.89 on average with smaller 
and larger multiparticulates, respectively. As shown before for samples of liquid vehicles 
without multiparticulates, the taste of formulations with vanilla flavour was deemed better 
than the taste of samples prepared with pure water, by 0.43 points on average (p < 0.001) 
On the contrary, no significant differences were found between XG and CMC samples in 
terms of taste which, again, confirmed the successful masking of any potential inherent 
taste of the polymer by addition of a small quantity of vanillin. 
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Figure 4.12. Interval plot for appearance (top) and mouthfeel (bottom) as a function of the vehicle 
used as suspending media and the size of the dispersed multiparticulates: 200-355 µm (Cellets 
200) or 700-1000 µm (Cellets 700). Markers represent the population mean for the hedonic ratings 
(where 1 is the best possible rating and 5 is the worst possible rating) and bars show the 95% CI 
for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency 
level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). 
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The mouthfeel of multiparticulates dispersed in liquid vehicles also received average 
ratings around the neutral range of the scale (Figure 4.13). Both the size of the 
multiparticulates and the vehicle used to disperse them had a significant impact on 
mouthfeel of the final formulation (p = 0.001 and p < 0.001, for size and vehicle, 
respectively). The mouthfeel of samples containing smaller multiparticulates was on 
average 0.30 points better than that of samples containing larger multiparticulates. In 
terms of the vehicle used, participants showed preference for samples dispersed in 
thickened vehicles over samples dispersed in water.  
In addition, participants preferred hydrogels with low and middle-range consistencies 
(Level 1 and Level 2) over the extremely thick ones (Level 3). According to the 
participants of the study, those samples achieved a good balance by “concealing the 
presence of particles in the mouth” but not being too thick (which has a detrimental 
impact on mouthfeel, as established in Section 4.4.3.2). Samples thickened to Level 1 
and Level 2 consistencies were rated on average 0.62 and 0.54 points better than water, 
respectively, whereas samples with Level 3 consistency were rated only 0.34 points 
better than water, on average. 
As depicted in Figure 4.13, swallowing of multiparticulates was considered more difficult 
with increasing particle size, from 2.36 on average for smaller multiparticulates to 2.91 
on average for larger multiparticulates (p < 0.001). Multiparticulates dispersed in 
polymeric hydrogels were easier to swallow than multiparticulates dispersed in water (by 
approximately 0.50 points), irrespectively of the size of the particles. Both XG and CMC 
hydrogels were similarly efficient in facilitating swallowing of the multiparticulates (2.52 
and 2.49 on average, respectively). Therefore, no significant differences were found 
between XG and CMC hydrogels in terms of ease of swallowing when administered with 
multiparticulates, despite their different rheological properties and the differences found 
when administered without multiparticulates (Section 4.4.3.2). 
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Figure 4.13. Interval plot for taste (top) and ease of swallowing (bottom) as a function of the 
vehicle used as suspending media and the size of the dispersed multiparticulates: 200-355 µm 
(Cellets 200) or 700-1000 µm (Cellets 700). Markers represent the population mean for the 
hedonic ratings (where 1 is the best possible rating and 5 is the worst possible rating) and bars 
show the 95% CI for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; 
the consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and 
L3 (Level 3). 
 155 
In agreement with the results for mouthfeel perception, participants showed preference 
for swallowing samples with thin and middle-range consistencies (Levels 1 and 2) as 
opposed to thicker samples. These samples performed best at “carrying the particles 
together” as a bolus and “providing cushioning”, facilitating swallowing, while not being 
too thick to “linger around” in the oral cavity for long. The contrast between samples of 
different consistency was reported in open-ended responses; e.g.: “the liquid in this 
sample was too runny and was unable to carry the particles along with it, so the liquid 
part was consumed first, leaving behind the solid part of the sample” (P02, Cellets 200 
in Water); or “I feel that this sample has the correct viscosity that is able to hold the 
particles together and is able to be easily swallowed” (P10, Cellets 200 in XG L1). 
Participants ratings of ‘grittiness perception’ confirmed the results obtained for mouthfeel 
and ease of swallowing: polymeric hydrogels masked the presence of multiparticulates. 
As shown in Figure 4.14, grittiness perception was lower for polymeric hydrogel 
formulations than for samples dispersed in water by approximately 1.0 point, on average, 
both for smaller and larger multiparticulates. This was supported by voluntary feedback; 
e.g. “without a thick solution to act as a lubricant and carry the particles along with it, the 
‘grainy’ feeling was enhanced, making it very unpleasant to take” (P02, Cellets 200 in 
water); compared to samples in thickened vehicles, e.g. “it is viscous, but that masks the 
overall 'particles feel', which is good” (P12, Cellets 200 in CMC L2).  
The use of polymeric hydrogels to disperse multiparticulates also reduced the ‘residue 
in mouth’, i.e. the feeling of particles in the mouth after swallowing (p < 0.001), for 
multiparticulates of both sizes evaluated (Figure 4.14). As described above, the 
thickened fluids were able to carry the particles as a bolus from the mouth to the throat, 
reducing the amount of multiparticulates left in the oral cavity after swallowing. The 
residual feeling of particles was reduced by approximately 0.5 points on average when 
using polymeric hydrogels as vehicles, as compared to water.  
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Figure 4.14. Interval plot for grittiness (top) and residue of multiparticulates in mouth after 
swallowing (bottom) as a function of the vehicle used as suspending media and the size of the 
multiparticulates: 200-355 µm (Cellets 200) or 700-1000 µm (Cellets 700). Markers represent the 
population mean for the 5-point magnitude scale (where 1 is the lowest possible and 5 is the 
highest possible intensity of the stimulus) and bars show the 95% CI for the mean. Water + v. 
represents water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC 
hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). 
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As demonstrated in previous studies, grittiness perception increased with increasing size 
of the multiparticulates (p < 0.001); samples of smaller multiparticulates obtained an 
average grittiness score of 2.50 compared to the 3.31 scored on average by samples 
containing larger multiparticulates. The feeling of residual particles in the mouth also 
increased with increasing size of the multiparticulates, 1.67 on average for Cellets 200 
compared to 2.14 on average for Cellets 700 (Figure 4.14).  
Surprisingly, no significant differences were found between XG and CMC hydrogels in 
their ability to mask the presence of particles, either during sample intake or after 
swallowing of the samples; although the trend suggests that CMC vehicles performed 
better when using multiparticulates of larger size. Moreover, no differences were found 
between vehicles thickened to different consistency levels. These findings suggest that 
the rheological properties of the vehicles were less important than initially predicted. It is 
important to consider that the rheological properties of the vehicles could have been 
dramatically affected by addition of multiparticulates; the inclusion of the solid particles 
is expected to produce and increase in consistency and in shear thinning behaviour 
(Mueller et al., 2010). Investigation of the rheological properties of samples with 
multiparticulates was not possible in the present study, since the rheometer used was 
not suitable to measure samples with particles of such large diameter.  
Contradictorily, anecdotal feedback indicated that thicker hydrogels performed better 
than thinner vehicles in terms of masking the presence of particles, e.g. “less thick than 
other samples, thus I can feel the particles when I swallowed it; need to drink water to 
remove the particles” (P16, Cellets 200 in XG L1). But perhaps the unpleasant mouthfeel 
of thicker samples negatively affected participants’ assessments of grittiness perception. 
This highlights the multifactorial nature of palatability and mouth-feel perception, which 
is influenced not only by rheological properties such as viscosity and shear thinning 
behaviour, but also by other physicochemical properties such as density, stickiness, 
ductility and lubrication capacity (Stokes et al., 2013). 
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The results of these trial are summarised in Figure 4.15, where the radar charts show 
the mean result for each palatability attribute as a function of the size of the 
multiparticulates and the administration vehicle (water with vanillin, which was used as 
a control, was excluded from the graphs to aid clarity). The graphs show the overall 
improvement of the samples when using oral vehicles of consistency thicker than water. 
Slight preference for thinner vehicles is also apparent from the graphs. 
 
Figure 4.15. Radar chart for appearance, taste, grittiness, mouthfeel, ease of swallowing and 
residue of multiparticulates in mouth as a function of the vehicle used as suspending media and 
the size of the multiparticulates: 200-355 µm (Cellets 200) or 700-1000 µm (Cellets 700). Each 
palatability item is described by its population mean for the 5-point scale (where 1 is the lowest 
possible and 5 is the highest possible intensity of the stimulus). The consistency level of XG and 
CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3). 
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4.4.3.4 Willingness to take multiparticulates 
As in previous studies with multiparticulates (Chapter 2 and Chapter 3), the willingness 
of the volunteers to take the formulation every day if it was a medicine was captured as 
a predictive measure of acceptability. Results are shown in Figure 4.16, as a function of 
the multiparticulate size and the vehicle used as suspending media. 
 
 
Figure 4.16. Proportion of volunteers ‘willing to take the sample everyday if it was a medicine’, 
expressed as a percentage of the total population (N = 30), for samples containing Cellets 200 
(top) or Cellets 700 (bottom) dispersed in different liquid vehicles.  
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In agreement with our previous studies, the willingness to take the formulation decreased 
with increasing multiparticulate size (p = 0.008). On average, 69% of the participants 
were willing to take formulations containing smaller particles, in contrast with the 57% 
who reported to be willing to take formulations containing larger multiparticulates. These 
values varied along the range of vehicles with different consistencies (p < 0.001). Water 
samples were the least preferred, as participants were willing to take these samples as 
a medicine only in 53.3% and 36.7% of the occasions, for formulations containing smaller 
and larger Cellets, respectively. On the positive end of the ranking, CMC L2 obtained 
80.0% and 70.0% and XG L2 received 73.3% and 70.0% of positive responses, when 
administered with smaller and larger multiparticulates, respectively.  
The willingness of participants to take the formulation as a medicine was determined by 
their previous evaluation of the samples. All attributes studied (appearance, taste, 
mouthfeel, ease of swallowing, grittiness perception and residue in mouth) played an 
important role in participants’ decision to be willing to take the formulation (Chi-squared 
test for association, p < 0.001 for all pair comparisons of sample attribute versus 
willingness). These findings reinforce the idea that patient acceptability is influenced by 
a broad range of formulation attributes, which all need to be identified and balanced to 
maximise patient acceptance of a medicinal product. 
4.5 Conclusions 
A set of liquid vehicles were developed using XG and CMC as model hydrocolloids, 
which produced hydrogels with contrasting rheological character (high and low degree 
of shear thinning, respectively). Such hydrogels were prepared at three different 
consistency levels (Level 1 – ‘syrup’, Level 2 – ‘custard’ and Level 3 – ‘pudding’) to 
investigate the effect of viscosity and shear thinning behaviour on the performance of 
the liquid vehicles as suspending media for the administration of multiparticulates. An in 
vivo sensory evaluation study was carried out in thirty healthy adult volunteers using 
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microcrystalline cellulose pellets as model multiparticulates, dispersed in oral hydrogels 
at a concentration of 250 mg in 5 ml. Multiparticulate formulations dispersed polymeric 
hydrogels and water (as a control) were administered on a medicine spoon and 
evaluated using a range of 5-point hedonic and magnitude scales. 
The use of hydrogels as administration vehicles improved a range of sample attributes 
(compared to water formulations), including appearance, taste, mouthfeel, ease of 
swallowing and grittiness perception during and after sample intake. This improvement 
was apparent for samples containing multiparticulates of both sizes investigated (those 
over 200 and those over 700 µm). Surprisingly, differences between XG and CMC 
hydrogels were minimal despite their opposing rheological behaviour; i.e. both sets of 
hydrogels were equally effective at concealing the gritty feeling of multiparticulates and 
assisting swallowing. Although the strongly shear thinning XG hydrogels were easier to 
swallow and provided better mouthfeel than the CMC vehicles when assessed on their 
own (i.e. without multiparticulates), these differences vanished when multiparticulates 
were added into the formulation. If anything, CMC hydrogels seemed somewhat better 
at masking the grittiness of the coarser and thus more challenging multiparticulates. 
Overall, polymeric hydrogels thickened to medium consistency (Level 2) demonstrated 
the best performance by virtue of their ability to conceal the grittiness of multiparticulates 
in the mouth and to aid swallowing of the formulation as a bolus, while maintaining a 
balanced consistency (not too thick) to ensure appropriate mouthfeel. These findings 
were in line with previous research in the field in that vehicles of very thick consistency 
tend to be disliked despite their ability to mask the presence of multiparticulates in the 
formulation (Kluk and Sznitowska, 2014; Lopez et al., 2016). The proportion of volunteers 
willing to take multiparticulates of the larger size was doubled by dispersing them in 
vehicles of middle consistency (from 36.7% in water to 70.0% in XG and CMC vehicles). 
For smaller multiparticulates, the willingness to take the product also increased, from 
53.3% in water to 73.3 and 80.0% in XG and CMC vehicles, respectively.  
 162 
Results of this study support previous research in that polymeric hydrogels could be used 
to improve palatability and acceptability of multiparticulate formulation. This study further 
indicates that swallowing of multiparticulates is facilitated using liquids of consistency 
thicker than water. With this in mind, multiparticulate formulations could be developed as 
a solid product for reconstitution into a liquid product with viscosity thicker than water. 
XG and CMC will both allow for the preparation as such products as these hydrophilic 
polymers exhibit rapid hydration and thickening in aqueous media. However, potential 
interaction with the API, in terms of drug release and in vivo bioavailability would also 
need to be considered during drug development studies. Moreover, there is also further 
need to investigate the acceptability of these vehicles in paediatrics and patients with 
swallowing difficulties, those who could benefit the most from these formulations.  
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Chapter 5 
5. Evaluating manufacturability and patient acceptability to guide 
the choice of excipients in (oro)dispersible tablet formulations 
 
This chapter describes an investigation of a range of co-processed excipients which may 
prove suitable for the preparation of (oro)dispersible tablets by direct compression. 
Excipients were pre-selected based on manufacturability criteria (compressibility, tablet 
friability, disintegration time and fineness of dispersion); then, a sensory evaluation 
experiment was carried out in a panel of healthy adult volunteers with the nine best 
performing excipients to investigate their organoleptic properties. Excipients were ranked 
in order of preference based on palatability evaluation and their overall acceptability was 
measured using 5-point facial hedonic scales. The most promising candidates for the 
preparation of (oro)dispersible tablets, ensuring robust manufacturing while maintaining 
appropriate palatability and patient acceptability, were identified. 
5.1 Introduction 
(Oro)dispersible tablets offer advantages over conventional solid and liquid dosage 
forms, which can be crucial for special populations such as paediatrics, geriatrics and 
patients with swallowing difficulties. (Oro)dispersible tablets are designed to disintegrate 
within a matter of seconds, avoiding the need for swallowing the tablet as a whole. As a 
solid product that is transformed into a liquid at the point-of-use, they offer improved 
stability over liquid formulations. Their administration can be adapted to the needs of the 
patient population (e.g. by pre-dispersing the tablet in a suitable vehicle before 
administration to facilitate administration to younger children).  
Despite the acknowledged benefits of (oro)dispersible tablets, evidence of acceptability 
(especially in the paediatric population) is scarce, as established in the semi-systematic 
literature review presented in the introduction to this thesis. Details about the formulation 
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design and composition are often not provided in the literature, which hinders the rational 
development of acceptable formulations. Understanding the formulation parameters that 
affect patient acceptability and identifying excipients with favourable organoleptic profile 
could guide the rational development of more acceptable formulations. 
(Oro)dispersible tablets can be manufactured by well-established techniques such as 
direct compression, which can expedite access to patients, although attaining the right 
balance between sufficient mechanical strength and quick disintegration can be 
challenging (Shukla, 2009). (Oro)dispersible tablets are required to disintegrate rapidly, 
have acceptable palatability and provide robust, cost-effective manufacturability on a 
commercial scale. As such, they often contain a range of excipients such as fillers, 
lubricants, disintegrants, sweeteners, dispersion aids and flavouring agents and the 
development process typically involves multiple investigations using a range of excipient 
grades and suppliers to attain the required functionality.  
(Oro)dispersible tablet formulations need to comply with a series of requirements to 
ensure the quality of the final product. A list of requirements for (oro)dispersible tablet 
formulations is proposed in Table 5.1. These criteria were defined based on the 
properties of (oro)dispersible tablets that are required to produce a robust product that 
also delivers patient acceptability. Rationale for the specifications is provided below.  
Table 5.1. Manufacturing specifications for (oro)dispersible tablets by direct compression. 
Formulation property † Ideal specification Minimum requirement 
Flowability (Carr’s Index) ≤ 15% ≤ 25% 
Maximum Tensile Strength ≥ 3.0 MPa ≥ 1.5 MPa 
Ejection Shear ≤ 3.0 MPa ≤ 5.0 MPa 
Friability < 1% in 15 minutes < 1% in 4 minutes 
Disintegration Time < 60 seconds < 180 seconds 
Dispersibility Passes 250-µm screen Passes 710-µm screen 
† Palatability is also a key attribute for (oro)dispersible tablets, but specifications are not yet proposed 
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The excipients used within (oro)dispersible tablet formulations need to exhibit good flow 
properties to ensure minimal segregation of materials, hence appropriate content and 
weight uniformity. This is particularly important for tablets manufactured by direct 
compression (since granulation, which often improves flowability, is avoided). A Carr’s 
index greater than 25 % is considered to indicate poor flowability, therefore a Carr’s index 
equal or below than 25% was set as the minimum requirement. However, the addition of 
typically poor flowing APIs into the formulation is likely to increase the Carr’s Index. Thus, 
Carr’s Index of less than 15 %, which indicates good flowability, was used as the ideal 
specification (Lachman et al., 1986; Zhou and Qiu, 2010). 
Tensile strength (TS) provides information about the crushing strength of the tablet. 
Tablets with TSs above 2.0 MPa are typically thought to be strong enough to withstand 
typical packaging and coating operations (Pitt et al., 2015; Zhou and Qiu, 2010). 
However, it has been shown that tablets with a TS as low as 1 MPa may be suitable 
when the product is not subjected to considerable mechanical stress and may also 
provide faster disintegration (Pabari, 2010; Pitt et al., 2015). Considering that drug 
substances are typically poorly compressible (and thus expected to have a negative 
impact on the tensile strength of the tablets), it was decided to set ideal and minimum 
specification values at ≥ 3.0 MPa and ≥ 1.5 MPa, respectively.  
Ejection shear is the stress required to eject the tablet from the die after compaction. A 
low ejection shear is preferable because it suggests that there is a reduced likelihood of 
defects to the tablets and reduced likelihood of damage to the tablet punches, hence 
ensuring robust manufacturing and reducing manufacturing costs. A maximum ejection 
shear of 5.0 MPa is thought to be acceptable to minimise tablet defects and punch 
damage although a value of less than 3.0 MPa is preferable (Pitt et al., 2015). As such, 
these values were set as the ideal and minimum specification values for (oro)dispersible 
tablet formulations, respectively. 
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Friability testing is typically used to test the physical robustness of tablets (Saleem et al., 
2014). Although tensile strength gives an indication of the mechanical properties of the 
tablets, friability testing is the pharmacopoeial standard to measure the tablets’ 
resistance to mechanical stress. Friability is the tendency of a solid to break into smaller 
pieces and, as such, minimal friability is desirable. The current standard suggest that 
tablets need to be less than 1% friable during testing for 4 minutes in a friability tester 
(Saleem et al., 2014), which was set as the minimum requirement for (oro)dispersible 
tablets. Tablets that withstand a longer time of 10 minutes under stress conditions 
maintaining less than 1% friable were considered ideal in terms of mechanical strength. 
Pharmacopoeial standards dictate that (oro)dispersible tablets need to disintegrate in 
less than 3 minutes (WHO, 2010). There is no consensus on the temperature used for 
disintegration testing of (oro)dispersible tablets, with specifications typically varying 
between 25 and 37 °C (World Health Organization, 2010). In this study, the minimum 
requirement for disintegration time was set at 3 minutes at 37 °C. However, since a 
number of currently marketed (oro)dispersible tablets have disintegration times between 
30 seconds and 1 minute (Parkash et al., 2011), it was decided that an ideal specification 
for disintegration time would be less than 60 seconds at 37 °C. Faster disintegration 
times are desired to enhance patient convenience and acceptability, 
Fineness of dispersion tests are performed to provide information on the expected 
mouthfeel of a dispersion (Brniak et al., 2015). The compendial test establishes that the 
dispersion is acceptable if it passes freely through a 710µm screen, which was set in this 
study as the minimum requirement. However, based on previous studies with ODTs, 
rough mouth-feel is expected to be pronounced for particles larger than 200 m (Kimura 
et al., 2015). Therefore, the additional use of a screen with 250 µm nominal aperture 
may indicate improved mouthfeel compared to formulations that produce dispersions of 
larger particles. Thus, this was set as the ideal specification for fineness of dispersion. 
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On top of the requirements discussed above, palatability must be a critical consideration 
in the development of (oro)dispersible tablets. Properties such as appearance, taste and 
mouthfeel of the resulting dispersion can play an important role in patient acceptability. 
To date, there are no standards for palatability and acceptability of (oro)dispersible 
tablets. However, consideration must be given to the choice of excipients to ensure 
appropriate palatability, especially for medicines intended for paediatric patients (EMA, 
2013). Patient acceptability should be evaluated at an early stage of the drug product 
development process rather than as a result of it.  
The formulation development of (oro)dispersible tablets can be very tedious. One way to 
ease the product development could be to use co-processed excipients (Gohel and 
Jogani, 2005; Sreekanth et al., 2013). Co-processed excipients are the combination of 
two or more excipients, often prepared by spray drying, wet granulation and co-
crystallisation (Jivraj et al., 2000; Rojas et al., 2012). Co-processed excipients may be 
advantageous by providing improved functionality in comparison to physical mixtures of 
individual excipients and reducing the number of separate materials required within the 
formulation (Russell, 2004), hence reducing development time and cost and improving 
patient access. Co-processed excipients could also provide improved organoleptic 
properties, based on a rational selection of excipients combined with advanced 
manufacturing techniques. 
5.2 Aims and objectives 
The aim of this research was to identify the most promising co-processed excipient(s) to 
be used within (oro)dispersible tablet formulations prepared by direct compression, 
based on manufacturability and patient acceptability criteria. Secondary objectives were 
to characterise a range of co-processed excipients against the manufacturability 
requirements set in Table 5.1; and to conduct a sensory evaluation study in adult 
volunteers to evaluate palatability and patient acceptability of co-processed excipients. 
 168 
5.3 Materials and methods 
5.3.1 Materials 
The range of excipients investigated in this study and their individual constituents are 
presented in Table 5.2.  
Table 5.2. Individual constituents of the co-processed excipients 
Excipient name Individual constituents Particle size (µm)† 
Avicel PH-102 100% microcrystalline cellulose (reference) 100 
Avicel HFE-102 90% microcrystalline cellulose, 10% mannitol 100 
Compressol SM Mannitol, sorbitol, <2% silicon dioxide 126 
CombiLac 
70% lactose, 20% microcrystalline cellulose, 10% 
maize starch  
160 (35-65% below) 
Emdex 92% dextrose, 4% maltose, 4% maltodextrin 190-220 
F-Melt Type C 
55-70% D-mannitol, 10-25% microcrystalline 
cellulose, 2-9% xylitol, 5-13% crospovidone, 2-9% 
dibasic calcium phosphate anhydrous 
120.8 
F-Melt Grade M 
55-70% D-mannitol, 10-25% microcrystalline 
cellulose, 2-9% xylitol, 5-13% crospovidone, 2-9% 
magnesium aluminometasilicate 
122.3 
Ludiflash 
90% D-mannitol, 5% crospovidone, 5% polyvinyl 
acetate dispersion  
170-210 
MicroceLac 75% lactose, 25% microcrystalline cellulose  160 (35-65% below) 
Pearlitol Flash 80-85% mannitol, 15-20% maize starch  200 
Pharmaburst 500 
85% mannitol, <10% silicon dioxide, <10% sorbitol, 
5% crospovidone 
130 
ProSolv ODT 
60-70% mannitol, 15-30% MCC, <10% fructose and 
silicon dioxide, 5% crospovidone 
52 
SmartEx QD 50 
D-mannitol, polyvinyl alcohol, low-substituted 
hydroxypropyl cellulose 
57 
SmartEx QD 100 
D-mannitol, polyvinyl alcohol, low-substituted 
hydroxypropyl cellulose 
86 
† Particle size provided by supplier (median particle size unless otherwise specified). 
 169 
Candidate co-processed excipients for (oro)dispersible tablets were selected based on 
a recent literature review (Rojas et al., 2012), with advice from excipient manufacturers. 
All excipients investigated were kindly supplied by their manufacturers, including: 
Avicel® HFE-102 (FMC biopolymers, Philadelphia,  Pensylvania, USA), Compressol® 
SM and Pharmaburst® 500 (SPI Pharma, Septemes Les Vallons, France), CombiLac® 
and MicroceLac® (Meggle Pharma, Wasserburg, Germany), Ludiflash® (BASF, 
Lampertheim, Germany), Emdex® and ProSolv® ODT (JRS Pharma, Cedar Rapids, 
Iowa, USA), F-Melt® Type C and F-Melt® Type M (Fuji Health Science, Toyama, Japan), 
Pearlitol® Flash (Roquette, Corby, Northamptonshire, UK), SmartEx® QD50 and 
SmartEx® QD100 (ShinEtsu, Tokyo, Japan); Avicel® PH-102 (FMC Biopolymers) was 
tested as a comparator against the co-processed excipients since it is a highly 
compressible non-co-processed excipient. Sodium starch fumarate (SSF) was used as 
lubricant (Pruv®, JRS Pharma, Cedar Rapids, Iowa, USA).  
5.3.2 Powder and tablet characterisation 
5.3.2.1 Powder flow testing 
Analysis of the flow properties of the co-processed excipients was performed by tapped 
and bulk density analysis by USP method <616> using a Varian Tap Density Tester. 
Carr’s index values were calculated to identify the flow properties of the excipients.  
5.3.2.2 Tablet compressibility and ejection shear 
All formulations were lubricated with 1% w/w sodium starch fumarate (SSF) by blending 
directly compressible excipients and lubricant for 2 minutes at 22 RPM using a low shear 
Turbula® blender.  
Tablets of 10.5 mm diameter (round, normal concave) and 500 mg ± 5% weight were 
produced in triplicate at varying compression forces using a Phoenix compaction 
simulator. Each tablet was characterised for weight (Mettler Toledo Analytical Balance), 
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thickness (Mitutoyo Caliper) and hardness (Dr. Schleuniger Pharmatron Tablet Tester 
8M). The compaction and ejection forces were captured by the compactor simulator for 
each individual tablet and used to determine tablet tensile strength, solid fraction, 
ejection shear and compaction pressure (Pitt et al., 1988). The maximum tablet tensile 
strength that was achieved was determined for the different formulations.  
Compression profiles were used to determine the compaction pressure required to yield 
tablets with a target tensile strength of 1.5MPa; such tablets were then produced for 
disintegration, fineness of dispersion and friability testing. 
5.3.2.3 Tablet friability 
Tablet friability testing was performed by accurately weighing 10 tablets and placing them 
into a friability tester (VanKel Friabilator). Friability testing was performed for either 4 
minutes (standard conditions) or 15 minutes (extended conditions) at 25 rpm. Following 
testing, the tablets were removed, dedusted and weighed to enable the calculation of the 
% friability. Those that lost more than 1% of their total weight were considered poorly 
friable and failed the test. 
5.3.2.4 Tablet disintegration 
Disintegration test was performed as per USP <701> except using four tablets instead 
of six at 37 ± 2 °C using a Pharmatron DisiTest 50 with discs. Disintegration times (DTs) 
were reported as the time taken for the last tablet to disintegrate. 
5.3.2.5 Tablet fineness of dispersion 
For each formulation, one tablet was immersed in 10 mL of water and allowed to disperse 
completely. The suspension was swirled to aid tablet dispersion and then poured through 
a sieve stack with 710 µm and 250 µm screens. The visual residue left on each screen 
was recorded. The test was passed if no residue was observed. 
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5.3.3 Physical characterisation of dispersions 
5.3.3.1 Optical microscopy 
The particle size and shape of excipients were investigated with the aim to link physical 
properties and palatability, especially mouth-feel. The morphological characteristics of 
excipients were investigated by optical microscopy. Excipients were pre-dispersed in 
water (1 g in 20 ml) and observed at different magnifications using an Evos FL optical 
microscope (Life Technologies, Carlsbad, CA, USA) with a digital camera incorporated.  
5.3.3.2 Particle size distribution  
The particle size distribution was assessed by laser diffraction using a Mastersizer 3000 
(Malvern Scientific, Worcestershire, UK). All samples were analysed using both dry and 
wet dispersion methods. For the dry dispersion method, the air pressure and feeding rate 
were individually optimised for each excipient before measurement. For the wet method, 
approximately 1 g of sample was pre-dispersed in 20 ml of dispersant (deionised water). 
In both cases, at least three replicates of each sample were analysed.   
In addition, the particle size of powder dispersions was compared to that of tablet 
dispersions. Tablets were dispersed in water and the particle size of the resultant 
dispersion was assessed by wet dispersion method. At least three replicates of each 
sample were analysed. 
5.3.3.3 Insoluble particle fraction 
The proportion of insoluble material in the co-processed excipients was measured by 
gravimetric analysis. Accurately weighed, 1 g of excipient was dispersed in 10 ml of water 
and the sample was swirled for approximately 1 minute to allow dissolution of the soluble 
components. Subsequently, the dispersion was filtered through a 0.45 µm filter by 
vacuum filtration. After filtration, the insoluble residue was collected from the Buchner 
funnel and was oven-dried at 60 °C until constant weight. The recovered insoluble 
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material was then weighed out to calculate the insoluble particle fraction, i.e. the 
proportion of insoluble material with respect to the total dry weight of the excipient. The 
experiment was conducted in triplicate for each sample.  
5.3.4 Evaluation of palatability and patient acceptability 
5.3.4.1 Sensory evaluation study design and outcome measures 
Nine excipients were evaluated in a single-centre, single-blind, randomised, preference 
and acceptability testing. The study was approved by the University College London 
Research Ethics Committee (ERN_4612-015) and was conducted in designated facilities 
at UCL School of Pharmacy. Twenty-four healthy adult volunteers were recruited for the 
study (aged 19-38 years, mean age: 25.2 ± 4.8 years, 41.7% males). All participants 
received a detailed information sheet and provided written consent to participate.  
The study was divided into two sessions (Figure 5.1). In Session 1, panellists tested each 
of the nine excipients investigated, in individually randomised order, in three blocks of 
three samples. Based on results of Session 1, the two least preferred excipients were 
excluded for Session 2 with the aim of improving discrimination between samples. In 
session 2, participants received seven samples in randomised order, two of which were 
repeated in the last block of samples. A weighted randomisation schedule was designed 
to ensure that all possible combinations of three excipients were evaluated. Repeated 
presentation of the same excipient never occurred within each group of three samples. 
Test samples were prepared by dispersing 500 mg of powder excipient in 5 mL of purified 
water. The untrained panellists were provided three different blind samples at a time, up 
to a total of nine samples. They were instructed to invert the sample to ensure 
homogenous dispersion of the excipients and then taste the sample by swirling the 
contents in the mouth for approximately 10 seconds before spitting the sample into a 
receptacle provided. Participants had free access to spring water and unsalted crackers 
and were instructed to cleanse their palate before each sample.  
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Figure 5.1. Sensory evaluation study design. In Session 1, each participant received nine samples 
(s1-s9) in randomised order, in three blocks of three samples. In Session 2, seven samples were 
tested, two of which were repeated (r1, r2) in the last block. 
Subject-reported outcomes were recorded after evaluation of each group of three 
samples using an online structured questionnaire (Qualtrics.com). Participants were 
asked to rank the samples in order of their preference (forced-choice preference, no ties 
allowed). The volunteers were also asked to assign the key attribute that contributed to 
the ranking selection, from the following list: appearance, mouth-feel, taste, cooling 
sensation and smell. Overall acceptability was evaluated using 5-point hedonic scales 
anchored from (1) “very acceptable” to (5) “very unacceptable”. An open-ended feedback 
section was also implemented to obtain a qualitative response of palatability and 
acceptability, which was used to interpret the results.  
5.3.4.2 Statistical analysis 
For data analysis, samples were assigned numerical values based on subject-reported 
preference in each group of three random samples (-1, 0, +1, for ‘worst’, ‘middle’ and 
‘best’ samples, respectively) and results of hedonic scales were assigned numerical 
values from 1 to 5 (from extremely acceptable to extremely unacceptable, respectively). 
Statistical analysis was performed using the non-parametric Kruskal-Wallis one-way 
analysis of variance with 95% confidence, with Dunn’s test for pairwise comparison. 
Results from Session 1 and Session 2 were compared and, given the negligible 
differences, analysis was carried on pooled data. Minitab 17 (Minitab Inc., State College, 
Pennsylvania, USA) was used for data analysis. 
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5.4 Results and discussion 
5.4.1 Powder and tablet characterisation  
5.4.1.1 Powder flow of co-processed excipients 
Data generated from tapped/bulk density is presented in Figure 5.2. The results suggest 
that Compressol SM, Emdex, F-Melt Type M and ProSolv ODT have ideal flowability with 
Carr’s index equal or less than 15 %. All other excipients evaluated showed acceptable 
flow behaviour with Carr’s index values between 15 and 20 %. Out of all the excipients 
tested, Emdex showed the best flow with a Carr’s index of 11 %; this can be explained 
by its non-hygroscopic, uniform porous spheres (Amin et al., 2012; Bolhuis et al., 1985).  
 
Figure 5.2. Carr’s Index of co-processed excipients; results expressed as mean (N=3). 
5.4.1.2 Tablet compressibility and ejection shear 
Compression profiles for the co-processed excipients lubricated with 1% w/w SSF are 
presented in Figure 5.3, which shows the relationship between tensile strength of tablets 
as a function of the compaction pressure. A compression profile for Avicel PH102 was 
included to provide a benchmark for excellent compressibility (Thoorens et al., 2014).  
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Figure 5.3. Tablet compression profiles (tensile strength as a function of the compaction pressure). 
Formulations prepared using Avicel HFE-102, Emdex, ProSolv ODT, MicroceLac, F-Melt 
Type C and F-Melt Type M, CombiLac, Pharmaburst 500, Compressol SM, SmartEx 
QD100 and Ludiflash all showed excellent compressibility with maximum tablet TS above 
3.0 MPa being achieved. SmartEx QD50 provided maximum TS greater than 2.0 MPa, 
although this was considered poor in comparison to other co-processed excipients; 
capping occurred when measuring hardness of SmartEx QD50 tablets manufactured at 
high compaction pressure, which explains the reduction in TS shown in Figure 5.3, thus 
tablets with TS greater than 3.0 MPa could not be prepared. Pearlitol Flash proved to be 
the least compressible of all co-processed excipients investigated, with a maximum TS 
of 1.61 MPa; capping was observed in tablets prepared at high compaction pressures, 
hindering the preparation of tablets with higher TS (Figure 5.4).  
Avicel HFE-102 and Emdex showed particularly superior compressibility compared to 
the other excipients tested, producing very strong tablets at low compaction pressures. 
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Avicel HFE-102 is a mixture of 90% MCC and 10% mannitol produced by spray drying 
(Rojas et al., 2012); its compression profile highly resembled that of Avicel PH-102, 
which could be expected due to high concentration of MCC in both products (Thoorens 
et al., 2014). Emdex is a dextrose-based co-processed excipients which compresses by 
plastic deformation mechanism with low elastic energy, demonstrating excellent 
compression properties (Amin et al., 2012; Olmo and Ghaly, 1999).  
 
Figure 5.4. Capping post-tableting (left) and after hardness testing (right), observed for tablets 
prepared using Pearlitol Flash and SmartEx QD50 at high compression forces (> 200 MPa). 
Formulations containing ProSolv ODT, MicroceLac, F-Melt Type C and Type M and 
CombiLac contain a combination of plastic (MCC) and brittle (lactose or mannitol) 
deforming materials which explains their good compressibility (Gharaibeh and Aburub, 
2013; Hentzschel et al., 2012). Similarly, Pharmaburst 500 and Compressol SM contain 
sorbitol which will provide good compressibility through plastic deformation and high 
mannitol content which will allow consolidation through brittle fragmentation (Amin et al., 
2012; Rojas et al., 2013); the inclusion of silicon dioxide is thought to offset the 
hygroscopic nature of sorbitol in these co-processed excipients (Çelik, 2011). Ludiflash 
and SmartEx QD100 primarily contain mannitol which can be expected to provide brittle 
fragmentation under compaction leading to weak tablets (Al-Ibraheemi et al., 2013; 
Koner et al., 2015). However, Ludiflash and SmartEx QD100 still exhibited good 
compressibility, reaching tablet TSs above 3.0 MPa.  
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SmartEx QD50 has the same composition as SmartEx QD100 with the difference 
between grades being the particle size. SmartEx QD100, which contains a larger-sized 
fraction, showed superior compression properties than SmartEx QD50. Improved 
compressibility of larger particles has been previously attributed to increased 
fragmentation and better rearrangement upon compression (compared to smaller 
fractions), leading to stronger inter-particle bonding, although there may be other 
unknown differences between the grades not readily disclosed by the excipient supplier 
(Šantl et al., 2012). Meanwhile, poor compression and capping of Pearlitol Flash could 
be attributed to the viscoelastic nature of starch, which represents 15-20% of the co-
processed excipient, providing good plasticity but high elastic recovery (Gharaibeh and 
Aburub, 2013; Li et al., 2013). 
In terms of ejection, all co-processed excipients provided ejection shear results below 
3.0 MPa when prepared to the target TS of 1.5 MPa.  
5.4.1.3 Tablet Friability 
All tablets prepared at TSs of 1.5 MPa were less than 1% friable after standard friability 
testing for 4 minutes, which suggests that all co-processed excipients investigated would 
allow for direct compression of tablets at a TS of 1.5 MPa whilst maintaining appropriate 
mechanical properties.  
Formulations that displayed adequate compression properties (max. TS > 3.0 MPa), 
ideal disintegration times (below 60 seconds) and low tablet friability (<1% over 4 
minutes) were investigated for extended friability over 10 minutes. The advantage of this 
test is that it provides a deeper insight into the tablets’ ability to withstand manufacture, 
transportation and patient handling. All the studied formulations passed the extended 
friability test. Compressol SM, Emdex, Pearlitol Flash, ProSolv ODT and SmartEx QD 
50 were not investigated for extended friability as these excipients failed to comply with 
requirements for compressibility, disintegration or standard friability. 
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5.4.1.4 Tablet disintegration 
The primary attribute of (oro)dispersible tablets, as it related to patient acceptability, is 
their prompt disintegration in minimal liquid; therefore, the disintegration time of less than 
60 seconds was set as the ideal requirement for (oro)dispersible tablets. Disintegration 
times for all formulations evaluated are graphically depicted in Figure 5.5.  
 
Figure 5.5. Disintegration time of co-processed excipients (oro)dispersible tablet formulations. 
Results expressed as the time taken for the last tablet to disintegrate (N=4). 
Disintegration times varied from 26 seconds to over 7 minutes. Formulations yielding the 
shortest disintegration times contained Avicel HFE-102, CombiLac, F-Melt Type C and 
F-Melt Type M, Ludiflash, MicroceLac, Pharmaburst 500, Pearlitol Flash, SmartEx QD50 
and QD100; all disintegrating in less than 60 seconds. In contrast, ProSolv ODT 
disintegrated in 2-3 minutes and formulations containing Compressol SM and Emdex 
exhibited disintegration times over 3 minutes (minimum requirement). 
 Both F-Melt products (Type C and Type M), Pharmaburst 500 and Ludiflash contain the 
disintegrant crospovidone which acts by wicking and swelling mechanisms, drawing 
water in by a capillary action associated with its porous morphology, resulting in rupturing 
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of interparticle bonds and disintegration (Pabari and Ramtoola, 2012). SmartEx QD50 
and QD100 contain the disintegrant L-HPC which swells when it encounters water 
leading to rapid tablet disintegration (Kawashima et al., 1994). PVA in SmartEx products, 
as well as in Ludiflash, may contribute towards their short disintegration times (Patel and 
Vavia, 2010). The inclusion of silicon dioxide in Pharmaburst 500 and MCC in F-Melt 
Type C and Type M may also help to reduce the disintegration time for these formulations 
(Shihora and Panda, 2011). The fast disintegration of CombiLac and MicroceLac can be 
attributed to MCC, which acts by wicking on contact with aqueous fluids (Thoorens et al., 
2014); while the quicker disintegration of the former can be ascribed to the additional 
maize starch (10% w/w) within its composition (Desai et al., 2016). 
The formulations containing ProSolv ODT, Emdex and Compressol SM displayed long 
disintegration times. This could be expected for Emdex and Compressol SM since they 
contain no disintegrant in their composition; although it was unexpected from ProSolv 
ODT, which contains 5% crospovidone as disintegrant along with 15-30% MCC. Poor 
disintegration could be overcome by blending of co-processed excipients with additional 
disintegrants before compression. Potentially, additional disintegrant and API could be 
added simultaneously to the formulation to minimise processing steps. However, the aim 
of this work was to identify the most suitable co-processed excipients for (oro)dispersible 
tablets which can be used as an “all-in-one, just-add-API” platform excipients without 
additional disintegrant. 
5.4.1.5 Tablet fineness of dispersion 
Tablets were tested for the fineness of dispersion using 250 µm and 710 µm sieves. A 
positive outcome of the fineness of dispersion in 100 mL of purified water using 710 µm 
sieve is a pharmacopoeial requirement for (oro)dispersible tablets. In this study, 
however, a smaller volume of water (10 ml) and an additional smaller sieve were used 
to resemble in-use conditions in paediatrics and to increase discrimination. 
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Results for the tablet fineness of dispersion are summarised in Table 5.3. All formulations 
except those containing Avicel PH-102, Avicel HFE-102, Compressol SM and 
Pharmaburst 500 created smooth dispersions that passed through sieve screens with 
nominal mesh apertures of 250 and 710 µm. Avicel HFE-102 and Pharmaburst 500 
tablets passed through the 710 µm screen but not the 250 µm screen. Avicel PH-102 
and Compressol SM formed coarse dispersions which failed to pass through both the 
250 and 710 µm screens. Results of the fineness of dispersion test could provide an 
indication of palatability, particularly mouth-feel, of the formulations. Coarse dispersions 
or poorly dispersed formulations would be expected to elicit a rough mouth-feel, as 
opposed to fine dispersions. 
Table 5.3. Fineness of dispersion results for (oro)dispersible tablets dispersed in 10 ml of water. 
Excipient 
Dispersion fineness 
Descriptor 
710 µm screen 250 µm screen 
Avicel PH-102 Fail Fail Inappropriate 
Avicel HFE-102 Pass Fail Not ideal 
CombiLac Pass Pass Ideal 
Compressol SM Fail Fail Inappropriate 
Emdex Pass Pass Ideal 
F-Melt Type C Pass Pass Ideal 
F-Melt Type M Pass Pass Ideal 
Ludiflash Pass Pass Ideal 
MicroceLac Pass Pass Ideal 
Pearlitol Flash Pass Pass Ideal 
ProSolv ODT Pass Pass Ideal 
Pharmaburst 500 Pass Fail Not ideal 
SmartEx QD50 Pass Pass Ideal 
SmartEx QD100 Pass Pass Ideal 
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5.4.2 Physical characterisation of dispersions 
5.4.2.1 Optical microscopy 
The perception of a powder in the mouth is dependent on physical properties such as 
size, shape and hardness of the material (Engelen et al., 2005). In other words, the 
morphology of the particles will influence the palatability of tested samples, particularly 
in terms of mouth-feel. The morphological characteristics of the co-processed excipients 
in water dispersion were thus investigated by optical microscopy. Optical micrographs of 
excipients in water are shown in Figure 5.6. 
 
Figure 5.6: Optical microscopy images of the co-processed excipients (powder dispersed in water) 
at 10x magnification (scale bar: 400µm). Only those excipients with adequate compressibility 
(max. TS > 3.0 MPa), disintegration time (< 60 s) and friability (< 1% in 10 min.) were imaged. 
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Avicel PH-102 is based purely on water-insoluble microcrystalline cellulose (MCC). As 
shown in the micrographs, Avicel PH-102 was characterised by irregular MCC fibres 
which seemed to agglomerate in aqueous environment. Thus, Avicel PH-102 can be 
expected to elicit rough mouth-feel upon ingestion.  
Similarly, the micrograph of Avicel HFE-102 clearly showed the irregular structures of 
MCC. The micrographs of F-Melt Type C and F-Melt Type M show almost identical 
irregular particles, possibly composed of a mixture of MCC plus the insoluble calcium 
and magnesium compounds present in their composition, respectively. It is likely that the 
particles present in CombiLac and MicroceLac are also MCC, since lactose is soluble in 
water; CombiLac micrographs also revealed small rounded particles attributable to 
starch. Ludiflash, Pharmaburst and SmartEx QD100, which are largely composed of the 
water-soluble mannitol, were characterised by small particles of insoluble materials, such 
as polyvinyl acetate in Ludiflash, silicon dioxide in Pharmaburst and low-substituted 
hydroxypropyl cellulose in SmartEx QD100; these excipients were predicted to have a 
relatively good mouth-feel. 
5.4.2.2 Particle size distribution 
The particle size distribution of the investigated excipients is presented in Table 5.4. All 
co-processed excipients had comparable particle size in dry form, with a median particle 
size between 81-125 µm. When dispersed in water, Avicel HFE-102 and Avicel PH-102 
exhibited an increase in size with respect to the particle size measured by dry dispersion 
(D50 increased 6.3 and 17.1%, respectively); such increase was attributed to moderate 
swelling of the insoluble microcrystalline cellulose upon contact with water. In contrast, 
the large majority of excipients suffered a size reduction when dispersed in water, which 
can be explained by dissolution of the soluble components in the formulation; the 
reduction in median particle size ranged between -40.5 and -74.3%. These findings 
confirmed what shown in the optical micrographs, where Avicel products could be clearly 
identified by having coarser particles than other excipients. 
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Table 5.4. Particle size distribution of co-processed excipients measured by laser diffraction. 
Excipient  
PSD powder dry (µm)  PSD powder wet (µm) Δ PSD (%) 
D10 D50 D90  D10 D50 D90 D50 
Avicel PH-102 37 112 234  35 119 236 6.3 
Avicel HFE-102 36 117 234  45 137 262 17.1 
CombiLac 36 115 246  7 30 97 -74.3 
F-Melt Type C 37 108 217  11 44 99 -59.4 
F-Melt Type M 44 111 211  11 46 103 -58.7 
Ludiflash 25 121 278  13 56 145 -53.7 
MicroceLac 39 125 249  10 57 132 -54.1 
Pharmaburst 500 23 98 199  18 54 106 -45.1 
SmartEx QD100 36 94 200  21 56 114 -40.5 
Δ PSD: Difference in mean particle size between dry and wet dispersion methods.  
 
Since (oro)dispersible tablets are dispersed in saliva in the mouth or pre-dispersed in 
water before administration, the particle size of the water dispersion can provide relevant 
information of the particle size of excipients during in-use conditions. The particle size of 
co-processed excipients measured by wet dispersion method is depicted in Figure 5.7. 
 
Figure 5.7: Particle size distribution of co-processed excipients evaluated by laser diffraction in 
wet dispersion using water as dispersant. 
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Particle size is known to be a critical parameter which influences palatability of excipients 
and based on previous studies with ODTs, rough mouth-feel is expected to be 
pronounced for particles larger than 200 m (Kimura et al., 2015). As discussed before 
based on optical micrographs, Avicel HFE-102 and Avicel PH-102 exhibited relatively 
larger particle size than other excipients, with a median diameter larger than 100 µm and 
D90 larger than 200 µm. On the contrary, all other excipients showed a median particle 
size below 60 µm and D90 below 150 µm when dispersed in water. 
The particle size of powder dispersions was compared to that of tablet dispersion (i.e. 
tablets prepared at 1.5MPa and subsequently dispersed in water) to assess the potential 
effect of compression on the particle size of excipients. As shown in Table 4, the particle 
size of excipients before and after compression was very similar, differences in median 
particle size being equal or smaller than 10.3%. The negligible differences found 
between the particle size distribution of powder and tablet dispersions justify the use of 
powders instead of tablets for the sensory evaluation analysis.  
Table 5.5. Particle size distribution of powder and tablet dispersions in water by laser diffraction. 
Excipient  
PSD powder wet (µm)  PSD tablet wet (µm) Δ PSD (%) 
D10 D50 D90  D10 D50 D90 D50 
Avicel PH-102 39 119 236  42 126 250 5.9 
Avicel HFE-102 45 137 262  50 150 285 9.5 
CombiLac 9 32 101  7 30 97 -6.6 
F-Melt C 11 44 99  10 44 106 0.0 
F-Melt M 11 46 103  12 47 103 3.5 
Ludiflash 13 56 145  14 61 148 8.2 
MicroceLac 9 38 103  8 42 105 10.3 
Pharmaburst 500 18 54 106  16 56 109 4.3 
SmartEx QD100 19 54 110  12 51 111 -5.0 
Δ PSD: Difference in mean particle size between powders and tablets dispersions in water. 
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5.4.2.3 Insoluble particle fraction 
The amount of the insoluble material after dispersion of a tablet in water may impact 
palatability of the product upon administration. Although taste and mouth-feel are highly 
interconnected attributes and the same excipient could affect both taste and mouth-feel, 
it can be hypothesised that insoluble excipients will be the main determinants of mouth-
feel, whereas soluble excipients will have a major impact on taste. The insoluble particle 
fraction (i.e. the proportion of insoluble material) in the co-processed excipients was 
calculated by gravimetric analysis and results are shown in Figure 5.8. 
 
Figure 5.8. Insoluble particle fraction of excipients calculated by gravimetric analysis after 
excipient dispersion and dissolution of soluble components in 10 ml of water (N=3). 
Large differences were found between co-processed excipients, with Avicel HFE-102 
showing the greatest proportion of insoluble material (87.9%) and SmartEx QD100 the 
smallest insoluble particle fraction (5.1%). Most of the co-processed excipients however 
had less than 30% insoluble components, with the only exception of Avicel HFE-102. 
Avicel PH-102, a pure MCC excipient, served as a control since 100% insoluble particle 
fraction can be expected; 97.1 ± 0.7 % insoluble particle fraction was calculated for this 
excipient by gravimetric analysis, which demonstrates the accuracy of the test. 
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Moreover, the theoretical proportion of insoluble material in the co-processed excipients 
can be estimated based on their composition (Table 5.6). Excipients such as lactose and 
mannitol are highly water soluble and will readily dissolve in water, not contributing to 
the insoluble particle fraction. On the contrary, excipients such as MCC, polyvinyl acetate 
(PVAc) or silicon dioxide (SiO2) are water insoluble and thus will not dissolve in aqueous 
media, possibly having a negative impact on mouth-feel and overall palatability. Other 
excipients such as crospovidone, starch or low-substituted hydroxypropyl cellulose (L-
HPC), which are commonly used as disintegrants, swell when in contact with cold water 
and could also contribute to the amount of insoluble material in the dispersion. However, 
these polymeric excipients would form a soft, swollen dispersion, which could have a 
positive impact on palatability by creating a smooth, creamy mouth-feel (Buck et al., 
2016). As shown in Table 5.6, there was a good agreement between the theoretical and 
the experimental insoluble particle fraction for all excipients evaluated. 
Table 5.6. Theoretical and experimental insoluble particle fraction of excipients. 
Excipient Poorly soluble material(s) 
Insoluble particle fraction (%) 
Theoretical Experimental† 
Avicel PH-102 MCC (100%) 100 97.1 ± 0.7 
Avicel HFE-102 MCC (90%) 90 87.9 ± 0.3 
CombiLac MCC (20%), starch (10%) 20-30 29.8 ± 0.1 
F-Melt C 
MCC (10-20%), CaHPO4 (2-9%), 
crospovidone (5-13%) 
21-43 29.1 ± 0.9 
F-Melt M 
MCC (10-20%), Al2Mg2O2(SiO3)3 (2-
9%), crospovidone (5-13%) 
21-43 29.1 ± 0.2 
Ludiflash PVAc (5%), crospovidone (5%) 5-10 8.2 ± 0.2 
MicroceLac MCC (75%) 25 23.2 ± 1.5 
Pharmaburst 500 SiO2 (<10%), crospovidone (5%) 5-15 14.8 ± 0.2 
SmartEx QD100 L-HPC (unknown %) N/A* 5.1 ± 0.6 
† Average result (N=3) ± standard deviation. * Composition of SmartEx QD100 is not available. 
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5.4.3 Palatability and acceptability of co-processed excipients 
The best-performing excipients based on in vitro testing experiments were selected for 
a sensory evaluation study to assess palatability and acceptability (Table 5.7). Based on 
manufacturability criteria, nine excipients were selected, all of which showed adequate 
compressibility (max. TS > 3.0 MPa), disintegration time (< 1 minutes) and friability (< 
1% in 10 minutes). Excipients of variable fineness of dispersion were purposely included 
in this study to investigate the effect of this variable on palatability. 
Table 5.7. Summary of in vitro tablet characterisation experiments 
Co-processed 
excipient 
Max. 
TS 
(MPa) 
Ejection 
shear† 
(MPa) 
Friability (%)† Dis. 
time† 
(secs) 
Dispersion fineness† 
4 min. 10 min. 710 µm 250 µm 
Top manufacturing performance – selected for sensory evaluation of palatability/acceptability 
Avicel PH-102 >3.0 1.04 0.03 0.11 38 Fail Fail 
Avicel HFE-102 >3.0 0.90 0.02 0.11 35 Pass Fail 
CombiLac >3.0 1.79 0.06 0.30 42 Pass Pass 
F-Melt Type C >3.0 0.57 0.06 0.19 30 Pass Pass 
F-Melt Type M >3.0 1.74 0.04 0.21 28 Pass Pass 
Ludiflash >3.0 2.16 0.21 0.72 47 Pass Pass 
MicroceLac >3.0 2.28 0.02 0.12 44 Pass Pass 
Pharmaburst 500 >3.0 0.74 0.08 0.55 26 Pass Fail 
SmartEx QD100 >3.0 2.08 0.18 0.82 27 Pass Pass 
Low manufacturing performance – candidates for additional excipients in the final formulation 
Compressol SM >3.0 2.64 0.22 NM 426 Fail Fail 
Emdex >3.0 0.57 0.32 NM 194 Pass Pass 
Pearlitol Flash 1.61 2.36 0.15 NM 49 Pass Pass 
ProSolv ODT >3.0 0.84 0.09 NM 149 Pass Pass 
SmartEx QD50 2.45 1.42 0.61 NM 26 Pass Pass 
† Average result for tablets manufactured at target tensile strength 1.5 MPa; NM: Not measured, since only 
excipients with adequate compressibility (max. TS > 3.0 MPa), disintegration time (< 60 s) and standard 
friability (< 1% in 4 min.) were investigated for extended friability (during 15 min.).  
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Forced-choice preference ranking 
Results of the forced-choice ranking comparison are presented in Figure 5.9, where the 
excipients are shown in order of preference, from most preferred to least preferred.  
Overall, the top performer was SmartEx QD100, which was ranked as the most preferred 
excipient in 90% of the occasions and was the only excipient not selected as the least 
preferred sample by any of the participants. This was followed by F-Melt Type C, F-Melt 
Type M, MicroceLac, Ludiflash, CombiLac and Pharmaburst 500. Both Avicel HFE-102 
and Avicel PH-102 were identified as the least preferred, being never ranked as the most 
preferred excipient by any participant and ranked as the least preferred option by more 
than 80% and 90% of participants, respectively.  
 
Figure 5.9: Forced-choice ranking order, shown as proportion of participants who selected each 
excipient as “best”, “middle” or “worst” within randomised combinations of three excipients.  
Key palatability attribute 
After participants ranked the samples in order of preference, they were asked to select 
the key palatability attribute (appearance, cooling sensation, mouth-feel, smell or taste) 
which explained their ranking. Results are shown in Figure 5.10. 
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Figure 5.10. Key palatability attribute selected by participants to justify ranking of excipients 
dispersions as ‘best’ or ‘worst’ out of three random samples. 
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From those who ranked SmartEx QD100 as their preferred excipient, 49% suggested 
that the taste of the dispersion was the ‘key attribute’ and 44% referred to the mouth-feel 
of the sample as the main reason behind their choice (the remaining 7% reported that 
the clear appearance of the dispersion was the key attribute). As such, a balance 
between taste and mouth-feel seemed to drive perceptions of the appropriate palatability 
of SmartEx QD100. However, from those participants who ranked Avicel HFE-102 and 
Avicel PH-102 as their least preferred samples, an overwhelming majority referred to 
mouth-feel as the key attribute for their choice (95% and 91%, respectively). Rough 
mouth-feel from Avicel products was expected, as morphological characterisation of the 
samples revealed irregular MCC particles often larger than 200 µm. Overall, taste and 
mouth-feel were most commonly selected as key palatability attributes, whereas smell, 
cooling sensation and appearance seemed much less important factors. 
Hedonic ratings of acceptability. 
Participants rated the overall acceptability of the samples using a 5-point hedonic scale, 
where 1 corresponds to ‘very acceptable’ and 5 to ‘very unacceptable’ (Figure 5.11).  
 
Figure 5.11: Interval plot of hedonic ratings (1 – very acceptable, 5 – very unacceptable). Markers 
represent the population mean and bars show the 95% CI for the mean. 
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Hedonic ratings confirmed the ranking of excipients. SmartEx QD100 seemed to be a 
very acceptable excipient, with a median rating of 1 (i.e. positive end of the scale). This 
was followed by F-Melt Type C, F-Melt Type M and MicroceLac, all with a median rating 
of 2, which suggests that these excipients were also acceptable. Ludiflash, CombiLac 
and Pharmaburst, with a median rating of 3, were considered neutral in terms of 
acceptance. Finally, Avicel HFE-102 and PH-102 were deemed very unacceptable, with 
median rating of 5 (i.e. negative end of the scale).  
Interestingly, a potential correlation between fineness of dispersion and acceptability was 
identified. Pharmaburst 500, Avicel HFE-102 and Avicel PH-102 were the only excipients 
in this study to fail the 250 m fineness of dispersion test and were also selected as the 
least preferred and least acceptable excipients. The association between fineness of 
dispersion through 250 µm sieve and hedonic ratings of acceptability was statistically 
significant (p < 0.001, Chi-square test for association). The negative effect of insoluble 
particle fraction and particle size on acceptability was also demonstrated (p < 0.001). 
Both particle size and insoluble particle fraction can be expected to affect fineness of 
dispersion which, in turn, will affect palatability (especially mouth-feel). 
The particle size distribution analysis confirmed the relatively large particle size of Avicel 
products, which explains their poor fineness of dispersion and thus poor palatability. 
Meanwhile, Pharmaburst 500 is mainly based on the water-soluble excipient mannitol 
and its dispersion in water exhibited a small particle size (D50 = 54 µm, comparable to 
excipients such as SmartEx QD100 which passed the fineness of dispersion test. Thus, 
the reasons behind the poor dispersion of Pharmaburst 500 remain unexplained. 
Hedonic ratings for each individual excipient are presented in Figure 5.12, where results 
are expressed as the proportion of participants who selected each level of the 5-point 
facial hedonic scale. A rational interpretation of results based on the individual 
composition of each excipient is attempted below.  
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Figure 5.12: Hedonic rating for each excipient, showing the proportion of participants which 
selected each level of the 5-point hedonic scale (1 – very acceptable, 5 – very unacceptable).  
SmartEx QD100 
SmartEx QD100 received remarkably positive responses, with no negative ratings (i.e. 
100% ratings in neutral-positive range) and over 65% of participants scoring the highest 
possible ratings in the hedonic scale. The exact composition of SmartEx QD100 has not 
been published by the manufacturer, but it is known to contain mannitol (diluent, 
sweetener), polyvinyl alcohol (binder) and L-HPC (disintegrant). The overall success of 
SmartEx QD100 was reflected in the open-ended comments provided by the volunteers, 
describing SmartEx QD100 dispersions as ‘sweet’, ‘smooth’, ‘clear’ or ‘least powdery’. 
The small particle size (D50 in wet dispersion = 56 m), insignificant proportion of 
insoluble material with respect to its dry weight (ca. 5%) and presence of mannitol could 
be responsible for a highly favourable mouth-feel and sweet taste. 
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F-Melt Type C and F-Melt Type M 
The second and third highest scores were observed for F-Melt products, with over 90% 
of neutral-positive responses. Essentially, the composition of these excipients is identical 
with a difference of one component: F-Melt Type C contains dibasic calcium phosphate 
anhydrous (Fujicalin®) and F-Melt Type M contains magnesium aluminometasilicate 
(Neusilin®) (Krupa et al., 2012; Sona and Muthulingam, 2011). The acceptable 
palatability of F-Melt products in fast disintegrating tablets was previously attributed to 
the presence of mannitol within its composition (Moutasim et al., 2017). In this study, 
participants described F-Melt products as being ‘moderately sweet’ and having ‘smooth’ 
texture, which support previous claims.  
Interestingly, these excipients contain 10-25% of microcrystalline cellulose, but the 
presence of this insoluble excipient with poor organoleptic profile did not affect the overall 
palatability. It can be hypothesised that the amount of MCC is not substantial as to elicit 
the negative palatability response. Moreover, other excipients in the F-Melt products 
composition could potentially mask the feeling of grittiness and/or the manufacturing 
process could have altered the mouth-feel of these excipients. 
MicroceLac and CombiLac 
MicroceLac and CombiLac were the only lactose-based co-processed excipients tested 
in this study. Lactose has been widely used as a filler in pharmaceutical preparations for 
many years, although its popularity has declined in favour of mannitol (Ohrem et al., 
2014) due to commonly reported lactose intolerance (Eadala et al., 2009), and risk of 
API-excipient interactions caused by the Maillard-reaction (Bharate et al., 2010). The 
additional constituents of MicroceLac and CombiLac include MCC (for both) and maize 
starch (in CombiLac). Starch, as a viscosity-modifying excipient, is often used to promote 
physical stability of dispersions while enhancing their organoleptic profile by creating a 
smooth, creamy mouth-feel (Buck et al., 2016). 
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In this study, MicroceLac organoleptic profile was preferred to CombiLac (77.6% versus 
60.4% neutral to positive responses). This could suggest that the presence of maize 
starch in CombiLac had a negative effect on its palatability, in contrast with the rationale 
to add starch to improve palatability. The anecdotal responses described the taste of 
CombiLac as ‘plain’ and ‘slightly unpleasant’. 
Ludiflash 
Overall, Ludiflash obtained 73.2% of neutral-positive ratings, which suggests a positive 
organoleptic profile. Ludiflash is reported by its manufacturer to have creamy and smooth 
mouth-feel with neutral to mildly sweet, pleasant taste. Although the taste of Ludiflash 
was confirmed to be neutral in this study (with participants describing it as ‘almost 
tasteless’ and ‘slightly sweet’), it was rated more negatively than other excipients such 
as SmartEx QD100 and F-Melt Type C and Type M (which perhaps had a sweeter taste).  
Moreover, the presence of mannitol in high proportion (80% w/w) was expected to 
produce an acceptable mouth-feel for Ludiflash, although many volunteers described this 
excipient as ‘grainy’ and ‘coarse’. When participants ranked Ludiflash as the worst 
sample, 75% justified their choice based on poor mouth-feel. The coarse feeling in the 
mouth perceived by some participants could be ascribed to polyvinyl acetate (PVAc), the 
only non-water-soluble excipient in its composition. Ludiflash had the third largest particle 
size (D90 = 148 µm) from the excipients investigated, after Avicel PH102 and HFE-102, 
which supports the results of the in vivo sensory evaluation. 
Pharmaburst 500 
It has been previously reported that, when compared against formulations containing 
pure MCC as filler (Avicel PH 101), the palatability of Pharmaburst 500 tablets are more 
acceptable due to the presence of a sweetener, mannitol, in its composition (Moqbel et 
al., 2016). This can be confirmed by the results obtained in this trial, where Pharmaburst 
500 performed better than pure MCC (Avicel PH-102).  
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However, Pharmaburst 500 was still among the worst performing excipients in this 
palatability study, with just 51.1% of neutral-positive evaluation. Interestingly, the high 
polyol concentration (73.8-93.8% w/w, based on manufacturers specifications) did not 
result in a highly favourable organoleptic profile. The proportion of volunteers providing 
negative ratings on hedonic scales (48.9%) exceeded those providing positive ratings 
(26.7%). Participants reported mouth-feel (60%), followed by taste (26%) and smell 
(14%), as the key attributes for the negative evaluation of Pharmaburst 500. Perhaps the 
presence of insoluble silicon dioxide in the composition, even if in small quantity, could 
had negatively influenced the overall organoleptic profile of this excipient. 
Avicel HFE-102 and Avicel PH-102 
Avicel PH-102, a pure MCC excipient, was the least acceptable candidate tested in this 
study. Its grittiness was negatively perceived by the volunteers who described the mouth-
feel as ‘sandy’ or ‘chalky’, and the lack of sweetener resulted in a ‘neutral’, ‘bland’ taste. 
Avicel PH-102 did not receive any positive response in the hedonic scale ratings, with 
an overwhelming 90.9% of negative evaluations. The rough mouth-feel of MCC is well 
acknowledged in the literature, e.g. (Ishikawa et al., 2001). 
To improve palatability of MCC, spray-drying was used as co-processing technique to 
combine MCC with mannitol (70/30 ratio) in the development of Avicel HFE-102. 
Hypothetically, the presence of mannitol should improve the taste due to its sweetness. 
The cooling effect resulting from the negative heat of solution of mannitol (Kearsley and 
Deis, 2006) could be also beneficial to reduce the sandy mouth-feel of the cellulosic 
material (Rojas et al., 2012). However, this study showed that the difference between 
both products was not significant. Avicel HFE-102 showed only a minor improvement in 
organoleptic profile compared to Avicel PH-102. It is possible that the influence of 
mannitol was overwhelmed by the high concentration of MCC (90% w/w). Experiments 
demonstrated the large insoluble particle fraction of this co-processed excipient and the 
coarse size of the insoluble MCC particles (D50 in wet dispersion = 137 m). 
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5.5 Conclusions 
This study investigated a range of co-processed excipients that may prove suitable for 
the preparation of (oro)dispersible tablets by direct compression. Formulations 
containing Avicel HFE-102, CombiLac, F-Melt Type C, F-Melt Type M, Ludiflash, 
MicroceLac, Pharmaburst and SmartEx QD100 exhibited acceptable flow properties 
(Carr’s index ˂  20), compressibility (max. tensile strength > 3.0 MPa) and ejection results 
(< 3.0 MPa at target tensile strengths) in addition to low friability (< 1.0% after 10 minutes) 
and short disintegration times (< 60 seconds), which suggest suitability for use in directly 
compressed (oro)dispersible tablet formulations. Such excipients were then further 
investigated to ascertain their organoleptic properties and patient acceptability. 
Other possible excipients that may be used in directly compressed (oro)dispersible tablet 
formulations include ProSolv ODT, Emdex, Compressol SM, SmartEx QD50 and 
Pearlitol Flash. SmartEx QD50 and Pearlitol Flash provided tablets with rapid 
disintegration but failed to compress into tablets with maximum tensile strength greater 
than 2.5 MPa; thus, these excipients would only be suitable providing appropriate 
compressibility is achievable with the addition of an API into the formulation. On the 
contrary, formulations containing ProSolv ODT, Emdex and Compressol SM produced 
robust tablets but failed to disintegrate sufficiently fast and thus would benefit from 
additional disintegrants in the formulation. All these excipients which showed poorer 
performance based on in vitro testing and may require additional excipients in the 
formulation were not considered for palatability and acceptability testing under the criteria 
established for this investigation. 
The sensory analysis of co-processed excipients revealed significant differences in their 
organoleptic profiles. SmartEx® QD100 was undoubtedly the most palatable out of the 
tested products, followed by F-Melt Type C, F-Melt Type M and MicroceLac (considered 
to have acceptable palatability), Ludiflash, CombiLac and Pharmaburst (with neutral 
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palatability). Avicel® HFE-102 was the least acceptable due to large and water-insoluble 
MCC particles that resulted in a gritty mouth-feel. Almost all co-processed excipients 
tested (with exception of Avicel HFE-102) provided improved palatability compared to 
the non-coprocessed excipient Avicel PH-102. Evaluation of particle size and shape, 
insoluble particle fraction of excipients and fineness of dispersion were proven to be 
useful to predict poor palatability in terms of granularity or mouth-feel.  
In this regard, modification of the compendial fineness of dispersion test by using 10 ml 
of water as dispersant (instead of 100 ml) and 250 µm screen (instead of 710 µm) was 
proven valuable to increase discrimination between samples. The three co-processed 
excipients that failed the fineness of dispersion test through the 250 µm screen (namely 
Pharmaburst 500, Avicel HFE-102 and Avicel PH-102) were considered the least 
palatable, although two of those three passed through the 710 µm screen (which is the 
current pharmacopoeial standard). Excipients with particle size in wet dispersion larger 
than 200 µm were considered poorly acceptable which supports the use of this value as 
a threshold for maximum particle size of excipients used within (oro)dispersible 
formulations, as previously proposed (Kimura et al., 2015). 
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Chapter 6 
6. General discussion, conclusions and future work 
 
The research described within this thesis evidences the value of palatability and patient’s 
acceptability testing to guide excipients selection and dosage form design. This chapter 
provides a general discussion of the work. Justification of the research is provided; 
experimental results and implications of the findings are overviewed; limitations and 
methodological considerations are discussed; and future work is outlined.  
6.1 Importance of evaluating patient’s acceptability 
Children need better medicines. Medicines have been traditionally designed to meet the 
needs of standard patients. Paediatric patients (and other non-standard patient 
populations, such as geriatrics and patients with swallowing difficulties) have been 
neglected. The advent of the European Paediatric Regulation in 2007 (and parallel 
regulations in other parts of the world) plus new guidelines on Clinical Investigation of 
Medicinal Products in the Paediatric Population  are changing the scenery, supporting 
the development of acceptable medicines (European Parliament and Council, 2006). 
Forthcoming regulations will set similar standards for older patients (EMA, 2018). 
A medicine will not elicit its desired therapeutic effect if the patient is not able or not 
willing to take it. Our understanding of medicines’ quality must evolve from the traditional 
balance of safety and efficacy to a more comprehensive balance of safety, efficacy and 
patient’s acceptability. Patient’s acceptability is determined by characteristics of the 
patient as well as characteristics of the medicinal product (EMA, 2018, 2013). The 
pharmaceutical characteristics of the medicinal product (e.g. route of administration, 
appearance, dosage form size and shape, dose volume and administration device) must 
be rationally designed to meet the needs of the target population.  
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It is well-established that pharmaceutical quality should not be merely tested on the final 
product but planned in advanced based on understanding of the product and processes 
(Quality by Design). Similarly, patient’s acceptability should not be simply determined on 
the final product but investigated during the drug product development and the outcomes 
of such investigation used to guide drug product design. This would enable development 
of patient-centric medicines that are acceptable by design (Figure 6.1). 
 
Figure 6.1. Diagram of the Acceptability by Design concept by which the selection of excipients, 
manufacturing process and dosage form are guided by understanding of patient’s acceptability. 
Companies are required to propose a formulation strategy in PIPs submitted early in the 
drug development process. The rationale for the choice of excipients and dosage form 
design needs to be discussed and justified. The research described within this thesis 
outlines an iterative process by which prototype formulations can be optimised based on 
sequential palatability and acceptability investigations which feedback into the selection 
of excipients and dosage form design until a final, acceptable product is reached.  
The outcomes of this research intend to highlight points to consider during the drug 
development of acceptable medicines for children, support dosage form selection and 
complement PIP discussions and justifications.   
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6.2 Rationale for investigating flexible solid oral dosage forms  
Liquid medicines are the traditional formulation of choice for paediatrics but the benefits 
of solid oral dosage forms over liquids are widely acknowledged. These include better 
stability profile (shelf life and in use), cost-effective, convenient and portable packaging 
and lower number of (potentially toxic) excipients. Recent exploratory studies using 
placebo mini-tablets have dramatically changed our views on appropriateness and 
acceptability of solid dosage forms in children and neonates (Klingmann et al., 2013; 
Kluk et al., 2015; Spomer et al., 2012; Thomson et al., 2009). These studies marked the 
beginning of a new stream of research, as the one described in this thesis. 
The choice of formulation in paediatric drug development studies may be determined by 
the properties of the API, target age group and disease to be treated (Wang, 2015), as 
well as socio-cultural reasons (Walsh et al., 2017). Flexible solid dosage forms, such as 
multiparticulates and (oro)dispersible tablets, offer potential to be appropriate for a wide 
range of age groups and to accommodate a wide range of APIs. The adaptability of 
flexible solid dosage forms also means that they are suitable as enabling formulations in 
bridging studies to support paediatric drug development (Ricci, 2013). For instance, 
(oro)dispersible tablets can benefit from a well-established manufacturing platform while 
being a suitable formulation for both adults and children. Meanwhile, multiparticulate 
formulations could be filled into capsules to be swallowed whole by adolescents and 
adults and to be sprinkled into a suitable vehicle for young children. For such reasons, 
these flexible solid dosage forms were the focus of this research. 
The aims of this research included: (1) to review knowledge and identify barriers for the 
development of age-appropriate medicines for children, (2) to optimise methodology for 
palatability and acceptability testing of pharmaceutical products in children and adults 
and (3) to generate evidence to fill some of the knowledge gaps around acceptability of 
flexible solid oral dosage forms. 
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6.3 Overview of original contributions and implications of the research 
The main findings of the work described in this thesis are summarised below, in relation 
to the original aims and objectives: 
▪ Review of the scientific literature identified lack of evidence on patient’s acceptability 
of flexible solid dosage forms, despite acknowledged potential as formulations of 
choice for paediatrics. The literature review also demonstrated lack of standardised 
methodology for assessment of palatability and patient’s acceptability. 
▪ Methodology for the assessment of palatability and patient’s acceptability of flexible 
solid oral dosage forms was developed, considering acceptability as ability and 
willingness to use a product as intended. When required, child-friendly questionnaires 
were designed to allow studies in children (minimum age of four years), without 
parents/caregivers’ intervention. 
▪ The swirl and spit methodology, typically used in the assessment of palatability, was 
compared to swallowing of the samples as methods to evaluate palatability and 
acceptability. The former methodology benefits from allowing assessment of a greater 
number of samples while the latter allows evaluation of ingestion and post-ingestion 
phenomena. Selection of the most appropriate method is required on a case by case 
basis depending on the objectives of the study. 
▪ A key outcome of this research was the realisation of the duality of the concept of 
patient’s acceptability. The ability to use a formulation as intended (e.g. ability to 
swallow a solid dosage form) does not always implies willingness to use it. The 
willingness to use a product is a broader aspect which depends not only on the skills 
of the patient to use a product but on other elements such as palatability and liking of 
the product. Evaluation of both aspects brings certain methodological challenges 
further explored in Section 6.4. 
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▪ Multiparticulates were found to be widely accepted by children in terms of ability to 
use as intended (i.e. swallow the complete dose). However, palatability issues related 
to oral grittiness perception were identified as a barrier to acceptability, as supported 
by previous research. Increasing particle size and amount of multiparticulates were 
found to be contributing factors to oral grittiness perception. Application of a polymeric 
coating did not seem to affect grittiness perception and overall acceptability. This 
information could guide the design of multiparticulate formulations. 
▪ Barriers to the administration of multiparticulates were encountered as pellets quickly 
settled down in water, being unsuitable for administration using a dosing cup. The use 
of a dosing spoon ameliorated this issue. This finding highlighted the importance of 
selecting the right dosing device to achieve dosing accuracy. 
▪ The presence of residual multiparticulates in the mouth after sample administration 
was a key issue identified in this research. This may have a critical impact on 
multiparticulates designed for taste-masking purposes since the prolonged residence 
time in the mouth might put at risk the integrity of the coating (by incentivising 
dissolution and/or chewing) leading to release of the (aversive) active ingredient. The 
residue in the mouth was rated in the positive range of the hedonic scales, suggesting 
small and acceptable deposit of multiparticulates. However, this perception can 
change dramatically if the aversive API is released in the mouth. This issue may thus 
require special attention when developing multiparticulate formulations. 
▪ Model oral hydrogels were developed to investigate the effect of liquid vehicles for the 
administration of multiparticulates on palatability and patient’s acceptability. Vehicles 
of viscosity higher than water were confirmed to improve palatability and acceptability 
of multiparticulates, as supported by previous research. A balanced viscosity should 
be sought to enable homogenous suspension of the particles while maintaining a thin, 
syrup-like consistency (which was favoured by participants).   
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▪ The most suitable co-processed excipients to use within directly compressible 
(oro)dispersible tablet formulations were identified, integrating manufacturability and 
patient’s acceptability criteria. Particle size of the excipients (in water dispersion) and 
proportion of insoluble materials in their composition were found to be key parameters 
which affect palatability and patient’s acceptability. This information can guide the 
development of (oro)dispersible tablet formulations. Evaluation of manufacturability 
and acceptability of formulations containing API will be required. 
▪ An in vitro test was developed based on modification of the compendial fineness of 
dispersion test. A more restrictive setting was employed using 10 ml of liquid and a 
250 µm nominal aperture sieve instead of 100 ml of liquid and a 710 µm sieve, as 
stated in the compendial test. This test was shown to be predictive of mouthfeel of the 
excipients and could expedite development of acceptable formulations by serving as 
a simple screening tool to pre-select candidates.  
▪ Overall, the value of conducting palatability and patient’s acceptability evaluations to 
guide drug product development was demonstrated. 
6.4 Methodological limitations in the evaluation of patient’s acceptability 
The lack of standardised methodology for palatability and acceptability testing is a barrier 
for the development of paediatric medicines. Several limitations of the methodology 
employed in this thesis merit discussion. Some of these limitations, which will require 
special attention in future studies in the field, are discussed below: 
Patient’s acceptability definition and scientific interpretation 
Patient’s acceptability has been defined by the EMA as “the ability and willingness of the 
patient and its caregiver to use a medicine as intended”. However, this definition is open 
to interpretation and there are no guidelines or standard criteria to measure acceptability 
in practice. Review of the scientific literature on patient’s acceptability of oral dosage 
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forms revealed that the outcome measures of acceptability varied greatly between 
studies, as discussed in the Introduction to this thesis.  
The heterogeneity in the outcome measures employed hinders interpretation of results 
and comparison between studies. The EMA acknowledges that “different methods to 
measure patient’s acceptability may result in different outcomes” (EMA, 2013). Ideally, 
pragmatic definition of patient’s acceptability should be developed, providing guidance 
on how this should be measured and interpreted. Given the lack of such guidance, 
outcome measures of acceptability were purposely defined in the present work.  
Patient’s acceptability is a multi-dimensional variable, influenced by several factors such 
appearance, palatability and swallowability. In an attempt to consider these contributing 
factors simultaneously, various outcome measures were employed in the present work, 
including the ability to swallow the dosage form, the palatability of the formulation and 
the willingness to take the product again. The different outcome measures provided 
complimentary results which require careful interpretation. 
The EMA indicates that “adequate patient’s acceptability is not to be understood as 100% 
acceptance of a medicine”, but the limits applied in each study “should be discussed and 
justified in terms of risk to benefit considerations” (EMA, 2013). 
Validity and reliability of the evaluation tools 
Age-appropriate questionnaires were developed to obtain patient reported outcomes of 
palatability and acceptability. However, consistency and reliability in interpretation of the 
questionnaires by different participants was dubious (especially in children). Moreover, 
the ability of participants to independently rate each palatability criteria on the hedonic 
scale was questionable, since ratings to the different attributes were found to be 
associated with each other (in both children and adults). These phenomena can be 
expected, especially from untrained assessors, and a number of studies have addressed 
these issues in the past (Popper et al., 2004; Prescott et al., 2011).  
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Given the questionable reliability of patient reported outcomes in children (and in other 
patients with communication impairments), researcher observations are recommended 
in studies involving such populations (FDA, 2009; Matza et al., 2013). In the study in 
children described in Chapter 3, facial expressions were visually interpreted by the 
investigators of the study. Interpretation of observational responses is subjective and 
might be affected by factors unrelated to the formulation (ASTM, 2003). When facial 
expressions suggested some level of discomfort with the sample, it was difficult to 
determine which of those were signs of non-acceptance. 
Results for the willingness of participants to take multiparticulates every day as a 
medicine also require cautious interpretation. Although this outcome measure could 
provide an indication of future acceptance, results are based on opinions of healthy 
participants after a single administration of the formulation. Nevertheless, previous 
research suggest that subject-reported attitudes towards taking a medication or to 
continue with a therapeutic regime are good predictors of patient adherence (Godin et 
al., 2005; Kreivi et al., 2014). 
In this research, time and effort dedicated to developing robust evaluation tools had to 
be balanced with the need to obtain empirical data to answer the research questions. 
Specific barriers for conducting acceptability studies in children 
The work presented in this thesis continuous to highlight the methodological and logistic 
barriers of conducting studies involving children. One of the greatest challenges is the 
reduced number of samples that can be tested in a single session, due to limited attention 
span of children. This allows evaluation of a limited number of formulations and thus 
limited number of formulation factors. Screening studies (in adults) proved useful to 
reduce the number of samples and refine the study design before conducting studies in 
children, as supported by previous guidelines (ASTM, 2003; Guinard, 2000). 
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The use of scales may differ between children and adults (e.g. children’s tendency to 
use preferentially the extremes of hedonic scales) and variability of results in children 
can be expected to be broader than in adults. Consequently, a larger number of children 
participants would be required to obtain the same level of significance.  
In addition, subjective interpretation of questionnaires can introduce a certain degree of 
variability in the results. This effect can be expected to be greater in younger children 
and ameliorate with age due to cognitive and language skills development. The 
questionnaire used in the study described in Chapter 3 was designed based on previous 
research with children and adolescents (Mistry et al., 2016), and was considered 
appropriate to the age of the children who participated. However, consistency in the 
interpretation of questions and sample attributes was still doubtful. Further research is 
required to support the development of age-appropriate evaluation tools. 
Generalisability and significance of results 
The studies described in this thesis were conducted in healthy subjects, in controlled 
environments, under supervision of a research team. This allows no definitive conclusion 
of the acceptability of the formulations by patients in hospital settings or at home. Results 
of this research were not intended to guide prescribing choices in clinical practice but to 
illustrate the use of palatability and acceptability testing during drug development studies 
to guide dosage form design. 
Arguably, the generalisability of outcomes such as acceptable size of multiparticulates 
or the preferred excipients in (oro)dispersible tablet formulations may be limited given 
the population size and the non-specific demographic. The evidence generated in this 
research is expected to help guide initial pharmaceutical development choices and 
product testing, rather than providing absolute guidance towards a final commercial 
product. Results of this research do not preclude the need to conduct product-specific 
acceptability studies during drug product development, on a case by case basis. 
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6.5 Future work: towards better medicines for children 
Potential areas of future work have been suggested in relevant parts of this thesis; they 
are summarised here together with other areas which merit investigation. 
▪ The most urgent research need is an agreeable and practical definition of patient’s 
acceptability. This may appear a trivial matter of nomenclature, but its effects on 
interpretation of results and comparison between studies are paramount. Based on 
the current definition of acceptability provided by the EMA, a simple measure of the 
ability to swallow the formulation should not be considered synonym of acceptability, 
as performed in previous studies. Efforts need to be directed towards assessment of 
not only the ability but also the willingness to use the product as intended.  
▪ A clear and practical definition of patient’s acceptability would enable the development 
of much-needed standardised evaluation tools. Validated tools such as the Treatment 
Satisfaction Questionnaire for Medication (TSQM) and the Satisfaction with Medicines 
Questionnaire (SATMED-Q) have been developed to measure patient’s satisfaction 
(Bharmal et al., 2009; Ruiz et al., 2008). Although these tools already account for 
convenience and satisfaction, the information provided might be insufficient and/or 
inappropriate to determine patient’s acceptability. However, these tools can serve as 
inspiration in the development of a Patient’s Acceptability Questionnaire that can be 
systematically used in different studies. 
▪ Additional work around patient’s acceptability of flexible solid oral dosage forms is 
necessary to confirm and expand the results obtained in this research. Studies with 
multiparticulates should be extended to younger children based on the positive results 
obtained (in terms of ability to swallow the formulation) by school-aged children. The 
maximum size and amount of multiparticulates (and other solid dosage forms) that 
can be accepted by children of different ages continues to be an important incognita, 
which requires an evidence-based answer. 
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▪ Extra attention must be paid to evaluating the effect of formulation factors on residual 
multiparticulates in the mouth and the spontaneous reflex of chewing the particles. 
One of the key advantages of multiparticulates is their suitability for taste masking 
based on polymeric coatings. Prolonged retention in the mouth and chewing of the 
particles would compromise such advantage. It is crucial to identify the formulation 
factors which play a role in this response, e.g. size and amount of multiparticulates, 
hardness and surface properties of the particles, properties of the vehicle used for 
administration and dosing device if any. 
▪ Future work should investigate (oro)dispersible tablets with addition of API in the 
formulation. Manufacturability and acceptability of (oro)dispersible formulations will be 
highly influenced by the physicochemical properties of the API and thus the 
formulation design (e.g. the need for taste-masking) must be considered on a case 
by case basis. Any of the top 6 or 7 co-processed excipients identified (out of 14 
candidates initially assessed) may be worth revisiting depending on the target API. 
▪ Researchers have already directed their efforts towards standardised approaches for 
selecting the most appropriate dosage form for paediatrics (Sam et al., 2012). Further 
work is required in this area. A Manufacturing Classification System (MCS) have been 
recently proposed to rank the feasibility of different pharmaceutical processing routes 
based on selected properties of the API and the needs of the formulation (Leane et 
al., 2014). In the same line of thinking, an Acceptability Classification System could 
be attempted to rank the appropriateness of different dosage form designs based on 
selected properties of the API and the needs of the target population.  
▪ Further work which was deemed out of the scope of this research should investigate 
the generalisability and clinical significance of results obtained in palatability and 
acceptability studies conducted in healthy subjects. It is important to understand the 
predictive value of these studies on acceptability in the target patient population. 
 209 
6.6 Conclusions 
The development of paediatric medicines which fulfils safety, efficacy, acceptability and 
manufacturability requirements is a challenging task. The specific needs of the target 
population should be taken into account to establish the Quality Target Product Profile. 
Evaluation of palatability and patient’s acceptability during drug development studies can 
contribute to define the Critical Quality Attributes as well as formulation and process 
parameters that may affect them. Only when these features are considered at an early 
stage of the drug development, medicines will be acceptable by design.  
The EMA acknowledges that adequate patient acceptability can be demonstrated by 
different means, including data from clinical trials, human factor studies with healthy 
volunteers or actual patients, market experiences and scientific literature. Evaluation of 
acceptability of model (placebo) formulations in healthy (adult) volunteers can be 
valuable by (i) providing fundamental evidence of patient’s acceptability to guide initial 
dosage form selection and (ii) generating knowledge to improve the design of future 
acceptability studies in the target population to optimise the final formulation.  
The outcomes of this research highlight methodology gaps and areas for improvement 
in the evaluation of patient’s acceptability. Unless successful and pragmatic criteria for 
the evaluation of acceptability are developed, there will always be a risk for medicines to 
lack fit for purpose. The available technology platforms for paediatric drug delivery do 
not meet the needs of all patients and innovation for better medicines will be misguided 
if suitable ways to measure acceptability are not developed. Collaborative endeavours 
from Industry, Academia and Regulators will be necessary to achieve this goal. 
The methodology explored in this research can be applicable beyond the development 
of medicines for children. Not only children but also other subsets of the population can 
benefit from medicines designed to meet their needs and preferences.   
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